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Abstract
Trang Andrea Vu
TOWARD PRECISION MEDICINE WITH NANOPORE TECHNOLOGY
2016-2020
Jiwook Shim, Ph.D.
Doctor of Philosophy

Currently, when patients are diagnosed with cancer, they often receive a treatment
based on the type and stage of the tumor. However, different patients may respond to the
same treatment differently, due to the variation in their genomic alteration profile. Thus, it
is essential to understand the effect of genomic alterations on cancer drug efficiency and
engineer devices to monitor these changes for therapeutic response prediction. Nanoporebased detection technology features devices containing a nanometer-scale pore embedded
in a thin membrane that can be utilized for DNA sequencing, biosensing, and detection of
biological or chemical modifications on single molecules. Overall, this project aims to
evaluate the capability of the biological nanopore, α-hemolysin, as a biosensor for genetic
and epigenetic biomarkers of cancer. Specifically, we utilized the nanopore to (1) study the
effect of point mutations on C-kit1 G-quadruplex formation and its response to CX-5461
cancer drug; (2) evaluate the nanopore’s ability to detect cytosine methylation in labeldependent and label-independent manners; and (3) detect circulating-tumor DNA collected
from lung cancer patients’ plasma for disease detection and treatment response monitoring.
Compared to conventional techniques, nanopore assays offer increased flexibility and
much shorter processing time.
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Chapter 1
Introduction
1.1 Cancer and Precision Medicine
Cancer is a group of diseases where abnormal cell growth can potentially spread to
the surrounding tissues. It arises from the accumulation of score alterations affecting the
structure and function of the genome. Most cancers belong to one of three groups—
carcinomas, sarcomas, and leukemias or lymphomas—with carcinomas being accountable
for approximately 90% of all human cancers.1
In the United States, there are over one million new cancer cases, and more than
500,000 cancer deaths, each year. With only 5-10% of all cancer cases coming from
inherited genetic defects, the majority of cancers are caused by environmental exposures
and lifestyles, such as viral infection (15%), tobacco use (22%), poor diet (35%), radiation,
stress, and environmental pollution.2
1.1.1 Molecular markers of cancer. The development of a malignant cancerous
tumor frequently results from a multistep process, rather than just a single genetic change.3
This multistep process originates from various genetic and epigenetic modifications, which
exert their pathological effects by causing defects in genes in one of two ways: (1) an
enhanced expression or activation of oncogenes (gain in function) and (2) repression or
inactivation of tumor-suppressor genes (loss of function).4 Several methods have been used
in research for detecting various cancer-causing factors and different techniques are applied
depending on the particular type of cancer.
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1.1.1.1 Genetic alterations. In cancer cells, somatic mutations occur and
accumulate at a significantly higher rate than in normal cells. These mutations cover a wide
range of structural alterations in the DNA. They consist of large chromosomal alterations
that encompass millions of base-pairs (e.g. translocation, deletion, or amplification) as well
as smaller changes in nucleotide sequences (e.g. point mutations). These different types of
genetic alterations often co-exist within a single tumor.5 Together, they cause defects in
DNA repair pathways, cell-cycle regulation, apoptosis, or create error-prone DNA
polymerase.5 The ability to quickly accumulate mutations is critical for cancer cells’ rapid
growth and development of resistance to cytotoxic cancer treatments.6
1.1.1.2 Epigenetic alterations. In contrast to genetic alterations, “epigenetic
alterations” refers to all heritable changes in gene expression and chromatin structure that
are not encoded in the DNA sequence itself.5 Epigenetic inheritance, such as DNA
methylation, histone modification and RNA-meditated silencing, are essential mechanisms
that allow stable propagation of gene activities.7-8 Disruption of these mechanisms causes
inappropriate gene expression (i.e. activation of oncogenes or inactivation of tumorsuppressor genes) that can lead to cancer development.9
A main distinguishing feature of epigenetic alterations compared to genetic changes
is that they are reversible, and thus, present an exciting opportunity for the development of
novel strategies for cancer prevention.5 Overall, both genetic and epigenetic alterations are
involved in the formation of a field for cancerization (i.e. cancers develop at multiple foci
in a tissue). However, their exact contribution is dependent on the major carcinogens
involved and their carcinogenic mechanisms.10

2

1.1.2. Toward precision medicine for cancer treatment. Nowadays, when a
patient is diagnosed with cancer, they often receive a combination of different treatment
approaches to combat the disease, including surgery, chemotherapy, radiation therapy,
immunotherapy, or any combination of the foregoing. The type of treatment and dosage
are often similar between patients with the same type and stage of cancer. Even so, different
people may respond differently. This is because a tumor’s genetic changes, which cause
cancer to grow and spread, can differ significantly among patients with the same cancer.
On the other hand, different types of cancers can also share the same cancer-causing
changes.
Precision medicine is an approach that matches patients to therapies depending on
their own genomic information, to maximize a patient’s response to treatment.11 Using the
concept of massively parallel sequencing, the development of high-throughput Nextgeneration sequencing (NGS) devices (e.g. Illumina, Complete Genomics, and Roche
Applied Science 454) have revolutionized personalized genomic medicines. In fact, for the
first time, several clinical samples of patients were obtained and analyzed with NGS,
providing an insight into the high complexity of diseases such as cancer.11-19 However, upto-date, clinical trials demonstrate that the level of patient benefit from precision medicine
in cancer treatment is still low.11, 20-23
A possible explanation for this unexpected result is that most current efforts are
based on the idea that cancers are just like other rare genetic disorders. Specifically, the
presence of epigenetic changes, lineage-specific drivers and non-oncogene-driven
vulnerabilities are often ignored.11 Over 90% of cancer death are caused by metastatic
spread of cancer to distant sites.24-26 During tumor manifestation and progression, treatment
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decisions are generally based on results of primary tumor specimens from diagnostic
testing. However, this method neglects a tumor’s genetic and epigenetic evolutionary
changes, which are shown to present a major challenge for treatment selection.27-30 Thus,
longitudinal monitoring of a tumor’s genetic and epigenetic variability are essential for
correct treatment selection and cancer eradication.31
While it is impractical for patients to undergo serial surgical biopsy along tumor
progression, liquid biopsy provides a minimally invasive and more sustainable alternative
to interrogate cancer cells longitudinally. Liquid biopsy is the sampling of non-solid
biological tissue, to extract tumor-derived materials (e.g. circulating tumor cells,
circulating tumor DNAs, and exosomes).31 Up-to-date, plasma-derived circulating tumor
DNA (ctDNAs) are the most commonly used blood-based biomarker in clinical practice,
and are utilized most frequently to (1) monitor a patient’s response to therapy, (2) detect
minimal residual disease along treatment, and (3) assess therapy resistance development.
Currently, the majority of liquid biopsy samples are analyzed with NGS, which can
be costly and require extensive processing times of up to several weeks, or digital PCR that
are restricted to a single locus (a fixed position on a chromosome). Furthermore, NGS
technologies employ several enrichment, amplification, and labeling steps, such as
polymerase chain reaction (PCR) and bisulfite conversions, which can cause the
performance to be time and cost intensive, and can also increase the possibility of false
positive results.32 Due to the need for a label-free, high throughput system, there has been
a growing interest toward using third- and fourth-generation sequencing, specifically
nanopore technologies, in cancer prevention and detection in the past decades.
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1.2 Nanopore Technology
Since its development and publication in 1996, the nanopore has become an
emergent and powerful technology for a direct and inexpensive method for DNA
sequencing, biosensing, and detecting biological or chemical modifications on single
molecules, as well as the kinetics of DNA and protein folding.33-37
1.2.1 Definition of nanopore technology. Formal definitions of nanopore
technology typically feature devices that contain a nanometer-scale pore embedded in a
thin membrane. Originating from the Coulter counter and ion channels, nanopore-based
devices can detect various charged biomolecules that are slightly smaller than the diameter
of the pore. In the nanopore-based analysis, a biological or a solid-state membrane
separates the experimental chamber into two compartments, referred to as the cis and trans
sides, to which a cathode and anode are attached, respectively. Negatively charged
biomolecules, such as DNA, are then introduced into the cis side of the chamber. Under
the electrophoretic force exerted by the external current, the biomolecule transports
through the nanopore to the trans chamber. As the molecule moves through the nanopore,
it interrupts the current signal, causing ionic current blockages. Physical and chemical
properties of the targeted molecule can be analyzed using the amplitude and duration of
current blockages through the nanopore.38-39
1.2.2 Types of nanopore. The two main types of nanopore—biological and solidstate nanopores—can be obtained or fabricated in numerous ways 40-45 and offer a wide
range of biomolecule detection. Biological nanopores are secreted from different bacteria,
of which the two most popular types come from α-hemolysin and MspA porin. These
biological nanopores are then usually inserted into different biological substrates, such as
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a phospholipid bilayer, liposomes, or polymer films. Biological membranes are structurally
well-defined and easily reproducible. Biological nanopores are mostly used for the
detection of single-stranded DNA (ssDNA), microRNA (miRNA), and disease
diagnostics.39 Most solid-state nanopores are fabricated in membranes made of silicon
oxide (SiO), silicon nitride (SiNx), hafnium oxide (HfO2), graphene, aluminum oxide
(Al2O3) and hybrid materials.46-48 With controllable pore size and membrane thickness,
solid-state nanopores have been beneficial for use in RNA sequencing, single-stranded and
double-stranded DNA sequencing, DNA-protein complex detection, and other biomolecule
detection.
1.2.3 Experimental setup. Detailed reviews on the experimental setups and uses
of the nanopore technology have been described in literature before.39-40, 47, 49-51 Figure 1A
shows a schematic of the biological nanopore experiment setup. Briefly, a Teflon film
divides the testing chamber into two separate compartments, named cis and trans
chambers, to which negative and positive electrodes are attached, respectively (as
described in 2.1 above). When 𝛼-HL protein is introduced to the cis chamber, it can insert
a mushroom-shaped channel into lipid bilayer, connecting the cis and the trans sides
(Figure 1B). α – hemolysin (𝛼-HL), a toxin released by the Staphylococcus aureus
bacterium, is well known for its ability to form a protein channel with a well-defined
structure as well as dimensions. Specifically, the 𝛼-HL α–hemolysin is a water-filled,
mushroom-shaped channel consists of a cis-opening (2.6nm), a nano-constriction (1.4nm),
and a trans opening (2.0nm).52 DNA or any other charged biomolecules are then injected
to the cis chamber. Under an electrophoretic force, charged molecules (e.g. DNA) can
translocate through the nanopore, resulting in a transient current blockage with
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characteristic amplitude (%I/Io), dwell time (∆𝑡), and event signature. Depending on the
specific sequence, ssDNA strands can adopt several common conformations, including
hairpin, G-quadruplexes and i-motif (among many others).47,

53-55

These secondary

structures, while different, can coexist at the same time in the solution, causing various
types of current-blockages as shown in Figure 1C. Depending on the size, conformation,
and kinetics of each biomolecule species, several types of current blockage can be
observed. These current blockages are characterized by their specific amplitudes and dwell
times, allowing different biomolecules to be distinguished.

Figure 1. The experimental setup of α-hemolysin nanopore. The experimental setup of the
𝒂-HL nanopore experiment. (A) The testing chamber contains two compartments, cis and
trans, separated by a Teflon film. (B) 𝒂-HL, a mushroom shape nanopore which connects
the cis and trans chambers. (C) When DNA molecules, or other charged biomolecules, are
inserted into the cis chamber, the applied current forces the biomolecules through the 𝒂HL nanopore, causing a current-drop (termed a blockage). Current blockages are analyzed
and characterized by their amplitudes and dwell times. Each blockage trace is unique to the
biomolecule species passing through the channel, depending on the size, conformation and
kinetics of the interaction between the biomolecule and the nanopore.
7

1.2.4 Nanopore technology for precision medicine. Nanopore technology offers
many advantages that NGS devices are incapable of: for instance, the nanopore has
demonstrated the ability to detect CpGs methylation (one of the earliest epigenetic
biomarkers in cancer hallmarks) without the need of PCR amplification and bisulfite
conversion.56-57 Thus, nanopore technology strives to be a potential genomic tool that is
label-free, has a high throughput, a small sample volume requirement, flexible runtime,
and minimal footprint.39 However, despite the past twenty years of significant progress in
single molecular sequencing and analysis, nanopore technologies have not yet been
translated into even distantly comparable advances in clinical settings. The aim of this
thesis is to explore the ability of α-hemolysin nanopore to detect genetic and epigenetic
changes on DNA, specifically ctDNAs. Through studying physical and electrical behavior
of short DNA fragments, we can enhance the nanopore readout resolution, allowing the
detection of DNA modifications. We believe that 𝛼-hemolysin nanopore is a good
candidate, as the pore size stays consistent, yielding replicable results.
1.3 Thesis Outline
As described above, despite its significant potential and technological
advancements in the past decades, applications of nanopore technology in clinical settings
still come up short. The objective of this research is to explore and enhance the ability of
α-hemolysin nanopore to study DNA fragments for cancer detection and precision
medicine. To establish this purpose, we developed protocols to optimize the ability of both
lab-based and commercially available nanopore assays in detecting DNA genetic and
epigenetic alterations. A more detailed description of the studies performed in this thesis
is listed below.
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In Chapter 2 we provide an overview of the recent developments and applications
of nanopore technology in studying cancer biomarkers. The development and progression
of cancer are influenced by numerous genetic and epigenetic factors (e.g. structural
variants, transcription factors, G-quadruplexes, methylations, histone modifications and
expression of microRNAs). While nanopore technology has grown rapidly as a versatile
DNA sequencer,39-40,

49, 58-61

its potential as a biosensor for cancer markers is still

significantly underdeveloped.
DNA is a flexible polymer that can adopt various structures depending on the
sequence and surrounding environment. It is essential to evaluate the ability of α-hemolysin
nanopore as a biosensor to detect and distinguish these structural changes. Therefore, in
Chapter 3, we set out a study of the structural changes of an i-motif sequence with the
surrounding environment’s pH level. Our results demonstrated that at high ionic
concentration, C-rich DNA can dynamically fold into an i-motif or compacted structure
according to the solution pH. These secondary structures, whose sizes were different,
generated distinct electrical signal events when captured by the nanopore.
The most appealing strength of biological nanopores, such as the α-hemolysin, is
their consistent dimensions and size selectivity. As the α-hemolysin nanopore only allows
single-stranded DNA to translocate, all secondary structure must first dissociate into a
linear strand at different rates, depending on its specific structural stability. In Chapter 4,
we performed a comparative study on the formability and stability of Ckit1 G-quadruplex
in K+ and Na+ environments. We further evaluated the effect of CX-5461 (a potential
cancer drug) on stabilizing Ckit1 G-quadruplex structure. Using the event translocation
time obtained from nanopore study coupled with K-nearest neighbor clustering analysis,
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we found that cations have a significant impact on the G-quadruplex structural stability and
volume. Our results demonstrate that combining machine learning classification with
nanopore results would allow different G-quadruplexes to be distinguished with over 80%
accuracy and sensitivity.
While CX-5461 has an amplified effect on unmodified C-kit1 DNA sequence to
halt cancer cell growth, activating mutations on C-kit1 have been observed in several types
of malignancy, notably leukemia, melanoma, and gastrointestinal tumors. 62-64 Thus, in
Chapter 5, we set out to evaluate the stability of G-quadruplex structure formed by
mutated C-kit1 DNA sequences and the altered efficacy of CX-5461 on these structures.
We designed the sequences containing between zero and six mutated guanines, to partially
or completely disrupt the G-quadruplex. In this study, we found that while G-quadruplex
stability depends strongly on the number of mutations present, the position of mutated
guanine was the main deciding factor for CX-5461 efficacy.
Another type of epigenetic marker we focused on in this thesis is methylated
cytosine, which is among the most studied epigenetic markers for cancer diagnosis,
therapeutics, and prognosis.65-69 Despite the enormous number of studies and papers
published on promoter methylation as potential cancer biomarkers, currently, there are only
two FDA-approved, DNA methylation-based biomarker assays available on the market. A
major challenge in the study of epigenetics is that most commonly used techniques,
including bisulfite sequencing, cannot directly identify 5-methylated cytosine (5-mC) from
native DNA. In Chapter 6, our study evaluates the feasibility of label-free detection of
methylated cytosine using the nanopore. Through employing a salt concentration gradient
between the two experimental chambers, we were able to decrease the DNA mobility and
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velocity through the pore; thus, increasing the detection resolution. This method allowed
us to distinguish methylated from unmethylated cytosine in mixtures with different
composition.
In Chapter 7, we employed methyl-binding protein (MBD2) as a specific tag, as a
method to enhance methylation detection with nanopore technology. Label-free detection,
while attractive for its simplicity, can be affected greatly by the local context of the DNA
sequence. Conjugation of MBD2 to methylated DNA resulted in a significant increase in
both event translocation time and current blockage amplitude. Coupling nanopore data
output with commonly employed machine learning algorithms, we were able to distinguish
methylated DNA from unmethylated DNA with optimal sensitivity and specificity of 88%
and 86%, respectively.
Having determined the sensitivity of nanopore technology, we evaluated the
feasibility of applying nanopore technology in a clinical setting. Recent studies found that
circulating-tumor DNA in the bloodstream exhibits the same genetic and epigenetic
alterations as the solid tumor they originated from,70 and thus ctDNA can reflect such tumor
type and stage. However, as circulating-tumor DNA are highly fragmented and present in
low concentrations in blood circulation, it is still challenging for nanopore assay to
effectively capture them. In Chapter 8, we developed and evaluated two novel protocols
that could be integrated: commercially available nanopore assay for sequencing and
analyzing circulating-tumor DNAs. We employed rolling-circle amplification and bluntend ligation methods to create long DNA fragments that could be captured by the nanopore.
Finally, in Chapter 9 we present a summary of our findings and discuss the
potential directions and future applications.
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Chapter 2
Piecing Together the Puzzle: Nanopore Technology in Detection and Quantification
of Cancer Biomarkers
2.1 Abstract
Nanopore-based technology has grown rapidly in recent years, which have seen
the wide application of biosensing research to a number of life sciences. In this chapter, we
present a comprehensive outline of various genetic and epigenetic causal factors of cancer
at the molecular level, as well as the use of nanopore technology in the detection and study
of those specific factors. With the ability to detect both genetic and epigenetic alterations,
nanopore technology would offer a cost-efficient, labor-free, and highly practical approach
to diagnosing pre-cancerous stage and early-staged tumors in both clinical and laboratory
settings. This chapter was adapted from our previously published paper (Vu, Trang, et al.
“Piecing together the puzzle: nanopore technology in detection and quantification of cancer
biomarkers.” RSC advances 7.68 (2017): 42653-42666.)2.2 Detection of Cancer
Biomarkers
2.2 Current State of the Art
2.2.1 Structural variants. Structural variants (SVs) are one of the first recognized
causal factors of cancer. A structural variant is a form of somatic DNA mutation, whereby
the SV promotes the development and progression of cancer while contributing to all the
important hallmarks of the instability in cancer genomes.71 The four main types of SVs are
large deletions, amplifications, inversions and translocations of nucleotides within a DNA
sequence. They are often responsible for the creation of fusion genes, copy number, and
other regulatory changes that lead to activation or overexpression of oncogenes, as well as
inactivation of tumor suppressor genes.72-76 In many cases, different SVs occur
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simultaneously in a specific pathway that amplifies their genetic effects on cell instability.
For example, with head and neck cancers, it was found that when the deletion of CDKN2A
and amplification of CCND1 happen together, there is a higher risk of recurrence,
metastasis, and death rather than when either genetic alteration occurs alone. 62-63
SVs are important indicators of human cancers.64-67 Complex SVs have been found
to cause approximately half of nucleotide deletions in pancreatic ductal adenocarcinoma
(PDAC).68-70 Furthermore, CDKN2A/p16 and SMAD4/DPaazC4 have been identified as
two of the most common deleted tumor suppressor genes. The ability to detect these
mutations is critically important to the healthcare industry, allowing the monitoring of
cancer patients for early detection of possible relapse.67-71 In mammalian cells with highly
repetitive genomes, studies of SVs frequently use a resequencing approach, in which the
read from the target genome is independently aligned from the reference genome to search
for SVs.72 In general, besides specificity and sensitivity, when detecting SVs, a method’s
quality is further judged by its ability to accurately predict breakpoint locations, the size of
variants, and changes in copy count.67, 73
As shown in Figure 2, Norris et al. demonstrated the value of detecting long SVs
using Oxford MinIONTM, to detect a series of well-characterized SVs, including large
deletions, inversions, and translocations that inactivate the CDKN2A/p16 and
SMAD4/DPC4 tumor suppressor genes in pancreatic cancer.67 Using Oxford Nanopore
barcodes, the Norris et al. produced libraries for all 12 PCR amplicons in one run, yielding
reads with PHRED scores of 10.9-11.50. PHRED, invented back in 1998 by Ewing and
Green, was originally a base-calling program for automated sequencer traces. In later
research, the term “PHRED score” has been used for the determination of quality and
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accuracy between consensus sequences. The higher the PHRED score, the higher the
accuracy. For example, a PHRED score of 10 stands for a 90% base call accuracy, and a
PHRED score of 20 is correlated with 99% base call accuracy.74 For this specific study,
the readings were averaged at 640 bps long with a PHRED score of 11.50. It was also found
that these reads are consistent for the entire bp length. The amplicons mapped with an
overall percentage of 99.6% for regions of hg19, while 79% of aligned reads accurately
matched to bases. Notably, the representation of amplicons does not change accuracy based
on the complexity of the sequence. Additionally, the researchers wanted to test their
method with low frequency SVs. In a 1:100 dilutions, the run produced 4,058 2D reads
from 270 of 512 channels. The average read length was 650 bps and had a PHRED score
of 10.9. Overall, the researchers proved their methods can be conducted in a timely manner.
For the two sequences (CDKN2A/p16 and SMAD4/DPC4) in this study, it took 15 minutes
and 33 minutes respectively, to generate 450 reads.67 In comparison, 2nd generation
sequencers can generate millions of reads simultaneously, but it can take hours to days to
complete. The experiment indicated the ability of nanopores to serve as a reliable and
efficient method of sequencing, allowing rapid detection of tumor-associated structural
variants. The two limitations of MinIONTM, as noted by the researchers, were (1) a
relatively high mismatch and index error rate and (2) a limited yield (on the scale of Mb or
Gb).
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Figure 2. Nanopore Library Prep Workflow. Oxford Nanopore barcodes were incorporated
into amplicons by PCR- individually for each SV, then resultant reactions were pooled (A).
After NEB End Repair and dA-tailing modules (B), hairpin and leader adapters were
ligated on, each containing a motor protein. Only the hairpin protein contained a his-tag,
which was used to enrich for molecules containing a leader adapter and his-tag (his-tag
selection step not shown). Tether attachment (C) allowed for direct attachment of the
molecules to the flow cell membrane. Within the MinION flowcell (D), DNA molecules
are pulled through a protein pore (blue), with motor protein (orange) affecting speed of
DNA translocation through the pore. One side of the DNA molecule is read, then the
hairpin, then the second side. Both reads were aligned to produce a 2D consensus read.

Compared to conventional genome-based methods, such as fluorescence in situ
hybridization (FISH), fiber-FISH, array comparative genomic hybridization (aCGH) and
paired-end mapping (PEM) (each of which have a read length of approximately 35 ~ 400
base pairs (bps)),73, 75 nanopore allows for much more flexible read lengths (of a few bps
to kbps). However, the average PHRED score of reads generated by MinION is still
relatively low compared to other sequencers (e.g. Illumina, 454, Ion Torrent, PacBio, and
others). At the moment, Illumina is the most popular DNA sequencer on the market. Still,
depending on the equipment model and sample size, sequencing using Illumina can take
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from 3-12 days to complete. Additionally, the current market price of Illumina ranges from
$50,000 (MiniSeq) to over $6M (Illumina HiSeq X Five), costing significantly more than
the nanopore-based sequencers.
2.2.2 Transcription factors. The second most well-known causal factor of cancer
is aberrant activity of transcription factors (TFs), which are often members of multigene
families with common structural domains.3 TFs are the main regulators of gene expression
and signaling pathways in all biological systems and bind to a specific sequence of DNA
to promote or inhibit gene expression. In cells, a major portion of oncogenes and tumorsuppressor genes are encoded by TFs.4, 76 Aberrant TF activity can occur due to changes in
expression, protein stability, protein-protein interactions, post-translational modifications,
and numerous other mechanisms.77 In a healthy cell, upstream transcriptional regulators
highly regulate all genes with similar functions. However, changes in TF activity leads to
deregulation of genes involved in promoting cancer cell proliferation, survival, and
inducing angiogenesis and metastasis of tumors.4, 76 For example, nuclear TFs, the signal
transducer and activator of transcription, has been linked to various human cancer cell lines
and primary tumors, including leukemia and lymphoma, as well as breast, lung, pancreas,
and prostate cancers.63, 79-87
Various direct and indirect techniques have been used to characterize TFs, along
with other sequence-specific DNA binding proteins, including electrophoresis,
electrophoretic mobility shift assay, nuclear magnetic resonance, X-ray crystallography,
atomic force microscopy, optical tweezers, and direct fluorescent visualization, among
others.78, 88-92 However, most of these methods require some combination of chemical
cross-linking between TFs and DNA, modification or tagging of the TF and DNA, and
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amplification assays. Furthermore, due to the complicated requirements, these methods
would lack the ability to resolve fine details of the TF and DNA complex (i.e. partial versus
full binding of the TF domains to DNA).78 The specific mechanism of TFs binding to DNA
sequences is still under intensive study and is a major area of interest in molecular
biology.78, 93
Squires et al. used solid-state nanopores as biosensors for the characterization of
DNA, RNA, and proteins (Figure 3). With the use of an electric field, the researchers
could guide the polymers through a nanopore and identify individual molecules. The
current-blockage patterns generated during translocation of charged molecules provides an
abundance of information about TF local properties, as well as TF-DNA interactions.78 As
previously noted, the regulation of TFs has not been well investigated, hence the use of
solid-state nanopores could be a novel technique in describing these molecular interactions.
As proof of technique, the Squires et al. has shown that their nanopores can distinguish
between specific and nonspecific binding of TF, by analyzing the ion current of the
canonical zinc-finger DNA-binding domain of Early Growth Response 1 (zif268).
Characterization of the zif268 was accomplished using the distinct blockage patterns of the
current within the nanopore.94 Through analyzing the data, the researchers found that there
are three main types of blockages, existing mostly in five distinct patterns rather than
randomly. These patterns have a direct correlation to preexisting data. Hence, the nanopore
presents great potential in characterizing DNA complexes because of its ability to detect
complex structures and protein conformations, with the possibility of removing TFs as
needed. Squires et al. note that their nanopore sensor can identify small TFs in DNA as
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well as distinguish between specific and nonspecific binding. This research technique
allows information-gathering availability with respect to TF-DNA interactions.

Figure 3. Distinguishing between specific and non-specific binding of TF—DNA with
solid-state nanopore. Translocation event traces and proposed mechanisms for (A) specific
binding, and (B) non-specific binding of TF to DNA.78

2.2.3 Telomeres. On average, telomeres are shortened by 19 bps per year due to
aging, oxidation, stress, mitotic activity of tissues, and lifestyle.95-98 When shortened to a
critical length, telomeres lose their ability to protect the DNA chromosomes 99 and restrict
the proliferation of normal somatic cells.98 This leads to chromosomal fusion and
degradation.100-101 In contrast, approximately 85% of human cancer cells can achieve an
“immortality” status by maintaining and elongating telomeres via the de novo synthesis of
telomeric DNA.100 Recently, a study was conducted on 47,102 individuals from the general
population, where these individuals were followed for up to 20 years to find out the
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relationship between telomere length and cancer. Although short telomere length is not an
indication of cancer,98 it was observed that cancer patients with shorter telomere length had
increased risk of early death. This result was observed in patients with lung and esophagus
cancer, malignant melanoma, and leukemia.98
Even though it has been years since the first research, the kinetics of telomeres in
cancer cells remains elusive. At present, measuring the length of telomeres and observing
the kinetics of folding are still challenging, as there is no gold-standard technique.102 In
order to fully understand the role of telomeres in cancer prediction or therapy, it is essential
to understand the kinetics of telomere folding and other conformational changes as a
response to different living and environmental conditions.
Work is currently underway to apply nanopore sensor in tracking the telomeric
DNA G-quadruplex folding/unfolding (Figure 4). Several research groups have used
biological nanopore to capture some or all four folded-structures of G-quadruplex,
including hybrid (hybrid-1 and hybrid-2), basket, and propeller structures.47,

103-105

Findings from these studies reported that even though the four G-quadruplex structures all
folded from the same DNA sequence, they produced very different electrical signatures. 105
This was attributed to the overall shape and volume of each secondary structure. It was
observed that both hybrid-1, -2, and basket forms had a diameter of 2.7 nm and 2.4 nm,
respectively. Since the cis opening of the α-hemolysin pore has a diameter of 3.0 nm, these
three folds can enter the large vestibule. However, the propeller fold, with a disk-shaped
structure and diameter of 4.0 nm, exceeds the diameter of the nanopore cis opening and
was unable to enter the vestibule.106
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Figure 4. Capturing unfolding process of the four G-quadruplex structures with biological
nanopore. (A) Schematic of the α-hemolysin nanopore, with the cis opening of 3.0 nm,
constriction of 1.4 nm, and trans opening of 2.0 nm. (B) Folding structures and dimensions
of G-quadruplex conformations: hybrid-1, hybrid-2, basket, and propeller. (C) Gquadruplex fold entered and unfold inside the nanocavity of α-hemolysin nanopore,
causing two distinct levels of blockage. (D) Except the propeller fold, all other Gquadruplex can enter the cis opening of α-hemolysin nanopore without unfolding, but
cannot pass through the pore constriction.114 (E) Models of the three conformations with
the additional 5’-dA25 tail unraveling through α-hemolysin pore. Both hybrid and basket
folds were able to enter the cis opening of the α-hemolysin pore, thus unraveled inside the
pore nanocavity. On the other hand, propeller fold, because of its size, could not enter the
nanopore. This conformation unraveled its structure outside of the pore, using the help of
the 5’-dA25 additional tail.105

Another inventive solution to capture and unravel G-quadruplexes is to employ a
25-mer poly-2’deoxyadenosine tail (d25A-tail) on the 5’ end of the telomeric DNA.
Applying this method, the Burrows group reported the analysis of various folding motifs
of the telomere sequence, with and without the 5’-d25A-tails.105 Among the four loop
topologies, only the basket fold was able to translocate through the nanopore without the
addition of the homopolymer tail to the 5’ end. For the G-quadruplex to move through the
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nanopore, it needs to unravel to a singular strand which would be able to translocate
through the narrow β-barrel, and the remaining G-triplex has to roll within the vestibule.
This is likely a favorable process for the basket fold because of its nearly spherical shape. 107
Even though the volume of the vestibule is large enough to accommodate all four Gquadruplexes within its cavity, the narrow entrance of the vestibule prevented the propeller
fold from entering the nanopore. However, with the addition of the 5’ tail, the propeller
fold was able to circumvent the problem of entering the cavity, and yet still had a very fast
translocation signature. This is attributed to the fact that the propeller fold was able to roll
outside of the vestibule while an electric force was applied to the dA25-tail as it threaded
through the ion channel, without having any molecular interactions or steric hindrance that
would have been experienced on the interior of the vestibule.105
In the light of those previous studies, for the first time, the unfolding kinetics of
human i-motifs were studied using the α-hemolysin nanopore. Under acidic conditions,
cytosine (C)-rich DNA sequences can adopt i-motif folds, since the hemi-protonation of
C- rich strands allow C+•C base pairs to form.54 The Ding et al. conducted experiments on
the human i-motif sequence at a constant ionic strength, but using various pH (5.0 – 7.2).
Since the dimension of an i-motif (2.0 nm x 2.0 nm) is smaller than the cis opening (~3.0
nm) of the α-hemolysin pore, it can enter the pore without unfolding and be captured in the
nanocavity.54 Hence, a d25A tail was attached to the sequence, in order to increase the
unfolding rate of i-motif. Upon the attachment of d25A, it was observed that at pH 5.0, the
folded structure entered the α-hemolysin pore, yielding characteristic current patterns.
However, when the pH were at 6.8 and 7.2 (higher than the transition pH 6.15), the
percentage of strands still folded was 4% and 2%, respectively. Furthermore, the force
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applied in this study was analogous to the forces exerted on genomic DNA by RNA
polymerases II (5-20 pN) and DNA helicase (6-16 pN).54 Hence, these studies strive to
show the potential of α-hemolysin as part of biosensor development, aiding in our
knowledge of the lifetimes of i-motifs of telomere sequences, and their biologically
relevant structures, which can be used as drug delivery targets for cancer treatments.108
These findings are steps toward a better understanding of the folding and unfolding
mechanisms of the telomere. When pre-detecting different cancer types, conventional
methods, such as FISH, Southern blot, and quantitative-PCR, require complicated metaanalyses, chemical-crosslinking and intensive preparation. This can lead to inconsistent
results.98, 109-111 Whereas nanopore analysis, lacking all those complications, allows a better
understanding of the kinetics and mechanisms, aiding in the analysis of how different
oxidation, stress and factors affect the length of telomeres, as well as the correlation
between cancer development and telomere immortality.
2.2.4 DNA methylations.
2.2.4.1 Hyper- and hypomethylation of CpGs. In humans, methylation of DNA is
an epigenetic modification that transfers a methyl group from S-adenosyl-methionine to
cytosine residues, forming 5-methylcytosine (5-mC). In mammalian cells, methylation of
CpGs can directly or indirectly repress gene expression. For example, hypermethylation of
CpG islands in the promoter region can directly lead to transcriptional silencing of tumorsuppressor genes. On the other hand, methylated CpGs can indirectly interfere with
transcription to prevent the binding of basal transcriptional machinery or ubiquitous TFs.
This process contributes to all of the typical hallmarks of a cancer cell originated from
tumor-suppressor inactivation.112 With aging, cell deregulation provides mutation
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accumulation and epigenetic alterations (i.e. aberrant methylation in DNA) the chance to
build up, causing proliferative advantages and genomic instability. Aberrant DNA
methylation, including loss of methylation (hypomethylation) and gain of methylation
(hypermethylation), has been classified as a common causal factor of many cancers.113-117
For instance, hypermethylation is linked to various types of cancers, including lung,
prostate, breast and colon cancers,118-121 while hypomethylation of CpGs has been reported
to be associated with kidney, liver, pancreas, lung, cervix, stomach and uterus cancers.122127

Hence, detecting aberrant DNA methylation can have an important role in cancer

treatment and precancerous detection.37, 56
The overall level of 5-methylcystosine contained in the cell sample can be
quantified using high-performance liquid chromatography (HPLC), high-performance
capillary electrophoresis (HPCE), bisulfite sequencing, methylation-specific PCR, among
many other methods.128-134 However, these methods have certain drawbacks. For example,
although HPLC and HPCE can accurately quantify the total amount of methylated CpGs,
they have incomplete restriction enzyme cutting, offer limited region of study, require
substantial amounts of high molecular weight DNA, and are labor intensive. Similarly,
with PCR-based methods, only the methylation status of CpG sites that are complementary
to the primers can be interrogated. Thus, the predominant methylation patterns in the
sample may not necessarily reflect the actual results (false positive results).
With nanopore analysis, current methods used in the detection of aberrant CpGs
methylation usually employ either a methylation specific labeler, or an electro-optical
tagging.56-57, 135 The first method, as proposed by Shim et al., employs an engineered
methyl-CpG-binding domain protein (i.e. MBD1x or Kaiso Zinc Finger proteins) as a
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selective labeler to detect and quantify hypermethylated CpG sites in double-stranded DNA
(dsDNA) ).56,

135

As the DNA translocated through the nanopore, the presence of 5-

mC·labeler complexes caused a signature current blockage, allowing the detection and
coarse quantification of 5-mC sites on a single molecule.135 Indeed, this method set an
initial application in screening for the presence of hyper- and hypomethylated DNA.
Moreover, Shim et al. pointed out that with the versatile binding affinity of KZF to various
methylation patterns, the studied assay can allow various patterns to be screened.56 Since
nanopore analysis requires low volumes of DNA for testing, the technique will be more
applicable and practical for clinical use. Without the need of DNA replication and
amplification, detecting CpG methylation using nanopores requires much less labor in
comparison to other conventional methods.
The second method, as previously discussed, uses an electro-optical solid-state
nanopore to detect and quantify hypomethylation in DNA.57 In this approach, enzyme
DNA MTases was assisted by small molecular weight synthetic cofactors to catalyze a onestep enzymatic reaction. This enzyme-cofactor complex was directly conjugated onto
fluorescent probes and attached to the unmethylated CpG sites. The Meller group was able
to detect and differentiate between fully methylated, partially methylated and unmethylated
dsDNA, using ultrasensitive electro-optical nanopore sensing as the tool for singlefluorophore multicolor quantification. Unlike MBPs, DNA MTase only labeled
unmethylated CpG sites of the target DNA. This allowed the direct targeting of
hypomethylated CpG sites in the genome (i.e. promoter regions of oncogenes).
Furthermore, this electro-optical solid-state nanopore showed a high potential for
employing multiple DNA MTases and other epigenetic biomarkers. With the aid of those
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biomarkers, orthogonal labeling/sensing of 5-mC can be achieved in the future.57 Further
research must be done in order to develop a calibrated scale to count the number of
unmethylated CpGs in the target sequence.
2.2.4.2 Other variants of CpGs methylations. The family of Ten-Eleven
Translocation (TET) proteins have been shown to oxidize methylcytosine (mC) into
hydroxymethylcytosine (hmC) and further oxidize hmC into formylcytosine (fC) and
carboxylcytosine (caC) (Figure 5).136-139 5-hmC normally exists at a high level in selfrenewing and pluripotent stem cells.136,
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Both mc and hmC influence mammalian

embryonic stem cell maintenance,141-142 angiogenesis,143 and development.144 Thus, hmC
is a promising molecular biomarker with predictive and prognostic value.145 As for fC and
caC, there is still very little research being done. Because the topic has just recently been
discovered, we currently lack a robust method to distinguish between these five chemical
modifications of cytosine. Even distinguishing between mC and hmC is a challenge for
available methods.142, 146
The presence of bulk 5-methylcytosine (5-mC) and 5-hydroxymethylcytosine (5hmC) on ss- and dsDNA has been successfully detected and distinguished using both solidstate and biological nanopores.147-149 For instance, the Drndic group proposed a method
using solid-state nanopore to discriminate two different structures that translocated through
the pore (5-mC and 5-hmC). Upon the addition of 3kbp dsDNA, a sequence of current
blockage was generated, in which the magnitude of each spike was related to the excluded
volume of biopolymer that occupies the pore. From the differences in ΔImax values, Wanunu
et al. was able to discriminate between 5-mC and 5-hmC. Shorter end-to-end distance of
the more polar 5-hmC indicated an increased flexibility in 5-hmC comparedg to cytosine
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and 5-mC. Moreover, it was shown that different proportions of 5-hmC in DNA fragment
containing cytosine and 5-mC can be quantified using ionic current signal.147 The second
device used in the detection of CpG methylation variants employed both the wild-type
phi29 DNA polymerase (phi29 DNAP) and MspA in the same assay.148-149 With this unique
approach, the Wescoe et al. reported a direction detection of all five cytosine variants (C,
mC, hmC, fC and caC). In this single-molecule tool, a phi29 DNA polymerase drew
ssDNA through the pore in single-nucleotide steps and the ion current through the pore
was recorded.148 Overall, the single-pass call ranged from approximately 91.6% to 98.3%
depending on neighboring nucleotides.148-149 Because the knowledge of the five cytosine
variants, especially fC and caC, is still very limited, the possibility of these variants having
an impact on genome-wide demethylation or other modifications in cancer cells should not
be eliminated.
These studies have shown nanopore analysis potential as a robust and efficient tool
for the study of DNA methylation. The technique can directly detect CpG methylation
without the need for DNA amplification or complicated preparation processes. Due to its
special characteristics, methylation of CpG is usually erased during replication and
amplification. Hence, nanopore analysis could be a more practical and reliable method to
screen and detect aberrant DNA methylation in cancer patients.
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Figure 5. Distinguishing variants of cytosine with biological and solid state nanopores. (A)
Chemical structures of cytosine and its variants. First row: mC (left) and fC (right). Second
row: cytosine. Third row: hmC (left) and caC (right).123 . (B) Schematic of the Phi 29
DNAP-MspA complex. MspA pore constriction is shorter and narrower compared to αhemolysin(as shown in the top), allowing short subtle structural changes to be
distinguished. (C) A typical trace of DNA translocation through the Phi 29 DNAP – MspA
complex.122 (D) Detection of DNA methylation with methyl binding proteins (MBP) using
solid state nanopore. MBPs bind to methylated CpGs on DNA, allow the detection and
differentiation between unmethylated, hypermethylated and locally methylated DNAs. (E)
Detection of DNA methylation with optical-tagging using solid-state nanopore.

2.2.5 Histone-DNA modification. Aberrant DNA-methylations are also linked to
the presence of aberrant modifications in histones,150-154 which are the gene activity’s
dynamic regulators. Histones go through several post-translational modifications, such as
acetylation, methylation, phosphorylation, ubiquitylation and others. Specifically,
methylation and acetylation of lysine residues on the nucleosomal core histones play an
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essential role in gene expression and chromatin structure regulation.155 In normal cells,
histones in DNA sequences are hypoacetylated and hypermethylated. The two key
regulators of histone modifications are histone deacetylases and histone methyltransferases
(MTases), which are associated with methyl-binding proteins (MBPs) and MTases.155-157
Several studies have been conducted on the translocation or unravelling of a
nucleosome and its subunit structure through nanopore.158-160 Generally, it was found that
DNA-histone complexes lead to higher applied voltage required and overall longer time
periods to translocate through the nanopore, most likely due to either: (1) the bulky disk
shape nucleosome experiencing a higher drag force comparing to a bare dsDNA, (2) the
positively charged histone core lowering the total net charge density of nucleosomes,
causing the translocation speed in electrophoresis to reduce, and (3) the unwinding process
of histone-DNA complex.159, 161
As previously discussed, epigenetic modifications have been known to affect the
structural integrity and stability of nucleosomes. Given this fact, it was hypothesized that
methylation of CpGs on dsDNA would affect the way nucleosomes fold and/or unravel.
To test this hypothesis, the Langecker et al. investigated the influence of DNA methylation
on the stability of unlabeled mononucleosomes.160 Similar to the results reported in other
studies, under the electrophoretic force, the nucleosomal DNA tail entered the pore and
gradually unraveled under increasing voltage, which was much higher in comparison with
free DNA capture.162 This experiment was repeated on nucleosomes with and without
methylated DNA sequences, yielding that methylation of CpGs did not affect the
nucleosome assembly, stability, or unraveling trajectories. This finding suggested that
histone modifications (e.g. acetylation and phosphorylation) play a much more dominant
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role in nucleosomal maintenance than DNA methylation. The confirmation of methylationindependent nucleosome stability indicated other possible mechanisms by which DNA
methylation alters gene expression, for example, modulating the binding of transcription
activators/repressor.160
The nanopore-based studies outlined herein lay the groundwork for understanding
and predicting the influence of different histone core modifications on the nucleosome
structure,160 about which our knowledge is still quite limited. Unlike conventional methods
(e.g. single-gene chromatin immunoprecipitation (ChIP), ChIP with a DNA array (ChIPon-chip),163-164 HPLC, HPCE, and many others), nanopore devices are more versatile,
because they do not rely heavily on the quality of the polyclonal antibodies or antibodies
that are available.154 Although the study here indicated that DNA methylation does not
affect the nucleosome assemble, further studies need to be done in order to confirm the role
of DNA methylation in other processes (i.e. regulating transcription activators/repressors
binding, or gene expressions), as well as the relationship between acetylation and
phosphorylation on nucleosome assembly and chromatin stability.
2.2.6 MicroRNA. MiRNAs are small endogenous biomolecules that are in length
of 18-22 bps. They play an important role in embryonic differentiation, hematopoiesis,
cardiac hypertrophy and numerous cancer-related processes, including proliferation,
apoptosis, differentiation, migration and metabolism.165-166 Because a single miRNA can
target up to hundreds of mRNAs,167 an aberrant miRNA expression may affect several
transcripts and cancer-related signaling pathways. In cancer cells, because of the genetic
diversity of tumors and cancer cell lines, an individual miRNA can be up-regulated in one
type of cancer and down-regulated in another.167 Overall, miRNAs function depends on
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their targets within the specific tissue.3 Usually, the up-regulated miRNAs function as
oncogenes by down-regulating tumor-suppressor genes, while the down-regulated
miRNAs function as tumor-suppressor genes by down-regulating oncogenes.
Detection of miRNAs faces several challenges, mainly due to the short length of
miRNAs. Some quantitative methods have been applied to miRNA detection with
enhanced sensitivity and/or selectivity, including quantitative reverse transcription realtime polymerase chain reaction (qRT-PCR) assays, microarrays, colorimetry,
bioluminescence, enzyme turnover, electrochemistry, molecular beacons, deep sequencing
and single-molecule fluorescence.168-171 Unfortunately, these techniques incur DNA
amplification errors, unavailable internal controls, and cross-hybridization. Also, the short
sequence of miRNAs makes the designing of probes and primers even more challenging.168,
170

MiRNAs have been investigated as potential molecular biomarkers, because their
expression levels are associated with various diseases.172 For instance, each year, lung
cancer causes approximately 1.2 million deaths worldwide.173 Since there is no effective
screening procedure available, more than 70% of lung cancer patients were diagnosed with
less than a 15% chance of a 5-year survival rate.173 More than 100 types of miRNAs have
been identified to deregulate lung cancer progression.172 Noticeably, high levels of miR155
and low levels of let-7a-2 have been associated with a significantly poor prognosis and
shorter survival times in lung cancer patients.174-175 Many research groups have used
biological and solid-state nanopores for the detection of miRNAs in different tissues
(Figure 6). For example, the solid-state nanopore was used for rapid detection of probespecific miRNAs (miRNA-122a and miRNA-153).176 Specifically, for every 1 fmol of
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miRNA duplex per mL solution, the capture rate was 1 molecule per second. In this study,
the p19 protein from the Carnation Italian ringspot virus was used to enrich miRNA-122a
and miRNA-153. Since miRNA concentrations were 1% relative to other cellular RNAs, to
detect a specific miRNA using a nanopore sequence, an enrichment step was required. 176
p19 binds 21-23bps dsRNA in a size-dependent, but sequence-independent manner.
Additionally, the highly affinitive and selective viral p19 protein does not bind ssRNA,
tRNA or rRNA. This eliminates the possibility of false results from mismatched binding. 177
Detection of 250 molecules in 4 minutes was sufficient to determine miRNA concentration
with 93% confidence.176
A different approach from using viral proteins for probe-specific miRNAs detection
is to employ an engineered-probe with a programmable sequence to differentiate single
nucleotide differences in miRNA family members.172 Wang et al. proposed a system that
enabled sensitive, selective, and direct quantifications of cancer-associated miRNAs in the
blood. In this study, the group constructed a robust protein nanopore-based sensor that
utilized an oligonucleotide probe (P155) to detect aberrant expression of miRNA-155 and
let-7a-2 from lung cancer patients.172 The generated signature electrical signals provided a
direct and label-free detection of the target miRNA in a fluctuating background, such as
plasma RNA extract.172 Probe (P155) has a programmable sequence and can be optimized
to achieve high sensitivity and selectivity. Additionally, using chemical modifications,
distinct probes can further be engineered with specific barcodes, allowing multiple
miRNAs to be simultaneously detected. Furthermore, with the development of miRNA
markers, manipulatable miRNA profile detection nanopore arrays can be constructed for a
noninvasive screening and early diagnosis of cancer.172
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Figure 6. Detection of a miR-155 using using solid-state and biological α- Hemolysin
nanopores. (A) Schematic of miRNA detection with viral proteins for probe-specific
miRNA, using solid-state nanopore. Protein from Carnation Italian ringspot virus was used
to enrich miRNA form background fluid. (B) Detection of probe-specific miRNA using
alpha-hemolysin biological nanopore. MiRNA-155 (shown in red) was attached to a DNA
P155 probe (shown in green). (C) At 8.0 pH and 100mV, translocation of the miRNA155P155 resulted in various current blockage patterns. (C) A typical current blockade with
three characteristic blocking levels, representing the mechanism of miRNA-155P155
complex dissociation and translocation through the pore (as shown in the right-hand
side).176

Compared to qRT-PCR assays, microarrays, colorimetry, bioluminescence, and
other current methods,168-171 nanopore arrays is a simpler, faster method that can be utilized
to detect miRNAs in cancer patients. This approach lacks all the complications that
conventional methods have, such as DNA amplification errors, unavailable internal
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controls, and cross-hybridization. Early detection is one of the most crucial contributors to
a higher survival rate, especially lung cancer patients.173
2.3 Summary and Conclusion
In this chapter, we have concisely reviewed the main genetic and epigenetic causal
factors of cancer, as well as summarized how nanopore have been used in the research of
each factor (Table1). Thanks to several unique features of this emerging technology, the
nanopore-based analysis offers four main benefits: First, nanopore analysis offers long
reads of genomic DNA (>10 kB). Therefore, linkages between modified cytosines may be
revealed that are biologically significant and otherwise difficult to discern. For example, it
was shown that histone-DNA interaction is not affected by methylation of DNA. Also, for
the first time, differences between caC, fC, and hmC from mC were successfully
distinguished. Second, the genomic DNA is read directly as it transports through the
nanopore. Thus, errors (false-positive results) caused by copying do not occur. Third, with
biological nanopore membranes, the study of biomolecules’ folding-unfolding kinetics and
mechanisms are possible to accomplish. Furthermore, the DNA fragment can be retained
in nanopore indefinitely, allowing rereads of a captured DNA fragment.149 Finally, many
conventional methods are still impractical for clinical testing, because these methods
require highly trained experts, intensive labor, a high capital cost, and a large footprint.
With nanopore technology, there are no such requirements, offering more flexibility and
practicality for research labs and clinics.
Although the concepts of nanopore analysis in early cancer detection are
exceptionally promising, several key technological challenges must be addressed before
this method can be implemented in clinical uses. First and foremost, the biggest drawback
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of nanopore-based methods is high mismatch and error rates. Because the nanopore
membrane thickness, especially with respect to biological nanopores, is relatively large
compared to a nucleotide, nanopore sensitivity is still low at the single-nucleotide level.
Furthermore, even though different DNA conformations and foldings yield distinguishing
characteristic current blockades, information about the molecular structure cannot be
determined by nanopore membrane alone in order to confirm the exact structure that causes
a signature blockades.
In utilizing nanopore technology, researchers need the aid of other equipment, such
as circular dichroism (CD), FRET, FISH, among many others. This limits the use of
nanopore membranes as an independent, stand-alone tool for molecular studies in general,
and early cancer detection, specifically. Moreover, since one single biological molecule
can quickly adopt multiple, complex conformations under different environments, many
research groups choose to use short/simplified sequences in their nanopore studies. Hence,
the complexity of cancer cells has not yet been demonstrated and/or fully investigated with
nanopore membranes.
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Table 1
Summary of nanopore applications in detecting cancer markers
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Chapter 3
Biophysical Properties of DNA - Investigation of Compacted DNA Structures
Induced by Na+ and K+
3.1 Abstract
DNA compaction is a highly promising method for gene therapy and delivery.
Experimental conditions to induce these compacted DNA structures are often limited to
the use of common compacting agents, such as cationic surfactants, polymers, and
multivalent cations. In this study, we showed that in highly concentrated buffers of 1M
monovalent cation solutions at pH 7.2 and 10, biological nanopores allowed real-time
sensing of individual compacted structures induced by K + and Na+, the most abundant
monovalent cations in human bodies. Since the binding affinities of each nucleotide to
cations is different, the ability of a DNA strand to fold into compacted structure depends
highly on the type of cations and nucleotides present. Our experimental results were
favorably comparable to findings from previous molecular dynamics simulations for DNA
compacting potential of K+ and Na+ monovalent cations. We estimated that the majority of
single-stranded DNA molecules in our experiment were compacted. From the current
traces of nanopores, the ratio of compacted DNA to linear DNA molecules was 30:1 and
15:1, at a pH7.2 and pH10, respectively. Our comparative studies revealed that Na +
monovalent cations had a greater potential of compacting the 15C-ssDNA than a K+ cation
did. This chapter was adapted from our previously published paper (Vu, Trang, ShannaLeigh Davidson, and Jiwook Shim. “Investigation of compacted DNA structures induced
by Na+ and K+ monovalent cations using biological nanopores.” Analyst 143.4 (2018):
906-913.)
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3.2 Introduction
In an aqueous solution, DNA is a long, highly charged polymer, and is usually in
an elongated conformation due to strong repulsion forces between the negatively charged
phosphate groups on the DNA backbone.178 Upon the addition of compacting agents, DNA
can quickly go through a conformational change, mainly due to the neutralization of
negatively charged DNA through cation binding.178-179 Interaction of cations with the DNA
phosphate backbone has been known to induce several DNA phase separation processes,
including DNA compaction, condensation, aggregation, and precipitation, without a clear
distinction between these processes.180 Previous literatures have intensively studied and
reviewed several in vivo and in vitro compacting agents, including multivalent cations,181
polycations,182 neutral polymers,183 cationic nanoparticles,184-185 and surfactants.186-188 In
addition, the presence of monovalent cations can also promote DNA compaction processes
in both concentrated and diluted solutions of DNA.180, 189-195 Several previous studies have
investigated the role and mechanism of cations in the process of binding and compacting
DNA.184-185 However, the existence of the DNA compacted structure has not been
discussed in the nanopore analysis setting yet, mainly due to the complex quantumchemical mechanism of the DNA compaction process.
In this chapter, we used 𝛼-hemolysin NPs to capture the cations-induced compacted
structure of a single-stranded DNA with a specific sequence containing only cytosine
nucleotides (5’-(CCC)5-3’). In order to investigate the ability of Na+ and K+ monovalent
cations as compacting agents for ssDNA, studies were conducted with buffers containing
high salt concentration at various pH values.
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3.3 Methods
3.3.1 Chemicals. Chemicals and reagents used in the experiments were purchased
from the following vendors: 1,2-diphytanoyl-sn-glycero-3-phosphocholine (Avanti Polar
Lipids); pentane (Sigma-Aldrich); potassium chloride (99.5%, Sigma-Aldrich); sodium
chloride (Sigma – Aldrich); Tris base (Promega); Ethylenediamine Tetraacetic acid
(EDTA) disodium salt dehydrate electrophoresis crystalline powder (Fisher BioReagents);
agarose (Bio-Rad); pentane (Fischer Chemical), hexadecane CH3(Ch2)14CH3 (Avantor);
and hydrochlodric solution 1M (LabChem). Synthetic oligonucleotides (Integrated
Technology) with the following sequences were used: 5’-CCC CCC CCC CCC CCC – 3’.
The

control

sample

is

an

18-bases

ssDNA

with

the

sequence

of

5’-

TAATCATCGCGTACTAAT-3’. Salt solutions were buffered with 10mM Tris and
titrated with HCl until the required pH of 5.0, 7.2, or 10.0. DNA solutions were suspended
in a buffer solution containing 10mM Tris, 1mM EDTA, pH 8.0 at room temperature before
usage.
3.3.2 Circular dichroism. CD spectra were collected using the Jasco CD
spectropolarimeter, model J-810. All measurements were measured at 15oC as maintained
by the temperature-control units affiliated to the spectrometer. All samples used for CD
measurements contained the same salt (1M) and ssDNA (1 𝜇M) concentrations, as used in
the single-molecular study. Spectra were captured in the 220-320 nm wavelength, 1.0 nm
bandwidth, 50 nm/min scanning speed, and a standard sensitivity.
3.3.3 Experimental setup. The experiments herein were performed following
previously described protocols.45, 196-198 Briefly, a Teflon film divides the testing chamber
into two separate compartments, named cis and trans chambers, to which negative and
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positive electrodes are attached to, respectively. Artificial lipid bilayer, acting as an electric
insulation, is formed over a premade orifice of 100𝜇m in diameter in the Teflon film. 𝛼hemolysin (𝛼-HL), a toxin released by the Staphylococcus aureus bacterium, is well known
for its ability to form a mushroom-shaped protein channel with a well-defined structure, as
well as dimensions. Specifically, the 𝛼-HL consists of a cis-opening (2.6nm), a nanoconstriction (1.4nm), and a trans opening (2.0nm).52 When 𝛼-HL protein is introduced to
the cis chamber, it can insert a mushroom-shaped channel into lipid bilayer, connecting the
cis and the trans sides. DNA or any other charged biomolecules are then injected to the cis
chamber. Under an applied current, DNA molecules are driven through the 𝛼-HL
nanopore, causing a current-drop (blockage). A lipid bilayer, 1,2-diphytanoyl-snglycerophosphatidylcholine (Avanti Polar Lipids), was formed spanning the hole, creating
a planar layer of insulation. The cis and trans chambers were both filled with symmetrical
salt solutions of 1M concentration, containing either NaCl or KCl as per the testing
conditions. The protein nanopore, α-hemolysin, was injected into the bilayer on the cis side,
creating a single open channel joining the two chambers. A final concentration of 1 𝜇𝑀
15C-ssDNA was introduced to the cis chamber. Ag/AgCl electrodes (1.5% Agarose in 3M
KCl) was attached to each of the cis and trans chambers, with the cis chamber being
grounded such that a positive voltage would drive the negatively charged DNA molecules
through the nanopore channel and into the trans chamber. Data acquisition included an
electrophysiological setup, with picoampere (pA) current traces being recorded as DNA
molecules moved through the single channel.
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3.3.4 Single channel analysis. An Axopatch 200B patch-clamp amplifier was
employed with Clampex 10.7 software (Molecular Device Inc.) to record and acquire data
through a Digidata 1550B A/D converter (Molecular Device Inc.) at a sampling rate of 20
kHZ, and an analogue, eight-pole, low-pass Bessel filter of 5kHz. The data were analyzed
using Clampfit 10.7 (Molecular Device Inc.), and Excel (Microsoft). Single-channel
currents were determined using amplitude histograms by fitting the peaks to Gaussian
functions. Dwell-time histograms fitted to an exponential distribution allowed us to
determine the duration of short-lived blocks for DNA translocation. Molecular modeling
and chemical structures were created using Maestro (version 2015-4, Schrödinge Suite).
All graphical presentations were organized and cleaned up using Illustrator (Adobe).
3.4 Results and Discussion
We chose single-stranded 15-mer oligonucleotides consisting only of cytosine,
annotated as 15C-ssDNA, as a proton-sensitive DNA strand to study the compacted DNA
structure. To emphasize the unique characteristic of 15C-ssDNA to adopt compacted
structures, control experiments were performed on an 18-bases ssDNA sequence
(containing all four nucleotides: A, T, C, G). Previous studies have shown that C-rich
ssDNA has the ability to form i-motif structures under slightly acidic environments (below
the transitional pH 6.15), and sustain in linear form under neutral or basic environments
(pH higher than 6.15).199-202 Thus, the cytosine-only sequence chosen for the current study
makes this DNA molecule highly improbable to form stem-loop intramolecular base
pairings (i.e. compacted structures) at pH ≥ 6.15. Moreover, a previous study showed that
using solid-state nanopore, the probability of DNA knots observed in long DNA molecules
(~2kbps) is 1.83%.203 Thus, the short length of the chosen sequence rules out the possibility
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of DNA knots formation in this study. All experiments herein were conducted with 15CssDNA, under constant electrophoretic forces at 100, 120, or 140mV, and symmetrical salt
concentration of either 1M NaCl or 1M KCl in both cis and trans chambers. Buffers with
various pH levels at 5.0, 7.2, and 10 were used in the experiments in order to investigate
the effect and compaction potential of monovalent cations on both folded and unfolded
single-stranded DNA. All events are characterized by their current blockage amplitude
(%Ib/Io, where Ib and Io are current amplitudes of the blocked and the empty pore),
translocation time through the nanopore (𝑡𝑏 ), and frequency (𝑓). All buffers are prepared
with 10mM Tris and 1mM EDTA and, hereafter, all buffers are named according to the
type of cation present (either K+ or Na+) and pH level of the buffer. For example, Na5.0
indicates 15C-ssDNA sample in 1M NaCl at pH 5.0. Current – voltage (I-V) curves of all
experiments fit the characteristic shape of the 𝛼-hemolysin nanopore I-V curve (Figure 7).

Figure 7. IV curves of the experimental conditions, containing 1M of either KCl or NaCl,
at 7.2 and 10 pH. All I-V curves fit the characteristic I-V plot of an -hemolysin nanopore.
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3.4.1 Effect of monovalent cations on the folded, i-motif DNA structure. To
analyze the nanopore ionic current signal for the fully-folded i-motif structure, we first
examined the translocation properties of 15C-ssDNA at pH 5.0 in both K5.0 and Na5.0
buffers. At pH 5.0, when the 15C-ssDNA was added to the cis chamber, and
electrophoretically driven through the 𝛼-hemolysin NP at 100, 120, and 140mV, long-lived
partial current blockage events were observed in both K5.0 and Na5.0 samples (Figure 8),
indicating the presence of i-motif inside the nanopore. Capture and analysis of the fully
folded i-motif structure in K+ environment has been investigated using α-hemolysin
nanopore before.54 Under slightly acidic conditions, the cytosine-rich DNA sequence
becomes hemi-protonated, allowing for the formation of the i-motif structure (Figure 8A).
This i-motif structure is approximately 2.0 x 2.0nm in diameter, 54 thus smaller than the cis
entrance to the mushroom-head shape nanocavity, but larger than the constriction and βbarrel of the nanopore. Thus, the folded structure of i-motif can enter the channel and reside
in the nanocavity. Then the folded i-motif structure can either exit back to the cis opening
or translocate through the nanopore to the trans side after unfolding in the nanocavity. The
process can last up to several seconds or minutes, causing event blockades with different
durations and amplitudes, as shown in Figure 8B (K5.0 and Na5.0), with no real statistical
difference between dwell times of i-motif structure in K+ and Na+ environments at pH 5.0.
Our data herein are fully consistent with previous studies, which demonstrated that halflife, 𝑡𝑓1/2 , of the i-motif structure at pH 5.0 can vastly vary from seconds to minutes.204-205
In these studies, 𝑡𝑓1/2, of a i-motif structure represents the amount of time it takes for half
of the sample population to become folded.205
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Figure 8. Formation of i-motif at pH 5.0. (A) Under slightly acidic conditions, the cytosinerich DNA sequence is hemi-protonated, and can adopt an i-motif structure. (B) reflects the
residence of i-motif structure inside the NP for both samples, containing either 1M KCl
and 1M NaCl, at pH 5.0. The residence of i-motif structure inside the nanocavity causes
current blockages that can last up to several seconds or minutes, with %I/Io ~ 50-60%. No
event with %I/Io < 30% was observed in both samples (K5.0 and Na5.0). (C) Circular
dichroism measurement confirmed the existence of i-motif at pH 5.0 in both K5.0 and
Na5.0 samples, which show a typical positive peak at 285nm and a negative peak at 265nm.
Other samples at higher pH do not exhibit the i-motif characteristic peaks. Overall, the
main differences in CD spectrum are between samples with a different pH, but not between
those containing different types of cations (K+ versus Na+) . Samples were labelled per the
type of cation in the buffer (either K+ or Na+), followed by the solution pH value (i.e, Na5.0
means experiment was conducted in 1M NaCl buffer solution, pH 5.0).

Circular dichroism (CD) spectroscopy analysis in our laboratories confirmed that
the DNA molecules K+ and Na+ buffer solutions reveal a typical i-motif conformation only
at low pH of 5.0 (Na5.0 and K5.0 samples), but a random coil at neutral and high pH
(Na7.2, K7.2, Na10 and K10 samples). Specifically, the CD spectrum of both Na5.0 and
K5.0 samples showed a strong positive peak near 285nm, a negative peak near 262nm, and
a cross over at 275nm, indicating the definite presence of i-motif structure in the
solutions.206 In contrast, at pH 7.2 and 10.0, all of the samples (Na7.2, Na10, K7.2, and
K10) exhibited a dramatic decrease in the CD signal and completely lost the characteristic
i-motif peaks. In general, the i-motif characteristic peaks were not present in samples with
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a higher pH, thus confirming that differences in CD spectra are due to differences in pH,
and not due to usage of different cations (K+ versus Na+) in samples. The results obtained
from the event data traces of K5.0 and Na5.0 (Figure 8B) and CD spectrum indicate that
under slightly acid conditions (pH 5.0), there is an absence of compacted DNA structure
going through the α-HL NP. The binding (or lack thereof) of monovalent cations to ssDNA
does not induce DNA compaction at pH level of 5.0. Thus, it is hypothesized that the C+C base pairing has a significantly higher affinity and can last much longer than cation-DNA
binding. Currently, it is unclear whether or not the binding of monovalent cations can slow
down the translocation speed of a fully-folded i-motif structure through the nanopore.
3.4.2 DNA compaction induced by 𝐊 + and 𝐍𝐚+ monovalent cations. In order to
investigate the effect of monovalent cations on ssDNA compaction, single-channel
nanopore analysis of the fully unfolded, linear 15C-ssDNA was conducted at pH 7.2 and
10 (Figure 9 and Figure 10). In an earlier single-channel study of C-rich DNA
translocation, it was shown that as the pH level was raised to above 6.15, most i-motif
structures unfolded into linear DNA, resulting in mostly short-lived blockage events.54.
Indeed, we observe a similar characteristic trend of unfolded, single-stranded DNA
translocation (%Ib/Io ≥ 80%) in all samples at both pH 7.2 and 10. However, in contrast to
the previous finding with specific sequencing of i-motif, our experimental data with
cytosine only sequencing DNA oligos exhibited two types of blockages: Type 1 is the
translocation events of linear ssDNA (%Ib/Io ≥ 80%), and Type 2 events are caused by the
encounter of DNA compacted structures with the cis opening of the nanopore (%Ib/Io ~
30%), as shown in Figure 9A-B and Figure 10A–B. A transmembrane voltage (+100mV)
was applied from the trans side, with the cis side grounded
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Figure 9. DNA translocation through nanopore at pH 7.2. Data traces of (A) K7.2 and (B)
Na7.2 were collected at 120mV applied current. Both samples exhibit two main types of
events: Type 1 are translocation events of DNA (%I/Io > 70%), and Type 2 are DNA
compacting events (%I/Io < 70%), caused by the encounter of DNA compacted structure
with the NP. (C) Correlation between amplitudes of current blockages and their dwell time
K7.2 (blue) and Na7.2 (red). All DNA compacting events have very short dwell times,
whereas deeper-current blockages can last several seconds in both type of cations (K+ and
Na+). The number of events observed in Na7.2 is slightly higher than in K7.2. Similar
results were obtained through the events frequency analysis for both (D) DNA compacting
events and (E) translocation events. (F) Correlation between the %I/Io and the applied
current
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Figure 10. DNA translocation through nanopore at pH 10. Data traces of (A) K10 and (B)
Na10 were collected at 120mV applied current. Both samples exhibit two main types of
events: Type 1 are the translocation events of DNA (%I/Io > 80%), and Type 2 are DNA
compacting events (%I/Io < 30%). (C) Correlation between amplitudes of current
blockages and their dwell time K10 (blue) and Na10 (red). All Type 2 events exhibite short
dwell times, whereas deeper-current blockages can last several seconds. Similar results
were obtained through the events frequency analysis for both (D) DNA compacting events
and (E) translocation events. (F) Correlation between the %I/Io and the applied current.

Hereafter, Type 2 events are also referred to as “DNA compacting events.” All
samples were captured at a sampling rate of 50 μs, and at any given voltage (100, 120, or
140mV), Type 2 events exhibit a significantly shorter dwell time (t cb ~ 100us) and smaller
current-blockage amplitudes than Type 1 events, forming two distinct clusters of event on
the amplitudes-dwell time scatterplots (Figure 9C and Figure 10C). Interestingly, as the
voltage ramped from 100 to 140 mV, a decrease in %Ib/Io is observed for Type 1 events
(Figure 9F and Figure 10F). For the control experiment, Type 1 events show a significant
increase in event occurrence, while Type 2 events cannot be observed (Figure 11 and
Figure 12). This result indicates that the control sample (18-bases ssDNA) cannot adopt
the compacted structure. Events with %I/Io ~ 50% are suspected to be the stem-loop
structures (hairpin) formed by nucleotides base-pairing (A-T and C-G) within the ssDNA.
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Figure 11. Negative control experiment at pH 7.2. (A) Event data traces of Control K7.2,
Control Na7.2, K7.2, and Na7.2. The control sample is an 18 bases ssDNA containing all
four nucleotide base types (A, T, C, G). The absence of shallow blockage event (%I/Io <
30) indicates the control sample’s inability to form compacted structures. (B) Scatter plot
represents the correlation between event blockage amplitude and dwell time of the CtrlK7.2 and Ctrl-Na7.2. The two event clusters indicate the presence of hairpin structure
(%I/Io ~ 50%) and the translocation of a linear ssDNA (%I/I ~ 90%). All events were
collected at 120 mV.

Figure 12. Negative control experiment at pH 10. (A) Event data traces of Control-K10,
Control-Na10, K10, and Na10. The control sample is an 18 bases ssDNA containing all
four nucleotide base types (A, T, C, G). The absence of shallow blockage event (%I/Io <
30) indicates the control sample’s inability to form compacted structures. (B) Scatter plot
represents the correlation between event blockage amplitude and dwell time of the CtrlK10 and Ctrl-Na10. The two event clusters indicate the presence of hairpin structure (%I/Io
~ 50%) and the translocation of a linear ssDNA (%I/I ~ 90%). All events were collected at
120 mV.
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3.4.3 Comparing between translocation and DNA compacting events. We
hypothesize that Type 2 events are produced by secondary structures, with dimensions
larger than 2.6nm (cis opening of the nanopore), and are the result of the DNA compaction
induced by monocations (K+ and Na+). Under electrophoretic force, these compacted DNA
structures are drawn toward the cis opening of the pore, but cannot translocate through due
to their large size, thus quickly bounce away. This process results in an abundant number
of short-lived blockages, with (%Ib/Io ~ 30%), and 𝑡𝑏𝑐 ~ 100𝜇s. At 120mV applied voltage,
the ratios between the frequency of Type 1 events and Type 2 events are approximately
1:36 (Na7.2), 1:29 (K7.2), 1:12 (Na10), and 1:14 (K10) (Tables 1 and 2). With increased
application of applied voltages, frequencies of both Types 1 and 2 also significantly
increased due to the high electrophoretic force. Most notably, as the voltage ramps from
100mV to 140mV, frequencies of Type 1 and Type 2 events rise approximately 2-fold, and
5- to 10-fold, respectively. Thus, single-channel analysis revealed that Type 2 events are
far more plentiful than Type 1 events in all four samples (Na7.2, K7.2, Na10, and K10),
implying that the abundancy of 15C-ssDNA was compacted by K+ or Na+ at pH 7.2 and 10
(Figure 9D-E and Figure 10D-E).

Table 2
15mer DNA event summary (pH 7.2)
Type 1 events
Type 2 events
I/Io (%)
∆t (ms)
𝒇(s-1)
I/Io (%)
∆t (ms)
𝒇(s-1)
Na7.2 85.4 ± 1.2 0.42 ± 0.02 0.38 ± 0.03 25.8 ± 6.7 0.1 ± 0.01 13.9 ± 8.48
K7.2 84. ± 1.8
0.42 ± 0.04 0.22 ± 0.02 29.5 ± 5.5 0.1 ± 0.01 6.34 ± 0.35
Note: All values were recorded at 120mV+ applied voltage.
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Table 3
15mer DNA event summary (pH 10)
Type 1 events
Type 2 events
I/Io (%)
∆t (ms)
𝒇(s-1)
I/Io (%)
∆t (ms)
𝒇(s-1)
Na10 81.8 ± 0.6 0.55 ± 0.09 0.29 ± 0.01 24.7 ± 5.8 0.09 ± 0.01 3.4 ± 0.65
K10
84.2 ± 1.7 0.37 ± 0.03 0.17 ± 0.01 23.7 ± 6.9 0.10 ± 0.01 2.4 ± 0.9
Note: All values were recorded at 120mV+ applied voltage.

3.4.4 Comparing DNA potential of K+ and Na+. Single-channel recordings of
the 15C-ssDNA reveal that, at both pH values of 7.2 and 10, most Type 1 events
(translocation of linear ssDNA) cause a current blockage, %Ib/Io, of ~ 80-86%. At 120mV
applied voltage, the ratios between Type 2 event frequencies, 𝑓 𝑐 (s-1), of Na7.2:K7.2 and
Na10:K10 are 2.188:1 and 1.409:1, respectively (Table 2 and Table 3). Thus, the results
indicate that between the two types of monovalent cations, Na+ has a higher compacting
potential for ssDNA.
Overall, the binding affinity and compacting potential of a monovalent cation to
DNA strands are characterized by several factors, including but not limited to: (1) its
hydrated radius, and (2) the chemical structure of the available nucleotides. 180, 207 It has
been shown that a smaller radius corresponds to stronger hydration, because the small size
of the hydrated cation allows for effective interactions with DNA because of higher
Coulomb electrostatic potential.180, 208 Subsequently, cations with a smaller hydrated radius
can bind to DNA stronger than those with a larger hydrated radius.180 In contrast, as a result
of partial dehydration of monocation in the compact state, higher binding affinity of cations
correlates to lower DNA compacting potential.180 Thus K+ has higher binding affinity, but
lower DNA compacting potential than Na+.180
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Moreover, previous studies have pointed out that due to the differences in their
molecular structures, the affinity for cations of the five nucleobases (guanine, adenine,
cytosine, thymine, and uracil) are also varied.209-212 Specifically, it was determined that the
affinity Na+ has for nucleobases, measured in kcal.mol-1, is 42.1 for guanine, 40.9
for cytosine, 31.3 for adenine, 33.0 for thymine, and 32.3 for uracil.210-211 With the aid of
exocyclic amino groups, guanine and cytosine can be involved in cation binding through
resonance effects; hence, have a much stronger cation binding than other nucleobases.211
In our present work, the chosen ssDNA sequence contains only cytosine, which is one of
the two nucleobases with the strongest binding affinity to Na+; thus, the effect of Na+ on
inducing DNA compaction is significantly enhanced. Thus, the difference in our results in
comparison to those of the previous group54 mainly arises from the characteristic affinity
of cations for nucleobases. The differences in event data traces caused by compacted and
non-compacted DNA can be seen in Figure 11 and Figure 12.
In the previous study, because the sample DNA strand also contained adenine and
thymine nucleotides,54 the effect of cation binding and thus, induced DNA compaction,
became much weaker and could not be observed with 𝛼-hemolysin nanopore (no Type 2
events). Thus, our findings in the current study fully agree with those from other
laboratories,180,

207

proving that Na+ monovalent cations have a greater compacting

potential on the 15C-ssDNA than K+ cation does.
3.5 Conclusions
In this chapter we have investigated the interaction of monovalent cations (K + and
Na+) with ssDNA using an 𝛼-hemolysin biological nanopore platform. Although many
studies have been done on capturing secondary structures formed by cytosine- or guanine-
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rich sequences, the focus of those studies was usually using nanopore technology to capture
the folding and unfolding of G-quadruplexes or i-motif structures. Thus, current-blockages
caused by compacted DNA structures in a solution can be easily overlooked or neglected.
Here, we presented our findings on the compacted structure of ssDNA induced by
monovalent cations using biological nanopore. The study herein lay the groundwork for
understanding and predicting the compacting process of ssDNA induced by monovalent
cations (K+ and Na+) in nanopore-based studies. Moreover, in the recent years, many
studies have been conducted to develop a nanocarrier for antisense oligonucleotides and
single-stranded siRNAs in drug delivery, as well as in cancer gene therapy.213-216 We
believe that the ability of monovalent cations to compact a short oligonucleotide, as
discussed in this current study, has a promising potential in the development of drug
delivery and gene therapy.
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Chapter 4
Investigation of Ckit1 G-Quadruplex Stability
4.1 Abstract
In this chapter, we investigated the formation of G-quadruplex on Ckit1 promoter
sequence, which plays an important role in several human malignancies. Ckit1 is a guaninerich sequence that can form stable G-quadruplex structures in the presence of cations,
causing gene downregulation and leading to suppression of cancer cell proliferation. Our
study evaluated Ckit1 G-quadruplex structural stability dependence on cations and CX5461. Conventional methods often utilize fluorescence spectroscopy and circular
dichroism to study CX-5461 efficiency on stabilizing G-quadruplex. However, these
methods cannot provide real-time molecular dynamic sensing of a structure’s
folding/unfolding behavior. This study utilized the nanocavity of a biological nanopore as
the main tool for single-molecule analysis of Ckit1 G-quadruplex. Specifically, Ckit1 Gquadruplex formation and stability with and without CX-5461 presence was analyzed using
α-hemolysin nanopore, circular dichroism and thermal denaturation. Our results showed
that Ckit1 G-quadruplex stability is cation-dependent (K+>Na+), resulting in longer
current-blockage events and significantly decreased event capture rate with K +. Addition
of CX-5461 drug enhanced Ckit1 G-quadruplex stability resulting in extended currentblockage events (seconds- to minutes-long) in nanopore study and a significantly increased
melting temperature. Using machine learning models, we were able to predict the binding
state of CX-5461 to Ckit1 G-quadruplex in an Na+ environment, with a 92.4% sensitivity,
70.3% specificity and 81.3% average accuracy, respectively.
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4.2 Introduction
G-quadruplexes are nucleic acid higher-order structures, made of one, two or four
guanine-rich DNA or RNA strands. G-quadruplex consists of stacked G-quartets, which
are cyclic arrangements of four guanines held together through Hoogsteen hydrogen bonds
and stabilized by a central cation (e.g. K+). G-quadruplex structures are frequently found in
the telomeres and gene promoter regions. To date, over 300,000 putative G-quadruplexforming sequences have been found in the human genome.217 These structures play a
functional role in regulating gene expression, controlling chromatin structure, and
destructing chromosomal stability.218-221 With more than 40% of human protein encoding
genes containing one or more putative G-quadruplex forming motifs in the promoter
regions, stabilizing G-quadruplex structures is a promising strategy to control gene
expression at transcriptional and translational levels.222
CKIT is a proto-oncogene encoding the Ckit transmembrane tyrosine kinase
receptor, which participates in the expression of genes, regulates cell differentiation,
proliferation, migration, and resists cell apoptosis.223-225 Overexpression and mutations of
the Ckit gene have been found in a number of cancers, including pancreatic, leukemia and
melanoma.226-228 Promoter region of the Ckit gene contains three guanine-rich regions that
can fold into stable G-quadruplex structures, known as Ckit1, Ckit2, and kit*.
For the Ckit proto-oncogene specifically, the presence of G-quadruplex structures
can prevent cancer cells from replicating. Stabilization of Ckit gene G-quadruplex has been
linked with inhibition Ckit tyrosine kinase receptor transcription and expression. This leads
to cell proliferation and cause DNA damage that would kill cells without nucleic acid
repair pathways, such as homologous recombination pathways.229 Thus, down-regulation
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of Ckit expression through stabilizing kit1 G-quadruplex is an attractive strategy for cancer
therapy.230-232 Certain molecules, such as CX-5461 (Figure 13), can bind and stabilize
Ckit1 G-quadruplex structures; thus, effectively blocking the replication of cancerous
cells.233 Upon binding to Ckit1 G-quadruplexes, CX-5461 reduces the binding affinity of
SL1 pre-initiation complex and RNA Pol I complex to rDNA promoters, leading to
apoptosis.234 This molecule was proven to be most efficient in tumorous cells that lack
DNA repair mechanisms such as the BRCA1 and BRCA2 tumor suppressor genes.235
In this study, we report the changes in formability and stability of Ckit1 Gquadruplex in the presence of K+ and Na+ cation. Through electrical current signatures, we
showed that binding of the CX-5461 molecule has a stronger stabilizing efficiency and
further alters the volume of Ckit1 G-quadruplex in an Na+ environment as compared to a
K+ environment. Ultimately, we employed a simple machine learning algorithm to predict
the CX-5461 bound/unbound G-quadruplex.
4.3 Methods
4.3.1 Chemicals and reagents. Chemicals and reagents used in the experiments
were

purchased

from

the

following

vendors:

1,2-diphytanoyl-sn-glycero-3-

phosphocholine (Avanti Polar Lipids); pentane (Sigma-Aldrich); potassium chloride
(Sigma-Aldrich); sodium chloride (Sigma

–

Aldrich); Tris

base (Promega);

Ethylenediamine Tetraacetic acid (EDTA); pentane (Fischer Chemical); and hexadecane
CH3(Ch2)14CH3 (Avantor). CX-5461 (Sigma Aldrich) was purchased in powder form,
and suspended in acetic acid (VWR). CX-5461 solution was then aliquoted and stored at
-20˚C.
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4.3.2 DNA samples. Synthetic single-stranded DNA oligos were designed and
purchased from Integrated DNA Technology (IDT – Coralville, IA). DNA oligos utilized
in this study had the following sequences:
Control (linear): 5’ – AGG GAT TTC GCT TTT AGG AGG G-3’
Ckit1: 5’ – AGG GAG GGC GCT GGG AGG AGG G-3’
Ckit1 2 tails: 5’– dT10 - AGG GAG GGC GCT GGG AGG AGG G - dT10 – 3’
Upon delivery, all DNAs were suspended in a standard DNA storage buffer
containing 10mM Tris, 1mM EDTA and titrated to 8.0pH. All samples were aliquoted into
small volumes and stored at -80˚C until usage, in order to prevent multiple thaw-freeze
cycles that can degrade and affect DNA quality. For both nanopore and CD experiments,
DNA final concentration of 1µM was used.
4.3.3 Experimental setup. We employed an electrophysiology setup and followed
a protocol described in previous studies.53, 236 Each experimental chamber was filled with
electrolyte solutions containing 1M KCl or 1M NaCl, buffered with 10mM Tris and 1mM
EDTA titrated to 7.2pH. α-hemolysin protein was inserted into the bilayer from cis side
forming a single-channel penetrated across the lipid bilayer. DNAs were inserted to the cis
side. For experiments with CX-5461, electrolyte solutions were titrated to 8.3pH, in order
to compensate for the acidity of CX-5461 solution.
4.3.4 Single channel recording. Single-channel recordings were performed using
Axopatch 200B (Molecular Device Inc.), filtered with a built-in 4-pole low-pass Bessel
Filter at 5kHz. Data were acquired with Clampex 10.7 (Molecular Device Inc.) and Axon
Digidata 1550B A/D converter (Molecular Device Inc.), at a sampling rate of 20 kHz. The
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data were analyzed using Clampfit 10.7 (Molecular Device Inc.), Excel (Microsoft) and R
software.
4.3.5 Data analysis and visualization. Events with %I/Io < 50% were considered
as brief interaction of DNA and the pore entrance, rather than DNA translocation; thus,
disregarded from data analysis.237 For every experimental condition, approximately 2000
DNA translocation events were included for the analysis. Event blockage amplitudes were
determined from amplitude histograms by fitting the peaks to Gaussian function. The
duration and occurrence of current-blockage event for DNA translocation were obtained
by fitting the dwell-time histogram to an exponential distribution. Data were given as the
mean ± SD, based on at least three separate pores. Plots were generate using Excel
(Microsoft) and ggplot2 package (R).
4.3.6

Circular

dichroism

and

thermal

denaturation.

Jasco

CD

spectropolarimeter, model J-810, were utilized for both normal absorbance and thermal
denaturation studies. For all CD measurements, 1µM DNA concentration, CX-5461: DNA
ratio of 5:1 (when applicable) were used, in consistency with nanopore studies. Spectra
were capture in the 220-300 nm wavelength, 1.0 nm bandwidth, 50nm/min scanning speed,
and a standard sensitivity. All experimental solutions contained 1M KCl or NaCl (for
normal CD) and 0.1M KCl or NaCl (for thermal denaturation studies). The thermal
denaturation was performed utilizing the same J-810 that was used for the CD portion of
this study. In addition, a Jasco PTC-423S temperature attachment was used to increase the
temperature from 20C to 95C at a rate of 1C/min. CD was recorded at temperatures below
100C to prevent the sample from boiling over and affecting the data. All CV results were
exported as .csv files for further analysis and plotting with Excel.
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4.4 Results and Discussion
4.4.1 Formation of Ckit1 G-quadruplex in K+ and Na+. In our experiment, we
first employed circular dichroism (CD) to confirm the ability of Ckit1 single-stranded DNA
(ssDNA) to adopt G-quadruplex structure. In CD, as circularly polarized light pass by,
optically active chiral molecules (e.g. DNA and protein structures) will absorb the light
differently, allowing them to be measured and quantified. In our study, CD spectra of Ckit1
DNA in Na+ or K+ solutions both exhibited strong negative and positive peaks at 237 and
263 nm, respectively (Figure 13D), confirming the formation of G-quadruplexes with
parallel topology. Unlike telomeric sequence, whose G-quadruplex folding topologies
depend on different cations,105 the folding topology of Ckit1 G-quadruplex does not depend
on cation nature (Na+ vs. K+).

Figure 13. (A) Schematic cross-sectional structures and dimensions of an α-hemolysin
nanopore embedded in lipid bilayers. (B) Spontaneous folding of a linear single-stranded
Ckit1 DNA into G-quadruplex structure in the presence of K+. The Ckit1 G-quadruplex
composes of three G-quartets (each yellow layer) stacking on top of each other, and
stabilized by K+ cations. (C) Chemical structure of CX-5461 cancer drug, which has been
shown to promote the formation and stabilize Ckit1 G-quadruplex structure. (D) CD
spectra of Ckit1 DNA in the presence of K+ or Na+ consisted a positive peak at 263nm and
a negative peak at 235nm. This result confirmed the presence a G-quarduplex structure
with parallel folding topology
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The transports events of Ctrl ssDNA and Ckit1 ssDNA through nanopores were recorded
in 1M KCl and 1M NaCl, with and without the presence of CX-5641 molecules (Figure
14). Ctrl DNA has the same length with Ckit1 DNA with substitution of two opposite
guanines of every G-tetrad with thymine (Figure 15). This substitution disrupts the
formation of G-quartet, preventing the Ctrl sequence from folding into the G-quadruplex.
Instead, Ctrl simply translocates through the α-hemolysin nanopore with a translocation
time (∆t) of 2.68 ± 0.14 ms and capture rate (𝑓) of 12.24 ± 0.13 s-1. These values are in a
similar range with those previously reported for linear, single-stranded DNA translocation
through the nanopore.238
Compared to Ctrl, Ckit1 DNA yielded current blockage events with significantly
longer ∆t and reduced 𝑓 (Table 1). Specifically, experiments on Ckit1 DNA yielded two
major event types, named Type 1 and Type 2. Type 1 consists of independent short-lived
blocks, whose open pore current blockage (%I/Io) was approximately 69.66 ± 1.81%.
These spike-like events had similar amplitude and durations with those resulted by the
linear single-stranded Ctrl DNA translocation through the nanopore. Whereas Type 2
events featured a deep current-blockage lasting milliseconds before returning to openchannel current level. The absence of Type 2 events in experiments with Ctrl DNA
confirmed that these long-lasting events result from the translocation of Ckit1 Gquadruplex. Strong DNA secondary structure, such as G-quadruplex, require high energy
to break up the stacked G-quadruplex structure, before it can enter the nanopore
constriction site, causing a large temporal dispersion and prolonged translocation time.53,
105, 239
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Figure 14. Data traces from a single α-hemolysin nanopore showing current-blockage
events of: (A) Control DNA (Ctrl) in Na+, and Ckit1 DNA in (B) K+, (C) K+/ CX-5461,
(D) Na+ and (E) Na+/CX-5461. The control DNA is incapable of folding into secondary
structure, causing spike-like events (top panel); whereas Ckit1 DNA spontaneously adopt
the G-quadruplex structure in the presence of K + or Na+, leading to long lasting current
blockages. In all experiments, the concentration of both DNAs was 1 µM. All traces were
recorded at +160mV in a 1M salt solution buffered with 10mM Tris, 1mM EDTA and
calibrated to pH 7.2.
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Figure 15. Stability of G-quadruplexes as determined by thermal denaturation analysis in
(A) 0.1M KCl and (B) 0.1M NaCl with and without the presence of CX-5461 molecules.
The secondary structure melting temperature, Tm, is a temperature, where 50% of the DNA
are folded. (C) Violin plots represent the distribution of current-blockage event dwell time,
∆t. Plots were arranged in the order of increasing mean ∆t ( Na+ < K+ < Na+ with CX-5461
< K+ with CX5661).

As Ckit1 DNA was instantaneously folded into G-quadruplex structure in the
presence of monovalent cations (Na+/ K+), the remaining unfolded Ckit1 linear structure
(Type 1 event) was significantly less than that of Ctrl DNA. Specifically, the occurrence
rate, 𝑓, of Ckit1 Type 1 in K+ was approximately 5.5 s-1, almost 2.25 times lower than the
12.24 s-1 for the Ctrl Type 1 event in the same solution. In order to determine the cation
and stabilizing molecule dependency, we calculated the equilibrium formation constant for
G-quadruplex in all experimental conditions. As shown in previous studies, equilibrium
formation constant for G-quadruplex, 𝐾𝑓 , is the concentration ratio between folded DNA
and linear DNA in the mixture.
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From the correlation between DNA concentration and event capture rate, 𝐾𝑓 can
also be calculated using the equation: 𝐾𝑓 =

𝑓𝑐𝑡𝑟𝑙
𝑓𝑐𝑘𝑖𝑡1,𝐿 − 1

.53 In which, 𝑓𝑐𝑡𝑟𝑙 is the capture rate

of the linear, single-stranded Ctrl DNA and 𝑓𝑐𝑘𝑖𝑡1,𝐿 is the capture rate of linear Ckit1 DNA.
The calculated 𝐾𝑓 for Ckit1 G-quadruplex was 3.83 in K+, 1.84 in Na+, 4.65 in K+/CX5461, and 4.23 in Na+/CX-5461.The equilibrium formation constants suggest the sequence
of most favored experimental conditions for Ckit1 G-quadruplex formation is: K+/CX5461 > Na+/CX-5461 > K+ > Na+ (as shown in Table 4).

Table 4
Ckit1 current blockage event summary

4.4.2 Stability of Ckit1 G-quadruplex. A thermal denaturation experiment was
performed to determine the stability of the G-quadruplex structures by comparing its
melting temperature in Na+ and K+ solutions, as well as investigating stabilization effect of
CX-5461. With the experimental solution being water-based, thermal denaturation studies
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must be halted under 100˚C, in order to prevent evaporation of sample. As Tm of Ckit1 Gquadruplex is approximately 88˚C in 1M NaCl, we decreased the solution ionic strength
(while keeping DNA concentration at 1µM), which allowed us to record the melting
temperature of the structures at a range sufficiently far away from the evaporation point as
to not affect the data (Figure 16). We decided that 0.1M would be the ideal concentration
for further testing. The final thermal denaturation study was performed in 10mM Tris-HCl
buffer (pH 7.2) containing 100mM cation (Na+ or K+). When applicable, CX-5461
concentration was 5 µM, which corresponds to a 5:1 ratio of ligand to DNA. Reduction of
ionic strength resulted in a lowering of Tm of unbound Ckit1 G-quadruplex to 70˚C and
49˚C in 0.1M KCl and 0.1M NaCl solutions, respectively (Figure 15A – B). Addition of
CX-5461 increases Tm of Ckit1 G-quadruplex structure, resulting in a ∆Tm of 13˚C and
11˚C in K+ and Na+ (Figure 15A – B). Higher melting temperature in K+ than in Na+ proves
that the structure is more stable in K+.
In order to visualize the distribution of G-quadruplex translocation time through the
pore, we constructed a violin plot for dwell time of events in each condition (Figure 15C).
It is important to note that only events lasting longer than 1ms were included in the violin
plots, as those with shorter dwell time were considered as translocation of unfolded linear
ssDNA (Type 1 events). The constructed violin plots for the dwell time, ∆t, of Ckit1 type
2 events exhibited a bimodal distribution with two populations of events lasting from
milliseconds to several seconds (Figure 14C). Using paired-wise testing, we found a
statistically significant difference (95% confidence interval) in dwell time when Type 2
events in Na+ compared to in K+ and Na+/CX-5461. Despite an overall increase in event
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dwell time in the presence of CX-5461, there was no statistical difference between event
dwell time in K+ and K+/CX-5461.
Previous studies showed that the unfolding rate constant (ku) of G-quadruplex is
an indicator of structural stability and can be estimated using ∆t, through the equation:
1

𝑘𝑢 = Δ𝑡.53 Moreover, the kinetic folding rate constant, 𝑘𝑓 , is the product of the equilibrium
formation constant and unfolding rate constant, or: 𝑘𝑓 = 𝐾𝑓 𝑘𝑢 .53 Using these equations,
we calculated the folding and unfolding rates for Ckit1 G-quadruplex, as shown in Table
4. In the absence of CX-5461, Ckit1 G-quadruplex folded much more rapidly in a K+
environment than in an Na+ environment (with a 𝑘𝑓 of 1.13 and 0.59, respectively), while
unfolding more slowly. On the other hand, in the presence of CX-5461, ku and kf of Ckit1
G-quadruplex were similar between Na+ and K+ environments. (see Table 4).
There are multiple factors that contribute to the stabilization of G-quadruplexes and
their topology, including stacking interactions, hydrogen bonding, solvation, and cation
bonding.240-241 To stabilize the G-tetrad stacks, the binding cation needs a sufficient ionic
strength, in order to compensate electrostatic repulsion between the phosphate oxygens of
four Guanines, instead of two in regular DNA duplexes.241 In general, K+ induced Gquadruplex is much more stable and has longer lifetime than Na+ induced G-quadruplex,
owing to the higher ionic strength and lower hydration energy of K+ ions.241-244
Furthermore, the smaller Na+ cations can be coordinated within the plane of tetrads,
and occupy a range of positions with lower steric constraints; thus, reducing the
electrostatic repulsions.241 While Na+ can alternatively occupy coordination sites and
become closer to the core of the tetrads, Na+ G-quadruplex confers a higher plasticity that
allows a better fit with a binding molecule.241 On the other hand, K+ is coordinated at the
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cavity between two G-tetrads and bridges together eight Guanines O6 atoms, thereby
becoming more stable and rigid.241
Previous studies involving thrombin binding aptamer (TBA) found that ∆Tm
between K+ and Na+ coordinating TBA decreases from 29˚C (free) to 12˚C (bound).241 This
can partially explain what we observed in our study: compared to Na+, K+ cation creates a
much more stable G-quadruplex structure. Presence of CX-5461 in K+ solution produced
extremely stable structures that could not be included in data analysis, as the event lasted
several hundred seconds to minutes. Therefore, the enhanced stability induced by CX-5461
was better observed in Na+ experimental buffers. This was reflected by significant increase
in event dwell time in Na+ (with CX-5461 versus without), but not in K+ buffer.

Figure 16. Thermal denaturation of Ckit G-quadruplex in buffers containing: 1M, 0.2M or
0.1M NaCl. Melting temperature, ∆Tm, is determined when there are 50% structure
unfolded. ∆Tm of Ckit1 G-quadruplex reduces approximately 30˚C as salt concentration
decrease 10-fold. DNA concentration was held constant at 1µM for every experiment.
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4.4.3 Changes in volume of Ckit1 G-quadruplex. As single-channel data traces
of Type 2 (i.e. G-quadruplex translocation) exhibited multiple events with well-defined
step-wise structure that varied in length (Figure 17A–D), we decided to examine the
hidden subgroups in Type 2 events of Ckit1 DNA. For this, we utilized an unsupervised
machine learning technique, which can identify similarities and patterns in datasets, to
cluster Type 2 events using their amplitude (%I/Io) and dwell time (∆t). Clustering is one
of the most common data analysis techniques used to explore the structure of the data.
Specifically, we used the kmeans function in R to classify the Type 2 translocation events
in each experimental condition. K-means is a randomly-initialized iterative clustering
method that partitions the dataset into k predefined distinct subgroups and the positions of
each group’s centroid.
Traditionally, dwell time is typically used as the main indicator to classify distinct
translocation events. However, the amplitude of current-blockage events is known to
reflect the size and interaction of the targeted molecule with the nanopore. Thus, we
selected both %I/Io and ∆t as features for unsupervised machine learning. The two selected
features (%I/Io and ∆t) have greatly different measurement scales of 0 – 100% and 1 –
1000s ms, respectively. To avoid bias introduced by one group being dominant in size, we
first converted each feature to a 0 to 1 scale. After clustering and calculation of centroids,
data were converted back to their original values for better visualization and comparison
between conditions. To determine the optimal parameter k for all data subset, we
constructed an elbow plot, which suggested that the optimal number of clusters in nanopore
Type 2 events was k = 2 (Figure 18). Figure 17E–H represents the scatter plots of the ionic
traces with respect to %I/Io and ∆t.
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Figure 17. Clustering analysis for all samples. Examples of Ckit1 G-quadruplex data traces
in buffers containing: (A) 1M KCl, (B) 1M KCl with CX-5461, (C) 1M NaCl or (D) 1M
NaCl with CX-5461. Current-blockage events exhibit step-wise changes in amplitude,
representing different stages of G-quadruplex threading and translocating through the αhemolysin pore. (E-H) Clustering analysis of all current-blockage events in all
experimental conditions using k-mean method. In each solution, there are two main clusters
of events with shallow (red) or deep current blockage amplitudes (blue), reflecting the stepwise current blockage amplitude changes. At least 1000 events were included in each
scatterplot. Events with ∆t ≤ 1ms were excluded in this scatter plotting since those events
were linear DNA translocation.

Figure 18. Elbow plot for determining optimal number of clusters for amplitude-dwell
time scatterplot.
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In each plot, there are two event clusters (showed in red and blue), named Type 2a
and 2b, respectively. Although the event translocation time is largely dispersed (as
discussed previously), event amplitude seemed to be the main deciding factor in Type 2
subgroups classification, as shown in Figure 17E–H. These level changes (Type 2a and 2b)
reflected the two stages of G-quadruplex translocation through the nanopore, which were:
(a) capturing and (b) unfolding of the DNA secondary structure (Figure 19B). The average
amplitude of Type 2a and 2b events were 67.4±3.9% and 85.1±2.9%, respectively.

Figure 19. Ckit1 G-quadruplexes volume. (A) Comparing changes in Ckit1 currentblockage amplitudes of level 1 and 2 in buffer solutions contains K+ or Na+ (with and
without CX-5461). The presence of CX-5461 exhibits minimal effect on Level 1 and level
2 %I/Io in K+, but significantly increases %I/Io of both levels in Na+ solutions. (B)
Schematic explaining different stages of Ckit1 G-quadruplex translocation through αhemolysin nanopore, corresponding to current-blockage level 1 and 2.
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Previous studies involving TBA G-quadruplex and beta-Cyclodextrin (𝛽-CD)
showed that the amplitude of current-blockage events reflected the change in volume of
the G-quadruplexes formed by different cations.53,

245

Thus, the current-blockage

amplitude, %I/Io, of event Type 2a and 2b reflect an overall trend that volume of K+ Gquadruplex is smaller than Na+ G-quadruplex (Figure 19A). This has been explained in
previous studies on G-quadruplexes. Briefly, as the Na+ ion is smaller (d = 0.95 Å), it can
fit in the plane of a quartet; while the larger K+ ion (1.33Å) is coordinated in the center of
the cavity between two planes. Position of cations within the G-quadruplex, in turn,
changes the cation-carbonyl distance (d), explaining the reason why volume of K+ Gquadruplex is smaller than Na+ G-quadruplex, as observed in previous studies and our
results herein.53 Specifically, dK-O is shorter than dNa-O, giving rise to stronger attraction
between cation and the carbonyl, and a more stable G-quadruplex in K+ presence.
Interestingly, the binding of CX-5461 changed the volume of Ckit1 G-quadruplex
differently. As shown in Figure 17E–H and Figure 19A, while the volume of K+ Gquadruplex remains mostly unchanged, volume of Na+ G-quadruplex significantly
increased when bound by CX-5461, reflecting through a 10 and 5 pA increase in the
amplitude of event Type2a and 2b, respectively.
4.4.4 Prediction of CX-5461 binding status. Having determined the changes in
formability and stability of Ckit1 G-quadruplex in correlation with cations and stabilizing
molecules, we sought to demonstrate the application of α-hemolysin nanopore as a
molecular screener for G-quadruplexes. To do this, we used a supervised machine-learning
to train classifiers for pattern recognition and discriminate Ckit1 G-quadruplex formed in
the different experimental conditions discussed thus far. In each experimental condition,
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we randomly selected 2000 current-blockage events, then divided the datasets into 80%
and 20% for model training and validation, respectively. Two features, ∆t and average
%I/Io, collected from the current blockages were used as inputs to a k-nearest neighbor
(KNN) classifier. We first trained the model using all event captured by the nanopore. This
first run yielded an average accuracy and sensitivity of 69.6 ± 2% and 72.2 ± 5%,
respectively. The model’s prediction ability was quite low, due to the fact that Ckit1 DNA
could instantaneously fold and unfold into G-quadruplex structure. Thus, the events
captured by nanopore comprised of both linear and folded DNA (Type 1 and 2 events), as
previously discussed. Thus, we retrained the model using only events lasted longer than
1ms, in order to exclude Type 1 events (linear DNA). With the filtered datasets, the model
performance was enhanced significantly, yielding a new average accuracy and detection
sensitivity of 81.3 ± 4 % and 92.4 ± 2 %. Table 5 shows the classification accuracy,
sensitivity, and specificity the model for different experimental condition pairs.

Table 5
KNN classification results for G-quadruplexes formed in different conditions

Distinguish Ckit1 Gquadruplex formed in
Condition 1
Condition 2

Sensitivity
(%)

Specificity
(%)

Balanced
Accuracy (%)

K+
Na+
93.55
77.78
85.66
CX-5461/K+
KCl
89.66
58.33
73.99
CX-5461/Na+
Na+
95.45
70.00
82.73
CX-5461/Na+
CX-5461/K+
90.91
75.00
82.95
*Note: Samples in Group 1 were considered as the positive result for classification.
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Results showed that the model’s ability to distinguish one type of G-quadruplex
from another is in the order of: (Na+/CX – Na+) > (K+ – Na+) > (Na+/CX – K+/CX > K+/CX
– K+. As we discussed earlier, the most pronounced changes in the structure’s volume and
stability occurred when CX-5461 binds to Na+ G-quadruplex; whereas no statistically
significant changes were found in for Ckit1 G-quadruplex in K+ solution with and without
CX-5461. Thus, the order of the model’s performance could be explained. A limitation in
our prediction model comes from having nonhomogeneous control samples. When
working with dynamic experimental conditions, such as those investigated here, the
process of ssDNA folding/unfolding and of CX-5461 binding/unbinding to the Gquadruplex structure constantly occurs. This lowers the model performance, as the training
dataset are nonhomogeneous.
4.5 Conclusions
In summary, we have presented the ability of α-hemolysin nanopore as a real-time
molecular dynamic sensing for Ckit1 G-quadruplex formation and stability in K+ and Na+
environments. While G-quadruplex structures can be extremely stable, their topology and
stability depend on many factors, including the length and sequence composition of the
total G-quadruplex motif, the size of the loops between the guanines, strand stoichiometry
and alignment, and the nature of the binding cations.240 Our study showed that Ckit1 Gquadruplex has a parallel folding topology in both environments, with a more tightly
packed structure in the presence of K+ cations. Binding of CX-5461 molecules significantly
enhanced the stability and increased the volume of Ckit1 G-quadruplex in Na+, but not in
K+. In the absence of CX-5461, Na+ G-quadruplex and K+ G-quadruplex featured greatly
different equilibrium properties. Specifically, Na+ G-quadruplex folds much slower and
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unfolds rapidly, compared to K+ G-quadruplex. On the other hand, presence of CX-5461
significantly enhanced the folding rate of linear Ckit1 DNA and slows down the unfolding
rate of G-quadruplex, leading to a similar equilibrium folding kinetic constant in both K+
and Na+.
Apart from determining the structural formation and stability, we further employed
clustering analysis to determine the hidden pattern of the nanopore current blockage
amplitudes, which have distinct levels reflecting the two stages of (i) capturing and (ii) Gquadruplex translocation through the pore. The volume of G-quadruplex is correlated with
the cation species and presence of CX-5461. These changes in the structure volume and
stability made it feasible to employ machine learning algorithms to classify Gquadruplexes formed in different experimental conditions. With the ability to
computationally predict the binding stage of cation and CX-5641 molecule to Gquadruplex, we believe α-hemolysin nanopore could be an interesting tool for real-time
monitoring the binding reference of G-quadruplex to cations and stabilizing molecule in
mixture solutions.
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Chapter 5
Mutations on Ckit1 G-Quadruplex Reduce CX-5461 Efficacy
5.1 Abstract
In this article, we employed α-hemolysin biological nanopore to the effect of point
mutation on Ckit1 G-quadruplex stability and drug efficacy. Our study employed six DNA
samples including Ckit1 and its mutated sequences (containing 1-6 mutations). The
signature blocks in the nanopore revealed that number and position of mutation have an
impact causing destabilization of the G-quadruplex structure. Specifically, sequences with
the same number of mutations on the same G-quartet layer exhibited similar stability.
Furthermore, CX-5461 significantly increases G-quadruplex structural stability only in
sequences with no mutation on the top G-quartet. Moreover, using a random forest
classifier on nanopore data, we were able to distinguish mutated from unmutated Ckit1
sequences with an overall sensitivity and specificity of 81.9% and 83.4%, respectively.
Understanding the effects of mutation on G-quadruplex stability is beneficial for
constructing methods to predict treatment response in personalized medicine approaches.
5.2 Introduction
In this study, we investigated the efficacy of CX-5461 on mutated C-kit1 promoter
sequences to elucidate the importance of each component G-tetrad in the overall stability
of the G-quadruplex structure. Activating mutations on C-kit1 have been observed in
several types of malignancies, notably leukemia, melanoma, and gastrointestinal
tumors.246-248 Our study employed a biological nanopore sensor and circular dichroism
spectroscopy to compare the stability of Ckit1 G-quadruplex and its mutated sequences in
the presence of sodium cations (Na+). Our earlier work revealed that while the overall
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structural stability is lower in Na+ than K+ environment, the effect of CX-5461 on
stabilizing the Ckit1 G-quadruplex was more pronounced in Na+ (see Chapter 4). We found
that CX-5461 affects the stability of the mutated Ckit1 G-quadruplex to varying degrees,
depending on the mutation position and number. Having more than one mutation on the
top G-quartet might inhibit binding of CX-5461 to the structure, leading to no significant
change in G-quadruplex stability. In addition, using nanopore data and machine learning
algorithms, we were able to distinguish mutated sequences from unmutated Ckit1 with
81.9% sensitivity and 83.4% specificity.
5.3 Methods
5.3.1 Chemicals and reagents. The chemicals and reagents used in this study along
with the associated vendors are as follows: Sodium chloride (Sigma-Aldrich); 1,2diphytanoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids); pentane (SigmaAldrich); Tris base (Promega); Ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich);
pentane (Fischer Chemical); hexadecane CH3(Ch2)14CH3 (Avantor); CX-5461
lyophilized powder (Sigma-Aldrich); and acetic acid (VWR). The CX-5461 was then
aliquoted into 1.5 mL microcentrifuge tubes which were wrapped in aluminum foil and
stored in a freezer at -20˚C.
5.3.2 DNA samples. All DNA used in this study were designed and purchased from
Integrated DNA Technology (IDT - Coralville, IA) and had the following sequences:
Ckit1: AGG GAG GGC GCT GGG AGG AGG G (0 mutation)
L1M1: AGG GAT GGC GCT GGG AGG AGG G (1 mutation)
L1M2: AGG GAT GGC GCT TGG AGG AGG G (2 mutations)
L2M1: AGG GAG TGC GCT GGG AGG AGG G (1 mutation)
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L2M2: AGG GAG TGC GCT GTG AGG AGG G (2 mutations)
M2C: AGG GAT TTC GCT TTT AGG AGG G (6 mutations)
Upon delivery, DNA samples were resuspended in a standard storage buffer
(containing 10mM Tris, 1mM EDTA and titrated to 8.0 pH). All samples were then
aliquoted and stored at -80˚C until experimentation. This was done to prevent the
degradation of the DNA quality caused by multiple thaw-freeze cycles. In both the
nanopore and circular dichroism experiments, the final concentration of the DNA was 1
µM.
5.3.3 Experimental setup. Detailed protocol and description of the α-hemolysin
nanopore experimental setup has been discussed in previous studies.47, 50 A 1 µM aliquot
of DNA sample was inserted into the cis chamber. The cis chamber was grounded, so that
when applying a positive voltage, the negatively charged DNA would be driven through
the nanopore to the trans side. Electrolyte solutions in the cis chamber were titrated to pH
8.15 in experiments using CX-5461, in order to compensate for the acidity of CX-5461
solution.
5.3.4 Data analysis and visualization. Event blockage amplitudes were
determined from amplitude histograms by fitting the peaks to Gaussian functions (singlesample and mixture models). The duration and occurrence of short-lived blockages for
DNA translocation were obtained by fitting the dwell-time histogram to an exponential
distribution. Only current-blockage events with %I/Io ≥ 60 % and ∆t > 1ms were selected
for data analysis.73 Those with %I/Io < 60% or ∆t < 1ms are considered as brief interaction
or translocation of linear ssDNA, respectively. Data were given as the mean ± SD, based
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on at least three separate experiments. RStudio was used to run ANOVA and Tukey’s HSD
tests to determine the significance of dwell-time data.
5.3.5 Circular dichroism and thermal denaturation. In the studies for both
absorbance and thermal denaturation, a model J-810 Jasco CD spectropolarimeter was
utilized. When measuring CD, a CX-5461:DNA (1 µM DNA concentration) ratio of 5:1,
when applicable, was used, which is consistent with pre-existing nanopore studies. Spectra
were captured within a 220-300 nm wavelength range, 1.0 nm bandwidth, 50nm/min
scanning speed, and a standard sensitivity. 1M NaCl experimental solutions were used in
normal CD studies and 0.1M NaCl experimental solutions were used in thermal
denaturation studies. J-810 is utilized in both normal CD and thermal denaturation portions
of this study. In order to increase the temperature from 20˚C to 95˚C, a Jasco PTC-423S
temperature attachment with a heating rate of 1˚C/min was utilized. To prevent the sample
from boiling and affecting the data, CD was recorded only at temperatures below 100˚C.
The results of the CD were exported as .csv files to be analyzed further and plotted in Excel.
5.4 Results and Discussion
5.4.1 Experimental design. This study aims to explore the effects of point
mutations on Ckit1 G-quadruplex formation and stability, as well as the effects of cancer
drug CX-5461 on mutated C-kit1 G-quadruplexes versus native C-kit1 G-quadruplexes. In
this study, we employed variations of the Ckit1 DNA, each containing different mutations
of guanine. Specifically, six DNA samples included: Ckit1 (positive control), L1M1,
L1M2, L2M1, L2M2, and M2C (negative control). Ckit1 is the unmutated sequence, while
M2C contains six mutated guanine bases in total, with two at each G-quartet layer. The
L/M scheme in sample naming convention was in reference to the position of G-quartet
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layer (“L”) and number of mutation (“M”), respectively. For example, “L1M2” refers to
C-kit1 DNA that has two-point mutations on the part of the sequence that would form the
first layer of the G-quadruplex. In Figure 20, the first column shows schematics of the
Ckit1 G-quadruplex, with the three layers of G-quartets (yellow layers), its central Na+
cations (red dots), and location of the mutated guanine (purple circles). As the Gquadruplex is symmetrical, we only ran experiments with mutations on the first and second
G-quartet, assuming CX-5461 effects on G-quadruplex stability if bound to the first or third
layer would be similar. In order to increase efficiency of the experimental design, we ran
experiments with C-kit1 DNA with up to two mutations. The G-quadruplex requires four
guanine bases in order to form. Therefore, two mutations on the C-kit1 G-quadruplex
sequence would have a sufficient effect on destabilizing of the G-quartet.
5.4.2 Changes in current-blockage events among conditions. First, we compare
raw data traces obtained from nanopore experiments of all samples in the same
experimental conditions (1M NaCl, +160mV, with and without presence of CX-5461). As
showed in Figure 20, all samples exhibited two types of events, which are spike-like (Type
1 events) and long-lasting blockages (Type 2 events). In Ckit1 DNA, addition of CX-5461
significantly increases the dwell time and frequency of Type 2 events (as discussed in
Chapter 4). However, compared to Ckit1, raw nanopore data traces of mutated sequences
exhibited a higher amount of spike-like events (Type 1), indicating that the mutated
sequences were less likely to form stable G-quadruplexes. Moreover, increased incidence
of Type 1 events also reflects higher amounts of linear DNA being captured. This result is
much more pronounced in the L2M2 and M2C samples, compared to other mutated
sequences. L1M1 appears to have the most similar pattern to Ckit1 DNA, compared to
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other samples. Similar to Ckit1 and L1M1, L1M2 and L2M1 data traces contain both Type
1 and 2 events; however, the increased frequency of Type 1 events indicated less Gquadruplex formation.113 Interestingly, addition of CX-5461 to L2M2 has shown slight
increases in the signal event length when compared to L2M2 without the addition of CX5461 (Figure 20).

Figure 20. Nanopore raw data traces. (Left) Schematics represent six variations of the
Ckit1 sequence, containing 0 – 6 mutation points (purple circles) and their location on the
G-quadruplex structure. Experiments were conducted in duplicate with and without CX5461 for all DNA sequences, including: positive control DNA (Ckit1), mutated sequences
(L1M1, L1M2, L2M1, L2M2 and M2C) (top to bottom). (Middle) The positive control
(C-kit1) DNA spontaneously adopts the G-quadruplex, leading to long lasting current
blockages (top panel); whereas M2C (containing 6 point mutations) is incapable of folding
into a unimolecular G-quadruplex, causing a significant increase in frequency of spike-like
events (bottom panel). (Right) Addition of CX-5461 did not show a clear visible effect on
mutated sequences. In all experiments, the concentration of both DNAs was 1 µM. All
traces were recorded at +160mV in a 1M salt solution buffered with 10mM Tris, 1mM
EDTA and calibrated to pH 7.2.
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Using circular dichroism (CD), we measured the optical absorbance of all the
sequences investigated in this study (Figure 21). Both Ckit1 and Ckit1_CX formed a
parallel G-quadruplex structure that was characterized by a strong positive peak at 263nm
and a negative peak at 237nm (Figure 21A). Compared to Ckit1, the CD absorbance spectra
of mutated sequences exhibited both positive and negative peaks between 220 – 300nm, as
shown in Figure 21B – F.

Figure 21. Circular Dichroism spectra of all tested sequences were measured between 220
– 320nm, at room temperature. Samples were measured without (black line) and with the
presence of CX415461 drug (dotted orange line). CD spectra of C-kit1 DNA had a positive
peak at 263nm and a negative peak at 235nm, reflecting the presence a G-quadruplex
structure with parallel folding topology. For all other sequences, these two peaks (at 235nm
and 263nm) were broadened and shifted, indicating a change in the DNA structural
topology.
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L1M1 and L1M1_CX spectra were similar to that of Ckit1 and Ckit1_CX,
respectively (Figure 21C). However, the peaks were significantly broadened and/or shifted
in L1M2, L2M1, L2M2 and M2C samples. Diminishing of 263nm and 235nm peaks in
mutated sequences indicate a reduction in parallel G-quadruplex formation and an increase
in topological changes. This effect varies with the number and position of mutations. In the
following sections, we will take a closer look at the structural volume and stability of these
structures.
5.4.3 Structural volume of Ckit1 and mutated sequences. We would like to
understand if the volume of Ckit1 G-quadruplex is affected by presences of mutations and
CX-5461. Previous work has shown that the potential volume of the secondary structure
of the DNA could be determined by the current blockage amplitudes.104 For each sample,
we selected at least 1000 current-blockage events that lasted longer than 1 ms for the
analysis, as those with shorter dwell time were considered as translocation of unfolded
linear ssDNA (Type 1 events). In accordance with the nanopore conductance with (I) and
without (Io) sample translocation, we calculated the current-blockage amplitude (%I/Io).
Without CX-5461, all samples folded into structures with a similar volume (for summary
statistics, see Table 6). Specifically, the mean current blockage amplitude of all samples
was approximately 69.7 ± 2.3% (Figure 22). Addition of CX-5461 greatly increased the
current-blockage amplitude of Ckit1 (similarly observed in Chapter 4) and M2C by over
5%, but exhibited little to no effect on other mutated structures (Figure 22).
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Figure 22. Average current blockage amplitude at +160mV of all samples, including:
Ckit1, L1M1, L1M2, L2M1, L2M2 and M2C without treatment (green) and with the
addition of CX-5461 (orange). All samples exhibited a similar average current-blockage
amplitude of 69 ± 2%. Addition of CX-5461 showed minimal effect on L1M1, L1M2,
L2M1 and L2M2, but increased %I/Io of both Ckit1 and M2C by approximately 5%. The
average %I/Io of each sample was found by selecting at least 1000 events to construct a
density plot, following by fitting with Gaussian normal distribution.

Table 6
Summary statistics of event amplitude (%I/Io)
Condition
Ckit1
Ckit1
L1M1
L1M1
L1M2
L1M2
L2M1
L2M1
L2M2
L2M2
M2C
M2C

With
CX
x
x
x
x
x
x

Mean
(%)
71.85
72.89
68.68
67.35
70.78
71.87
72.03
72.78
72.75
73.79
68.81
77.23

Max
(%)
101.87
100.76
86.26
101.63
98.71
101.13
101.61
99.04
99.04
94.00
98.34
99.91
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Min
(%)
50.15
50.08
51.22
50.14
50.48
51.02
50.41
50.76
50.76
51.84
53.75
52.67

Median
(%)
71.21
74.27
67.64
66.20
69.77
69.93
69.13
70.89
70.88
71.07
67.47
76.09

Std
(%)
10.94
10.08
9.34
8.34
8.58
9.81
9.05
8.14
8.14
8.09
5.42
6.75

5.4.4 Effect of CX-5461 on mutated Ckit1 G-quadruplex stability. Stability of
the G-quadruplex structure is measured in relation to length of the current blockage. First,
we constructed a box-and-whiskers plot for all the experimental conditions (Figure 23A).
Upon calculating the summary statistics of these samples, we found that the majority of
the event dwell times were between 1-100ms (with the exception of Ckit1_CX), with
median ∆t decreasing in the sequence of: Ckit1 > L2M1 > L1M1 > M2C > L2M2 > L1M2.
Addition of CX-5461 increased the samples’ ∆t to varying degrees, except for L2M1 and
M2C, whose ∆t significantly decreased (Table 7). Specifically, the median ∆t of all samples
in the presence of CX-5461 can be listed in decreasing order as follows: Ckit1 >> L1M1 >
L2M2 > L1M2 > M2C > L2M1 (Table 7). In all experimental samples, there were multiple
outliers, which were events with extremely long ∆t (several seconds to minutes). This was
a result of metastable state of DNA—a phenomenon that was well described in previous
studies.249-251 Thermal denaturation experiments were performed to assess the stability of
the Ckit1 G-quadruplex and its mutated structures in each experimental condition (Figure
22B – E). The melting curves were collected at 263 nm (which was the positive peak in the
circular dichroism experiments), with temperatures ranging from 20 - 95oC. The melting
temperature is determined when 50% of the DNA is unfolded. As discussed in Chapter 4,
while the nanopore experiments were conducted in buffer containing 1M NaCl, thermal
denaturation experiments were carried out in 0.1M NaCl environment, in order to keep the
melting temperature of DNA secondary structure below 100˚C.
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Figure 23. Stability of mutated Ckit1 G-quadruplex. (A) Grouped boxplot representations
of the distribution of event dwell times for all samples, including: Ckit1, L1M1, L1M2,
L2M1, L2M2 and M2C. All experiments were conducted in duplicate with (orange, right
side) and without (green, left side) the addition of CX-5461. Ckit1 DNA is relatively more
stable than its mutated sequences, as indicated by a higher median dwell time. Presence of
CX-5461 increases stability of most sequences to varying degrees, except for L2M1, whose
stability decreases. (B) Thermal denaturation studies were performed to determine the
stability of G-quadruplex structures formed by mutated sequences with (orange dotted line)
and without (solid green line) the presence of CX-5461. The secondary structure melting
temperature, Tm, is the temperature, where 50% of the DNA are folded. Circular dichroism
spectra were collected at 263nm, with temperature ramping from 20 – 95˚C.

Among the samples, The L1M1 condition exhibited a melting curve that was
remarkably similar to the positive control Ckit1 DNA, with the addition of CX-5461
slightly shifting the melting curve to the right. Specifically, the observed melting
temperature of L1M1 and L1M1_CX were approximately 65˚C and 70˚C, respectively
(Figure 23B). This indicates excellent stability of the G-quadruplex both with and without
CX-5461. Notably, Tm of L1M1 was slightly higher than that of Ckit1 in the same
experimental buffer. This increase in structural stability was also reflected through a slight
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increase in nanopore event dwell time of L1M1 sequence in comparison to Ckit1 DNA.
However, this increase in dwell times was not statistically significant. On the other hand,
L2M1 exhibited a straight down trending line and no inflection point in the melting curve
(Figure 23D). The addition of CX-5461 to L2M1 somewhat rescued the sigmoidal shape
that was characteristic of the melting curve of the positive control, but offbeat degrees of
ellipticity persisted, indicating poor stability of the G-quadruplex. In other samples (e.g.
L1M2, L2M2, and M2C), the behavior bore little to no resemblance to the positive control
Ckit1 DNA with relatively low G-quadruplex stability at its peak degree of ellipticity.
Moreover, the addition of CX-5461 did not rescue this aberrant behavior.

Table 7
Summary statistics of event dwell time (ms)
Condition
Ckit1
Ckit1
L1M1
L1M1
L1M2
L1M2
L2M1
L2M1
L2M2
L2M2
M2C
M2C

With
CX
x
X
X
x
X
X

Mean
(ms)
4432.63
11587.29
4283.26
1887.54
9.43
629.38
2153.12
31.49
31.42
6175.41
15.27
314.18

Max
(ms)
114411.35
152850.00
51802.34
39545.14
296.95
39771.09
65396.62
1447.89
1447.89
119939.50
3449.96
29303.41

Min
(ms)
1.05
1.02
1.02
1.04
1.02
1.02
1.02
1.03
1.03
1.02
1.02
1.02

Median
(ms)
5.75
47.36
4.94
11.73
3.00
5.04
5.53
3.50
3.51
8.54
4.17
4.94

Std
13919.90
26625.04
10577.08
6195.79
24.21
3552.46
7404.17
135.46
135.28
16886.62
123.22
1869.56

5.4.4.1 Having more than one mutation destabilizes Ckit1 G-quadruplex. All
three of the examined sequences with at least two mutations within the same level had
significantly different dwell times than the positive control Ckit1 DNA (p < 0.001 for
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L1M2, L2M2, and M2C), with all exhibiting decreased dwell times (as shown in Table 8).
This indicates that having multiple mutations within the same level of Ckit1 compromises
the overall stability of the G-quadruplex, while having just one mutation did not.
Furthermore, there were no significant differences between the dwell times of L1M1 and
L2M1 or L1M2 and L2M2, but there were significant differences between L1M2 - L1M1
and L2M2-L2M1, suggesting that the number of mutations has a much more relevant
impact on G-quadruplex stability than the position (G-quartet level) of the mutation (Table
9).
5.4.4.2 The outer G-quartet layer is crucial to the binding of CX-5461. Addition
of CX-5461 created significant changes in the stability of Ckit1, L2M1 and L2M2 with
opposite effects, suggesting different interactions of CX-5461 to the mutated Ckit1
structures (Table 10). As expected, the addition of CX-5461 to the positive control Ckit1
DNA proved to significantly increase Ckit1 G-quadruplex stability, as discussed in Chapter
4. This was also the case with L2M2 (p < 0.001), which makes sense given that addition
of CX-5461 somewhat rescued the shape of the denaturation curve. CX-5461 did not
appear to have significant effects on L1M1, L1M2, or M2C (p = 0.091 , p = 0.976 , p =
0.967 , respectively), although L1M1 did exhibit a notable, but not significant, increase in
dwell time with the addition of Cx-5461. Because CX-5461 stabilizes G-quadruplex by
binding to the DNA sequence,252 this may implicate the outer G-quartet (L1) is critical for
an efficiency binding of CX-5461), because its mutation results in abrogation of the
stabilizing effect. Having more than one mutated guanine on the first layer inhibits the
formation of layer 1 G-quartet, thus interfering with CX-5461 binding to the structure. This
is supported by the ability of CX-5461 to rescue stabilization of the G-quadruplex in the
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Ckit1 and L2M2 conditions, both of which lacked mutations in the first layer of G-quartet
(L1). However, addition of CX-5461 to L2M1 produced a significant difference that
resulted in a decrease in dwell time, and thus a decrease in structural stability. This is
indicative of a destabilizing interaction of unknown cause that L2M1 has with CX-5461.
This follows the trend that was illustrated in the thermal denaturation curve produced by
L2M1, where the addition of CX-5461 resulted in a drastically offbeat degrees of ellipticity
from the expected melting curve.

Table 8
Statistical comparison between dwell times of mutated sequences and Ckit1.

Groups
Adj. p-value
L1M1-Ckit1
1.0000
ns
L1M2-Ckit1
0.0000
***
L2M1-Ckit1
0.0003
***
L2M2-Ckit1
0.0000
***
M2C-Ckit1
0.0000
***
*Note: adjusted p-values was obtained from using Anova on all samples, followed by Tukey’s
post-hoc test.

Table 9
Statistical comparison between dwell times of mutated sequences.
Groups

Adj. p-value

L1M2-L1M1
0.0000 ***
L2M2-L2M1
0.0003 ***
L2M1-L1M1
0.0950
ns
L2M2-L1M2
1.0000
ns
L2M2 - M2C
1.0000
ns
L1M2 - M2C
1.0000
ns
L1M1 - M2C
0.0000 ***
L2M1- M2C
0.0000 ***
*Note: adjusted p-values was obtained from using Anova on all samples, followed by Tukey’s
post-hoc test.
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Table 10
Effect of CX-5461 on Ckit1 DNA and mutated sequences.
Groups
Adj. p-value
Ckit1_CX-Ckit1
0.0000 ***
L1M1_CX-L1M1
0.0907 ns
L1M2_CX-L1M2
0.9761 ns
L2M1_CX-L2M1
0.0003 ***
L2M2_CX-L2M2
0.0000 ***
M2C_CX-M2C
0.9666 ns
*Note: adjusted p-values was obtained from using Anova on all samples, followed by Tukey’s
post-hoc test.

5.4.5 Distinguishing unmutated Ckit1 sequences from mutated ones. We
explored the feasibility of detecting mutated Ckit1 sequences by employing machine
learning classification models on data obtained from nanopore single–molecular analysis.
In particular, there were five models, including: K-nearest neighbor (KNN), Random
Forest (RF), Logistic Regression (LG), Linear Discriminant Analysis (LDA), and
Quadratic Discriminant Analysis (QDA), employed for the binary classification of mutated
and unmutated Ckit1 DNA.
To minimize the potential issue of overfitting one group, we sampled a balanced
dataset, in which the number of mutated and unmutated sequences are represented
eqrrrrrually (i.e. approximately 1000 events each). The dataset was comprised of two
distinct groups. The first group, called “Ckit1”, was comprised of the current-blockage
events of Ckit1 DNA. The second group, called “Mut”, consisted of an equal mixture of
all the mutated sequences (e.g. L1M1, L1M2, L2M1, L2M2, and M2C). The dataset was
then split into 80% and 20% portions for model training and validation purposes,
respectively. Current – blockage amplitude (%I/Io) and dwell time (∆t) were selected as
input features for the model. To evaluate the model’s performance, we compared their
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AUROC values. We ran the same five algorithms in duplicate on a dataset containing (1)
all current-blockage events and (2) only those with %I/Io > 75%. The first one (1) yielded
extremely poor results, with all algorithms returning an AUROC value of approximately
0.5 (data not shown). Results obtained from the latter dataset (2) were similar, except for
RF, whose median AUROC value was approximately 0.89 ± 0.04 (as shown in Figure
24A).

Figure 24. Machine learning models for classification of mutated C-kit1 sequence from
unmutated one. (A) Evaluation of model performance based on the distribution of their
AUROC value: models were ranked based on the median AUROC score and arranged from
best to worst performance (top to bottom). (B) Confusion matrix shows results of random
forest classification for mutated sequence from unmutated one using nanopore events.
Unmutated sequences contained Ckit1 DNA and mutated group consists of all other
sequences (i.e. L1M1, L1M2, L2M1 and L2M2). The random Forest classifier model
yielded an overall sensitivity of 81.9%, specificity of 83.4% and balanced accuracy of
82.7%.

To visualize the true positive and false positive rates, we constructed a confusion
matrix for the RF model (Figure 24B). This matrix shows the true positive and true negative
prediction corners (black boxes) at the top left and bottom right, respectively. On the other
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hand, the false negative and false positive predictions are placed in the lower left and upper
right corners (orange boxes). Thus, for mutated and unmutated Ckit1 sequences, the RF
classifier yielded an 82.7% accuracy, 81.9% sensitivity and 83.4% specificity. As
determined before, point mutations have varying effects on the secondary structural
volume and stability. It was surprising to see that most classifiers yielded a poor
performance since point mutations can increase or decrease the mutated structure’s volume
and stability concurrently (depending on the number and position of mutation). This
hindered the model performance. Applying the same classifiers on datasets containing
Ckit1 and only one mutated sequence will enhance the accuracy of classifiers. However,
this would not be practical in a real-world scenario, where the number and position of point
mutation is unknown.
5.5 Conclusions
Through this nanopore single-molecule study, we determined the effect of point
mutations on stability of Ckit1 G-quadruplex and CX-5461 stabilizing efficiency using the
event dwell time. With a maximum width of approximately 2.1 nm,253 the G-quadruplex is
able to fit within the 2.6 nm wide nanocavity entrance. However, the β-barrel entrance
(constriction site) of the nanopore is just 1.4 nm wide, making it impossible for the Gquadruplex structure to translocate without unfolding. Therefore, electrophoretic force
drives the analyte into the nanocavity where it becomes trapped and either (1) unravels and
translocates through the β-barrel and into the trans side of the test chamber, or (2)
regurgitates backward into the cis solution.47 Previous studies have demonstrated that
translocation events with G-quadruplex have significantly longer dwell times on the order
of several seconds due to the extra time needed for the structure to unravel while it is
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trapped in the nanocavity.47,
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By contrast, simple linear DNA produces very short,

transient current blockages.47 Taken together, this indicates that dwell time provides a
valuable assessment of the structural stability of the G-quadruplex, with higher dwell times
indicating a more stable structure.
Results obtained from our study suggest that the number and position of mutations
have an impact on G-quadruplex structural stability. Furthermore, addition of CX-5461 to
samples does not have a significant effect on the stability of samples with a mutation on
the top G-quartet (layer 1), implicating it as a crucial factor in the binding of CX-5461 to
the DNA structure. Lastly, addition of CX-5461 to conditions with an intact level 1 (Ckit1
positive control, L2M1, and L2M2) resulted in an increase in G-quadruplex stability, with
the exception of L2M1 which oddly exhibited a decrease in stability. Using Random Forest
algorithm on nanopore data, we were able to distinguish mutated Ckit1 sequences from
unmutated ones with an overall sensitivity of 81.9%, specificity of 83.4% and balanced
accuracy of 82.7%. Excessive activation of the C-kit1 gene is implicated in several human
malignancies and its expression is downregulated by the stabilization of its G-quadruplex
structure.254 Knowing the effect of mutation on drug efficiency can have implications in
the implementation of cancer therapies, particularly the drug CX-5461. As mutations on
G-quadruplex sequences have been observed in several cancers, this research may be
helpful in constructing methods to predict therapeutic responses and personalizing cancer
treatment.
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Chapter 6
Employing LiCl Salt Gradient to Slow Down DNA Translocation for Label-Free
Detection of Cytosine Methylation
6.1 Abstract
In this chapter, we demonstrate a label-free detection, biological nanopore-based
method to distinguish methylated cytosine (mC) from naked cytosine (C) in sample
mixtures containing both C and mC at prolonged translocation duration. Using 15-fold
increase in LiCl salt concentration going from cis to trans chamber, we increased the
translocation dwell time of ssDNA by over 5-fold and the event capture rate by 6-fold in
comparison with symmetric concentration of 1.0M KCl (control). Moreover, salt gradients
can create a large electric field that will funnel ions and polymers towards the pore,
increasing the capture rate and translocation dwell time of DNA. As a result, in 0.2M –
3.0M LiCl solution, ssDNA achieved a prolonged dwell time of 52 𝜇s/nucleotide and a
capture rate of 60 ssDNA per second. Importantly, lowering the translocation speed of
ssDNA enhances the resulting resolution, allowing 5’-mC to be distinguished from C
without using methyl-specific labels. We successfully distinguished 5’-mC from C when
mixed together at ratios at 1:1, 3:7 and 7:3. Distribution of current blockade amplitudes of
all mixtures adopted bimodal shapes, with peak-to-peak ratios coarsely corresponding to
the mixture composition (e.g. the density and distribution of events shifted in
correspondence with changes in 18b-0mC and 18-2mC concentration ratios in the
mixture).This chapter was adopted from our published article (Vu, Trang, et al.
"Employing LiCl salt gradient in the wild-type α-hemolysin nanopore to slow down DNA
translocation and detect methylated cytosine." Nanoscale 11.21 (2019): 10536-10545.)
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6.2 Introduction
Cytosine methylation is the most well-established and understood epigenetic
modification on DNA, affecting the activity and stability of genomic regions.118, 255-256
Specifically, methylation of cytosine is the gain or loss of a methyl group on cytosine in
the 5-position,56, 257-258 which is frequently found at CpG dinucleotides.256 These CpG
nucleotides often occur in bunches widely known as “islands” which are linked to promoter
regions of genes. Aberrant methylations of these regions can lead to gene inactivation or
loss-of-function mutations.259 Beside DNA promoter regions, cytosine methylation of
various types of RNA (e.g. tRNA, mRNA, and non-coding RNAs) has gained increasing
attention in recent years.260-263 For instance, it was shown that specific signature
methylation pattern of microRNAs (miRNA1, miRNA9, miRNA124 and miRNA137)
could be used to identify ulcerative colitis patients with elevated risk for colorectal
neoplasia.264 Unlike genetic mutations, which can occur anywhere in a gene, cancerspecific cytosine methylation mostly locates at defined regions (e.g. the promoter of genes
or on specific sequences), making it easier to devise targeted probes for molecular
alterations.
Currently, bisulfite-conversion is the “gold-standard” to detect and profile DNA
methylated cytosine.265 However, bisulfite-conversion cannot directly identify 5methylated cytosine (5-mC) from native DNA. Unmethylated cytosine must first be
converted to uracil, consequently, increasing the complexity of library preparation and the
potentials for artifacts and biases. Due to extensive fragmentations in the bisulfiteconversion process, any breaks at inserts can prevent downstream amplification of DNA.265
Recently, several studies using both solid-state and biological nanopores have
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demonstrated different ways to detect and quantify the presence of 5’-mC on both ss- and
dsDNA by long-read sequencing,266-267 employing methyl-CpG-binding domain protein
(MBD),56, 268 Kaiso-Zinc Finger (KZF),56 optical-tagging,57 among many others.145-148, 275
Comparing to PacBio and bisulfate conversion, methylation detection with nanopore
technology has yet to match the performance, but shows advantages on maintaining the
DNA sequence complexity and imprinting.267
In this chapter, we investigated the ability of wild-type α-hemolysin nanopore in
label-free detection of methylation on cytosine, with a focus on slowing down translocation
velocity to enhance the result readout and accuracy. Through research and analytics,
several methods have been proposed to impede translocation velocity via decreasing
experimental temperature, altering bulk density, changing applied potential, or using an
alternating electric field.269 However, compared to those physical conditions, the effect of
cation nature, electrophoretic, electroosmotic, and diffusioosmotic flows are far more
significant on the translocation of DNA.269-271 In our study, electrophoretic, electroosmotic,
and diffusioosmotic flows have been adopted to slow down the translocation velocity of
ssDNA through biological nanopores, enabling label-free detection of 5-mC from C in
ssDNA mixtures.
6.3 Methods
6.3.1 DNA samples. Synthetic 18-mer, single-stranded DNA purchased from
Integrated DNA Technology (Coralville, IA) have the following sequences:
Sample 1 (18b-0mC): 5’-TAA TCA TCG CGT ACT AAT-3’
Sample 2 (18b-2mC): 5’-TAA TCA TMG MGT ACT AAT-3’ (with M represents 5’-mC)
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DNAs were suspended in a buffer solution containing Tris (10mM) and EDTA (1.0mM),
titrated to 8.0 pH, then aliquoted and stored at -80oC until usage. For all experiments, DNA
final concentration of 1 μM in the cis chamber was used.
6.3.2 Experimental setup. Each chamber was filled with electrolyte solutions with
either LiCl or KCl solution, with a salt concentration of 0.2M, 1.0M or 3.0M, buffered with
10mM Tris and titrated to pH 7.2. The salt concentrations in each chamber varied based on
the experimental conditions being tested.
6.3.3 Single-channel recording. Single-channel recordings were performed using
Axopatch 200B (Molecular Device Inc.), filtered with a built-in 4-pole low-pass Bessel
Filter at 5kHz. Data were acquired with Clampex 10.7 (Molecular Device Inc.) and Axon
Digidata 1550B A/D converter (Molecular Device Inc.), at a sampling rate of 20 kHz. The
data were analyzed using Clampfit 10.7 (Molecular Device Inc.), Excel (MicroSoft) and
MatLab (2017a) software. Event blockage amplitudes were determined from amplitude
histograms by fitting the peaks to Gaussian functions (single-sample and mixture models).
The duration and occurrence of short-lived blocks for DNA translocation were obtained by
fitting the dwell-time histogram to an exponential distribution. Only current-blockage
events with %I/Io ≥ 70% were selected for data analysis. 35 Those with %I/Io < 70% are
considered as brief interaction of DNA and the pore entrance (e.g. interaction of hairpin
structure with vestibule), rather than DNA translocation, thus, were disregarded.237 Data
were given as the mean ± SD, based on at least three separate experiments.
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6.3.4 Mixture analysis. Current blockage events were calculated as the percent
blockage of the open pore current (%I/Io). To predict the distribution of the two samples in
mixture solutions, %I/Io was first calculated, then fitted with Gaussian Mixture Model (two
components) in MatLab (2017a).
6.4 Results and Discussions
We employed the α-hemolysin nanopore as a single channel sensing element to
detect ssDNA at single-molecule level. Experiments were performed on two singlestranded DNA samples with identical sequences, containing either cytosine, or 5methylcytosines at the center, hereafter, called C-DNA and mC-DNA. C-DNA has a
sequence of 5’-TAA TCA TCG CGT ACT AAT-3’, and mC-DNA has a sequence of: 5’TAA TCA TMG MGT ACT AAT-3’ (with M standing for 5’-mC). Most of the studies
have largely investigated long nucleotide sequences (hundreds to thousands bases), thus,
in this study, we selected 18-mer sequences to investigate the effect of electrophoretic,
electroosmotic and methylation hydrophobicity on shorter strands, such as tRNA and
miRNA. All experiments were reproduced multiple times, yielding comparable results.
The open pore conductance varies upon the change of solute ionic concentration and
gradient. Let Ctrans/Ccis be the ionic concentration ratio between the trans and cis chambers.
With Ctrans/Ccis > 1 (higher salt concentration in the trans side), there is a constant diffusion
of cation from the trans to cis chamber, creating a negative current even if there is no
external voltage applied.
The α-hemolysin nanopore is water-filled, thus, the charge distribution inside the
pore is relatively consistent, reflected by the approximately linear I-V curves of α-
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hemolysin nanopore (Figure 25). The 5kHz low-pass Bessel filter in Axopatch 200B and
20,000 s-1 sampling events were selected for all measurements in this study.

Figure 25. Current -voltage (I-V) curves of the α-hemolysin nanopore at various
experimental conditions.

6.4.1 Li+ and salt gradient increase translocation time. Cations, depending on
their ionic radii and concentration, can affect the electrophoretic mobility of DNA
differently.272-274 To examine this, we conducted two sets of experiments on both samples,
18b-0mC and 18b-2mC DNAs, at various conditions of: (1) symmetric and (2) asymmetric
salt concentration in the cis and trans chambers. For symmetric 1.0M – 1.0M solutions, we
found that the ratio for the translocation time, ∆t, of ssDNA is KCl : LiCl ~ 1 : 2.3 (Figure
26A – B). When comparing within the same type of sample (either 18b-0mC or 18b-2mC)
translocated through the pore at +120mV, as the ionic concentration in the trans side
increases from 1.0M LiCl to 3.0M LiCl, the translocation time, ∆t, increased approximately
1.3 times (Figure 26 C – D). More notably, the addition of a salt gradient is shown to further
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intensify the magnitude of ssDNA translocation time through the nanopore. With a 15-fold
increase in ionic concentrations going from the cis to the trans chambers (0.2M – 3.0M
LiCl), the average translocation times of 18b-0mC and 18b-2mC DNA are 0.945 ms and
0.765 ms, respectively, at biased voltage of 120 mV. In other words, the addition of a salt
gradient (0.2M – 3.0M LiCl in cis/trans) increases the translocation times of both samples
by 2-fold and 5-fold, when compared to the results obtained from 1.0M – 1.0M LiCl and
1.0M – 1.0M KCl solutions of the same sample type (either 18b-0mC or 18b-2mC, as
shown in Figure 26A – D). Note that the open pore current depends on the electrolyte’s
conductivity and ionic concentration. Thus, amplitudes of open pore current decreases with
decreasing ionic concentration in the cis side, reflected by current blockages with various
amplitudes (Figure 26E – F).
Overall, an increase in salt concentration gradient going from the cis to the trans
chamber results in a proportional elongation of individual DNA translocation time.
Notably, in any given experimented solutes and applied voltages, mC-DNA translocate
through the nanopore faster than C-DNA does. This result agrees with findings from a
previous study, showing that addition of a methyl group on Cytosine (mC) increases the
local hydrophobicity and rigidity of G-mC bps, thus leading to a smoother and faster
translocation of mC-DNA through the nanopores.275
To understand the changes in ∆𝑡 observed in this experiment, we scrutinize the
effect of Li+ ions on ssDNA and its surrounding environment. Li+ ions can effectively
reduce the mobility of ssDNA through the α-hemolysin nanopore, because of its counterion effect and physical-chemistry properties. In theory, electrolyte solution containing
monovalent counter-ions can alter the electrophoretic mobility of DNA in different ways,
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including changing water’s bulk properties,276 modifying DNA conformation, and
affecting the preferential binding of counter-ions to DNA.272, 277-279 More specifically,
binding of counter-ions partially neutralizes the negatively charged phosphate backbone;
which in turn decreases the overall effective net charge and mobility of DNA molecule. 272,
280

Figure 26. Comparison of cation effects on DNA translocation time. (A – D) 18b-0mC and
18b-2mC DNA translocation time, ∆t, in: (A) 1.0M – 1.0M KCl (control), (B) 1.0M – 1.0M
LiCl, (C) 1.0M – 3.0M LiCl, (D) 0.2M – 3.0M LiCl (optimal condition). The recorded ∆𝒕
were plotted as a function of applied voltage at 100mV, 120mV, and 140mV. All points
are the value of the fit with standard error. Each data is overlaid with over n = 2000
separated translocation events recorded per data point. The 18b-2mC DNA, with an
increased in hydrophobicity due to the addition of methyl groups, can translocate through
the nanopore faster than 18b-0mC DNA does at any given experimental condition. At 0.2M
– 3.0M LiCl (cis/trans), event translocation times were prolonged approximated by 6-fold
for both DNA samples, when compared to 1.0M KCl (control). (E-F) Characteristic current
blockade signatures representing the 18b-0mC DNA (left) and 18b-2mC DNA (right)
through the α-hemolysin nanopore are shown. 18b-2mC DNA generates shallower current
blockages than 18b-0mC does for all applied voltages. Overall, the current blockage
amplitude, ∆𝑰, is a dependence of cation and its concentration in the experimental solution.
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Previous studies showed that binding affinities of cations to DNA are inversely
proportional to the radius of the specific binding ion. Thus, binding affinity of cations to
DNA increases with decreasing ion radius, explaining the increased bond strength of
binding Li+ as opposed to K+. The measured radii of Li+, Na+ and K+ has been reported as
follows: 0.69, 1.02 and 1.38 Å, respectively.276, 281 Lithium shows the strongest binding
affinity, as well as the longest binding time, resulting in increased translocation times of
ssDNA in solid-state,271 and in biological nanopores, as shown here.
However, the physical-chemistry properties of Li+ in fact are a greater contributor
in decreasing the mobility of DNA. Studies show that the effects of these binding counterions are due to changes in viscosity of the electrolyte solution, and perturbed hydrogen,
leading to a decrease in the mobility of both ss- and dsDNA.282 Specifically, lithium is
considered a water making ion, since it has a greater number of hydrogen bonds in solution
compared to neat water (∆NHB). In lithium, the ∆NHB is 0.28, whereas potassium, a water
breaking ion, has a ∆NHB of -0.58.272 A positive ∆NHB indicates an increase in the friction
between water molecules due to its effect on hydrogen bonding.272 The rotational
correlation times of water molecules may indicate DNA mobility since they are related to
the number of hydrogen bonds between the water molecules.279 Overall, the viscosity
coefficient of lithium is higher than the viscosity coefficient of potassium, further
indicating that DNA is less mobile in lithium ion solution than potassium ion solution.272
Higher viscosity leads to a decrease in DNA mobility; and therefore, its increased
translocation time.283
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6.4.2 High ionic concentration decreases DNA mobility. Increase in solute bulk
conductivity at high ionic concentration can prolong the translocation time of DNA.284 An
approximate 2-fold increase in ∆t is observed as the ionic concentration switches from
symmetric 1.0M to 3.0M of KCl or LiCl (Table 11 and Table 12). This can be explained
by the interionic effects at high concentration, which as a result, increases the resistivity of
the ionic solution.284 Interionic effects occur when ions are submerged in an ionic space
with a net charge opposite that of the ion’s.284-286 Thus, this ionic solution diminishes the
mobility of the ions within through a drag force. This interionic effect is related to the
concentration of the ionic solution in that a weak electrolyte solution promotes weak effects
whereas a strong electrolyte solution promotes strong effects. Furthermore, in highly
concentrated solute (e.g. 3.0M LiCl), DNA molecules are saturated with counter-ions that
can decrease effective charges on the DNA and therefore, prolong the translocation time.
Notably, lowering the ionic concentration in the cis chamber, while keeping the trans
chamber with the same concentration (1.0M – 3.0M LiCl and 0.2M– 3.0M LiCl) can
further increase the translocation time of ssDNA (Table 13). This phenomena were
explained in a previous study.287 Briefly, longer translocation time of DNA under
asymmetric salt concentration is an effect of increasing electroosmotic flow of counterions along the DNA. With the salt concentration lowers in the cis than in the trans chamber,
cations move from trans to cis, down the direction of both electrical and chemical potential
gradients. Thus, electroosmotic flow of cation is significantly increased.287 This further
provides a drag force opposed to DNA motion in the pore, hence, hindering the
translocation speed of DNA. Through lowering the ionic concentration of electrolyte
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solution in the cis side, while keeping trans side constant, we achieved the highest
electroosmotic flow of cation (trans to cis) at 0.2M – 3.0M LiCl.

Table 11
Summary of event analysis for 18b-0mC sample in KCl solutions

1M-3M KCl
1M-1M KCl
3M-3M KCl
3M-1M KCl
3M-0.2M KCl

Amplitude (pA)
Mu
Sigma
-179.05
3.82
-101.79
6.67
-282.99
4.84
-169.38
4.56
-109.72
2.34

Dwell time (ms)
Tau
S.E.
0.32
0.04
0.17
0.003
0.47
0.015
0.13
0.011
0.14
0.067

Frequency (s-1)
Tau
S.E
10.08
0.38
6.72
0.43
1.30
0.06
0.98
0.08
0.24
0.04

Note: All data were collected at 120mV, pH 7.2. Experiments with asymmetric
concentration are denoted in the order of cis – trans concentration.

Table 12
Summary of event analysis for 18b-0mC sample in LiCl solutions

Condition
0.2M-3M LiCl
0.3M-3M LiCl
0.5M-3M LiCl
1M-3M LiCl
2M-3M LiCl
3M-3M LiCl
3M-1M LiCl
3M-0.2M LiCl
1M-1M LiCl
1M-1M KCl

Conc.
Trans/
Cis
15
10
6
3
1.5
1
0.33
0.067
1
1

Amplitude (pA)
Mu
Sigma

Dwell time (ms)
Tau
S.E.

Frequency (s-1)
Tau
S.E.

-79.63
-88.35
-87.14
-137.4
-152.3
-166.4
-168.1
-149.2
-79.27
-101.8

0.945
0.88
0.81
0.67
0.57
0.52
0.19
0.18
0.38
0.17

55.62
52.03
47.62
34.53
2.44
0.68
1.47
0.94
4.8
6.72

2.49
0.47
0.21
4.39
3.65
3.39
4.31
0.61
3.54
6.67

0.08
0.05
0.06
0.02
0.07
0.02
0.02
0.01
0.02
0.01

3.32
4.70
2.08
1.72
0.16
0.09
0.13
0.13
0.31
0.43

Note: All data were collected at 120mV, pH 7.2. Experiments with asymmetric
concentration are denoted in the order of cis – trans concentration

100

Table 13
Effect of salt concentration on the translocation events

1M-1M KCl
1M-1M LiCl
1M-3M LiCl
0.2M-3M LiCl

I (pA)
-101.79 ±
6.67
79.27 ±
3.54
137.40 ±
4.39
79.63 ±
2.50

18b-0mC
∆t (ms)
0.17 ±
0.01
0.38 ±
0.02
0.67 ±
0.02
0.95 ±
0.08

𝒇 (s-1)
6.72 ±
0.43
4.80 ±
0.31
34.54 ±
1.72
55.62 ±
3.33

I (pA)
101.06 ±
4.38
77.50 ±
5.25
131.21 ±
4.73
74.03 ±
2.56

18b-2mC
∆t (ms)
0.16 ±
0.01
0.36 ±
0.02
0.63 ±
0.02
0.76 ±
0.08

𝒇 (s-1)
10.29 ±
1.08
7.04 ±
0.77
35.31 ±
4.35
59.84 ±
1.82

(Note: All data were collected at 120mV, pH 7.2. Experiments with asymmetric
concentration are denoted in the order of cis – trans concentration)

6.4.3 Effect of salt gradient on the event occurrence. Salt concentration
asymmetry (0.2M – 3.0M LiCl) results in a significant increase in the event capture rate.
A series of experiments were conducted by varying the ionic concentration between the cis
and the trans sides revealing significant changes in the amplitudes, as well as dwell time,
and occurrence of current blockage events. Both of the latter properties are inversely
proportional to Ctrans/Ccis (the ionic concentration ratio going from trans to cis chamber).
In other words, ∆t and 𝑓 s significantly increases when Ctrans/Ccis > 1 and decreases rapidly
with Ctrans/Ccis < 1 (event data traces are shown in Figure 27 and Figure 28). Interestingly,
although the event capture rate is controlled by multiple factors (e.g., ionic concentration,
voltage amplitude, and cation’s nature), ionic concentration gradient between the cis and
trans sides exhibits the most abundant effect. Figure 29A–D shows sample traces for
typical events of 18bp ss-DNA translocations in 1.0M – 1.0M KCl, 1.0M – 1.0M LiCl,
1.0M – 3.0M LiCl, and 0.2M – 3.0M LiCl salt solutions (from top to bottom). We found
that for 1.0M solutions, the ratios for the experimental event occurrence (or event
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occurrence, 𝑓 s) of ssDNA are KCl/LiCl ~ 1.40 and 1.46 for C-DNA and mC-DNA samples,
respectively. Upon changing the salt concentration between cis and trans chambers from
1.0M – 1.0M LiCl to 1.0M –3.0M LiCl and 0.2M – 3.0M LiCl, occurrence increase
significantly. As shown in Figure 29E – F, while the translocation times are found to
gradually increase, the event occurrences, 𝑓 s, quickly reached maximum value as the
trans/cis concentration ratio exceed 2-fold. Specifically, C-DNA sample increase
approximately 12 and 82 times upon changing the solute from symmetric 1.0M – 1.0M
LiCl to 0.2M – 3.0M LiCl, and from symmetric 3.0M – 3.0M LiCl to 0.2M– 3.0M LiCl,
respectively (Table 13). Interesting, both of the plots obtained from Figure 29E – F have a
logarithmic trendline (R2 ≥ 0.92), different from a linear one obtained previously in solidstate nanopore system.271, 287

Figure 27. Sample data traces and current blockage events of 18b-0mC in KCl electrolyte
buffers with varied concentrations. Different ionic concentrations between the cis- and the
trans side lead to significant changes in events dwell time and occurrence. All data were
collected at 120mV, pH of 7.2.
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Figure 28. Sample data traces and current blockage events of 18b-0mC in LiCl electrolyte
buffers with varied concentrations. Different ionic concentrations between the cis- and the
trans side lead to significant changes in events dwell time and occurrence. All data were
collected at 120mV, pH of 7.2.

Figure 29. Effect of salt concentration on event occurrence. (A – D) Raw data traces of
18b-0mC and 18b-2mC DNA translocate through the nanopore at: (A) symmetric 1.0M
KCl, (B) symmetric 1.0M LiCl, (C) asymmetric 1.0M – 3.0M LiCl, (D) asymmetric 0.2M
– 3.0M LiCl. (E) Correlation between trans/cis concentration ratio and event occurrence of
both samples, and (F) Correlation between trans/cis concentration ratio and dwell time of
both samples. For all experiments, ionic concentration of the trans side was fixed at 3.0M
LiCl, while cis concentration decreases from 3.0M to 0.2M LiCl. At any given
experimental condition, the event occurrence of both samples was comparable, while the
translocation time of 18b2mC were shorter than 18b0mC DNA. All data presented were
collected at 120mV applied voltage.
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In the presence of salt concentration asymmetry, the drastic increase in attraction
of ssDNA toward the nanopore is a consequential result of two main factors:
electrophoretic effects and diffusioosmotic flow.288 Specifically, as the constant current of
ions flowing through the nanopore, it creates a long range electric field funneling ions and
DNA toward the pore,287-291 increasing the DNA electrophoretic motion.288 Moreover,
because of the asymmetric salt concentration between the cis and the trans sides, there is
a constant diffusion of ions between the two chambers, creating an additional electric field.
For concentrations lower on the cis than the trans side of the pore, the created electric field
is larger than if the concentrations were reversed.292 The stronger the electric field, the
better the pore is able to pull cations through the membrane.292 Since the asymmetric salt
concentration is increasing the electric field within the pore, it is also increasing the
effective voltage in the cis side without reducing translocation times.287 This effect is
mostly due to the conductance of the pore which is dependent on both the polarity and
magnitude of the voltage applied.281 Thus, using asymmetrical salt concentration can
greatly enhanced capture rate, proven in previous studies by successful detection of
extremely low concentration samples (at pico- and nanomolar range).293-294
6.4.4 Label-free detection of cytosine methylation. Following the analysis of Li+
and salt concentration asymmetry effect on ssDNA, we further investigate the ability of the
α-hemolysin nanopore to detect and discriminate methylated cytosine in both pure and
mixed samples with unmethylated cytosine. Using various methods, previous works have
shown that both solid-state and biological nanopores can be used to distinguish 5’-mC from
C.56-57, 135, 283, 295-296 Because of the principle of electrical current spectroscopy, the α-
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hemolysin nanopore can discern subtle structural changes on a single molecule through
electrical current signatures.

Figure 30. Detect and distinguishing methylated cytosine. (A) Peak values of gaussian
fitting for current blockage, ∆𝐼 (pA), of pure samples containing only 18b-0mC DNA
(orange) or 18b-2mC (yellow) at: 1.0M – 1.0M KCl (control), 1.0M – 1.0M LiCl, 1.0M
– 3.0M LiCl, and 0.2M– 3.0M LiCl (optimal condition). Peak-to-peak distance increases
as a function of the difference in salt concentrations between the cis and trans chambers,
with the highest peak discrepancy achieved at 0.2M – 3.0M LiCl (cis/trans). (B) Gaussianfittings for the distribution of current blockage amplitude for both samples at 0.2M – 3.0M
LiCl. (C) Raw data trace of the 1C – 1MC mixture contains current blockage events with
two different levels, denoted as ImC for mC-DNA events and IC for C-DNA events,
respectively. (D-F) Distribution of current blockages of 18b-0mC and 18b-2mC mixtures
of different ratios: (D) 1:1, (E) 3:7, and (F) 7:3. The distribution of event blockages exhibits
bimodal shapes for all mixtures. All data were collected at 120mV applied voltage.
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Figure 31. Gaussian fittings of 18b-0mC and 18b-2mC samples’ event blockages at: 1M1M KCl, 1M-1M LiCl, 1M-3M LiCl, and 0.2M-3M LiCl. As the concentration gradient
between cis- and trans chamber increases, the peak-to-peak distance between two samples
also increases. All data were collected at 120mV at pH 7.2 solutions.

The two samples employed in this study, C- and mC-DNAs, have an identical
sequence, but differ in 5’-mC content. Gaussian-fittings of their current blockade
information were then overlaid, revealing the changes in current blockages with regards to
the electrolyte (see Figure 30A). Under symmetrical salt concentration of 1.0M KCl on
both cis and trans sides, 5’-mC and C show the least discrepancy between one another
(Figure 30A and Figure 31). Whereas in LiCl electrolyte solutions, the two Gaussian peaks
are clearly separated from one another, with a peak-to-peak distance increase in direct
relationship with the asymmetric concentration difference of LiCl between the cis and trans
sides (Figure 31). The difference in peak position is most pronounced for experiments
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conducted at 0.2M – 3.0M LiCl (Figure 30A – B). This finding agrees with our hypothesis
that reduced translocation speeds of DNA through the nanopore can increase the resolution
of readout results, allowing 5’-mC to be distinguished from C. Notably, C-DNA causes a
slightly deeper current blockade than mC-DNA does, at any experimental conditions.
To further examine the ability of α-hemolysin nanopore in distinguishing 5’-mC
from C within the same solution, we performed experiments on the mixtures of C- and mCDNA samples at different ratios (C : mC): 1:1, 3:7, and 7:3 (see Figure 30D – F). As
discussed in previous sections of this study, the 0.2M – 3.0M LiCl experimental condition
has the most pronouncing effects on the event occurrence and dwell time of ssDNA; thus,
was chosen for this second set of experiments. A sample current trace of the C-DNA : mCDNA mixture (1:1 ratio), with two level event blockades, is depicted in Figure 30C. Herein,
we developed a MatLab code employing a Gaussian-fitting for a mixture with n
components (n = 2). Histograms of current blockades of all mixtures adopted a bimodal
shape, contributing to the presence of 5’-mC and C. The predicted Gaussian-fittings yield
peak-to-peak ratios that are coarsely corresponded to the mixture composition, specifically,
with the density and distribution of events shifted in correspondence with changes in 18b0mC and 18-2mC concentration ratios in the mixture (Figure 30E – F).
Different methods to detect and quantify 5’-mC on both ss- and dsDNA using
nanopores have been demonstrated in previous studies.56-57, 135, 295-296 In theory, the current
blockade amplitude is directly corresponded to the size of the molecule translocating
through the pore. Although the addition of a methyl group slightly increases the size of the
5’-mC base, whether 5’-mC DNA cause a smaller or larger current blockage than C DNA
is dependent on the near sequence of the DNA strand. The magnitude of the current
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blockade produced by mC, compared to C, translocating through the α-hemolysin nanopore
is found to be varied between ours and previous studies,295-296 this inconsistency in current
blockage amplitude indicates that the size of a methylated DNA strand is sequencedependent. It is well-known that cytosine methylation can alter the local DNA structure.297299

Cytosine methylation has influence on DNA curvature and can induce local distortion

in the structure of DNA.297-298 Moreover, the presence of methyl groups can exert an effect
on A-tracts position up to three base pairs away from the site of methylation.299
Furthermore, the presence of hydrophobic methyl group can subtly widen the major
groove, and in turn, narrow the minor grove, leading to steric hindrance.300
Moreover, presence of a cytosine methylation can increase the angle of DNA roll
by 6º or decrease its propeller twist by 5˚, depending on the local sequence.301 Thus, we
suggest that in order to achieve successful label-free detection and profiling methylated
cytosine using α-hemolysin nanopore, the interaction between epigenetic modification and
neighboring nucleotides should be carefully considered. Recently, the Rohs group
developed a high-throughput method, named methyl-DNAshape,301 which could be used
to predict the effect of cytosine methylation on DNA. This should be a promising tool to
couple with nanopore assay for cytosine methylation detection.
6.5 Conclusions
In this study, we have investigated the effect of salt gradients and the nature of
monovalent cations (Li+ and K+) on ssDNA translocation dwell time through the 𝛼-HL
nanopore. Firstly, the attraction of cations to DNA is shown to be an important factor in
affecting translocation speeds. Cations reduce the overall charge of DNA molecules and
the interactions between DNA and counter-ions cause significant changes in the physical
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properties of DNA.292 The counter-ions binding to DNA effectively lower the overall
charge on DNA, lessening the electrophoretic drive of the system, and lowering
translocation speeds. Ion binding to DNA is independent of the ion type, however, bond
strengths are not equal; Li+ bonds last longer on average in comparison to Na+, which last
longer than K+ bonds. The difference in bond strengths lead to different net forces acting
on the DNA, and thus velocity differs depending on the type of electrolyte solution.302
Notably, the stronger electroosmotic flow in the presence of LiCl than KCl can further aid
in the prolonged translocation time of ssDNA through the α-hemolysin nanopore.
Secondly, previous experiments show that DNA is saturated with counter-ions,
thus, increasing the salt gradient will decrease the charge on the DNA.269 Additionally, the
continuum flow theory based on the Navier-Stokes equations assumes the state variables
(such as density) do not significantly change over intermolecular distances. However,
observations showed fluctuations in fluid density close to the surface in molecular
dynamics simulations and experiments, hence, shear viscosity near the nanopore wall
dramatically increases, leading to slower translocation times.284 Salt gradients can create a
large electric field that will funnel ions and polymers towards the pore, 309 increasing the
capture rate and mean translocation time of DNA.288 For concentrations lower on the cis
than the trans side of the pore, the created electric field is larger than if the concentrations
were reversed.287 The stronger the electric field, the better the pore is able to pull cations
through.292
Through a series of comparative studies between C-DNA and mC-DNA, we found
that in a pure sample (containing only either 18b0mC or 18b2mC) with any of the salt
gradient conditions listed in this study: (1) mC-DNA has a shorter translocation time, and
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(2) a smaller current blockage amplitude than C-DNA does. In the presence of cytosine
methylation, the local structure of DNA strands is altered in a sequence-specific manner,
thus, increasing or decreasing the current blockage amplitude of methylated DNA
comparing to an unmethylated strand. Interestingly, in mixtures containing both cytosine
and methylated cytosine, mC-DNA exhibits a lower pore selectivity than C-DNA does.
Using the LiCl salt concentration asymmetry, we were able to detect and distinguish mCDNA from C-DNA without the use of labels, or chemical modifications.
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Chapter 7
Enhancing Cytosine Methylation Detection with MBD2 Protein
7.1 Abstract
In this chapter, we explored the feasibility of enhancing the nanopore signal for
methylated cytosine using engineered methyl-binding domain 2 (MBD2). Dissociation and
translocation of double-stranded DNA through a biological nanopore causes a current
blockage event with distinct levels. Our results showed that cytosine methylation increases
DNA duplex stability, thus, significantly increasing the event translocation time.
Moreover, our results showed that the presence of MBD2 protein significantly increased
the event amplitude and strand dissociation time. Finally, we explored the feasibility of
distinguishing unmethylated from methylated DNA using supervised machine learning
models. Addition of MBD2 protein significantly increased the models’ performance,
yielding the optimal classification model with 88% sensitivity and 86% specificity.
7.2 Introduction
In Chapter 6, we investigated the possibility of label-free detection of DNA
methylation using the 𝛼-hemolysin nanopore. With the aid of an ionic gradient between
the cis and the trans chambers, we were able to distinguish between ssDNA containing
methylated and unmethylated cytosine in mixtures with various composition. In theory, the
current blockade amplitude directly corresponds to the size of the molecule translocating
through the pore. However, label-free detection of 5-methyl-cytosine (5mC) using the 𝛼hemolysin nanopore remains challenging because current blockade amplitude of 5mC is
dependent on its interaction with the neighboring nucleotides, which can induce possible
local conformational changes.
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Methyl-CpG-binding proteins (MBPs) are proteins that are able to identify
methylated cytosine paired with guanine dinucleotides (CpGs), to recruit co-repressor
molecules and modify the surrounding chromatin to block transcription.303 MBPs play an
important role in mediating the silencing of gene expression, and are of particular interest
because they serve as great identifiers for DNA methylation.
In this chapter, we explore the feasibility of using MBP, specifically methylbinding domain 2 (MBD2 protein) as a tag for detection of methylated DNA. Specifically,
we designed synthetic dsDNA fragments containing the GREM_1 promoter region
sequence, with single-stranded overhangs. MBD2 and methylated DNA conjugate to form
MBD2-DNA complexes, which can amplify the signals of current-blockages caused by
methylated cytosine on the dsDNA.304-306 Additionally, the single-stranded overhangs can
translocate through the constriction part of the pore and reside in the long 𝛽-barrel stem,
allowing DNA duplex to unzip with a voltage pulling force. Using ionic spectroscopy, we
showed that binding of MBD2 significantly enhanced the current amplitude difference in
methylated and unmethylated DNA fragments. We also evaluated the effect of adding
MBD2 protein on the overall performance of five supervised machine learning algorithms,
to classify unmethylated from methylated DNA.
7.3 Methods
7.3.1 DNA samples. Synthetic double-stranded DNA with single-stranded
overhangs were designed and purchased from Integrated DNA Technology (IDT –
Coralville, IA). DNA oligonucleotides utilized in this study had the following sequences
(underlined = single-stranded region, bolded
methylated cytosine):
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= GREM_1 promoter region, M

=

u100 DNA (unmethylated DNA):
Forward strand: 5’ – CTT CTG ACT GGG GAG AGG CGC GGC CCC GGG
CCG CGC TCT GCC GCCGC ATT TAA ACG GGA GAC GGC GCG ATG CCT
GGC ACT CGG TGC GCC TAT CTA TGT G– 3’
Reverse strand: 5’- GCG CAC CGA GTG CCA GGC ATC GCG CCG TCT
CCC GTT TAA ATG CC GCG GCA GAG CGC GGC CCG GGG CCG CGC CTC
TCC -3’
m100 DNA (Methylated DNA):
Forward strand: 5’ – CTT CTG ACT GGG GAG AGG CGC GGC CCC GGG
CCG CGC TCT GCC GCMGC ATT TAA ACG GGA GAC GGC GCG ATG CCT
GGC ACT CGG TGC GCC TAT CTA TGT G– 3’
Reverse strand: 5’- GCG CAC CGA GTG CCA GGC ATC GCG CCG TCT
CCC GTT TAA ATG CM GCG GCA GAG CGC GGC CCG GGG CCG CGC CTC
TCC -3’
m100•MBD2: methylated DNA (m100) sequence conjugated with MBD2 protein.
Forward strand: 5’ – CTT CTG ACT GGG GAG AGG CGC GGC CCC GGG
CCG CGC TCT GCC GCMGC ATT TAA ACG GGA GAC GGC GCG ATG CCT
GGC ACT CGG TGC GCC TAT CTA TGT G– 3’
Reverse strand: 5’- GCG CAC CGA GTG CCA GGC ATC GCG CCG TCT
CCC GTT TAA ATG CM GCG GCA GAG CGC GGC CCG GGG CCG CGC CTC
TCC -3’
Upon delivery, all DNAs were suspended in a standard DNA storage buffer
containing 10mM Tris, 1mM EDTA and titrated to 8.0pH. All samples were then aliquoted
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into small volumes and stored at -80˚C until usage, in order to prevent multiple thaw-freeze
cycles that can degrade and affect DNA quality. For both nanopore and circular dichroism
(CD) experiments, a final DNA concentration of 100 nM was used.
7.3.2 Methyl-binding domain 2 (MBD2) protein. Recombinant binding-domain
of MBD2 protein was kindly provided by LumiMac Inc. (South Korea). The purified
MBD2 protein monomer (MW = 10.7kDa) was stored at 1.3mg/ml of buffer containing
25mM Tris (pH7.5), 500mM NaCl, 0.1% Tween 20, 0.1mM EDTA, 0.5 mM DTT and 50%
glycerol. The MBD2 protein samples were shipped in dry ice and immediately stored at 20˚C upon arrival. Prior to experimentation, MDB2 protein was reactivated in a solution
containing 10mM Tris (pH7.2), 1mM MgCl2, 1mM DTT, 5% glycerol for 15 minutes at
room temperature. This step was critical for assuring optimal MBD2 binding activity.
Then, the reactivated MBD2 protein was incubated with methylated DNA at a 2:1
concentration ratio for 15 minutes at room temperature, before being added to the
experimental buffer.
7.3.3 Single-channel recording. Single-channel recordings were performed using
Axopatch 200B (Molecular Device Inc.), filtered with a built-in 4-pole low-pass Bessel
Filter at 5kHz. Data were acquired at 180mV with Clampex 10.7 (Molecular Device Inc.)
and Axon Digidata 1550B A/D converter (Molecular Device Inc.), at a sampling rate of 20
kHz. We used Clampfit 10.7 (Molecular Device Inc.), Excel (Microsoft) and R software
for data analysis and processing.
7.3.4 Data analysis and visualization. Events with translocation time < 2ms or
%I/Io < 50% were considered as either translocation of single-stranded DNA or brief
interaction of DNA and the pore entrance; thus, they were disregarded from data
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analysis.237 We used ggplot2 package (R) to generate boxplots for the overall event dwell
time and histogram of current blockage amplitude.
7.4 Results and Discussion
In this study, we employed three DNA samples with identical sequences but
differences in methylation status: (1) unmethylated DNA (u100), (2) methylated DNA
(m100), and (3) MBD2 bound methylated DNA (m100•MBD2). All DNA samples contain
a double-stranded section (78 bps) and two overhang single-stranded ends (11 bps each).
The specific length of the overhangs was designed to ensure that a sufficient number of
nucleotides resided within the pore 𝛽-barrel at all times, to initiate the unzipping of DNA
duplex upon electrical pulling force.307-311
7.4.1 Mechanism of DNA unzipping through the nanopore. As shown in Figure
32A, when dsDNA unzips in a nanopore it undergoes two distinct steps. The first step is
when the ssDNA tail is caught in the nanopore and begins to translocate,319 while the
ssDNA tail is simultaneously pulled through the bulk solution to the nanopore because of
the DNA’s negative charge.307 As the ssDNA tail gets caught in the nanocavity, the
dsDNA region cannot translocate through the nanopore constriction section without
melting into single-stranded DNAs (e.g. strand dissociation).60 After the dsDNA region
is unzipped, the two strands are physically separated (Step 2).60
Translocation of MBD2-dsDNA complex through the nanopore is similar to that of
unbound dsDNA, with an extra step of protein dissociation (Figure 32B). As the distance
between base pairs of DNA is approximately 0.34nm, the total length of the DNA
sequences would be approximately 34nm total, with single-stranded overhangs of 3.74nm
each.
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Figure 32. Mechanism of DNA translocation through the nanopore. (A) Translocation of
and unbinding dsDNA occurs in two steps: (1) single-stranded tail gets captured by the
pore and (2) complimentary strand dissociates under constantly pulling force of the
electrophoretic field. (B) Mechanism of m100•MBD2 DNA translocation through the
nanopore is similar to that of u100 and m100; however, MBD2 must detach prior to duplex
full dissociation. (C) Typical step-wise function of a translocation event, reflecting the two
stages: (1) DNA capture and (2) strand dissociation. (D) Box-plot of the event amplitude
at each translocation step.

Since the methylated CpG is located at the 44th base from the 5’ end, the doublestranded DNA dissociation (Step 1) must happen prior to MBD2 protein dissociation (Step
1). Specifically, as the MBD2-methDNA complex threads through the 𝛼-hemolysin
nanopore, the MBD2 protein gets stuck at the pore entrance for a short period, then
transiently dissociates from the DNA strand, causing a prolonged current blockage event.
This initial ssDNA blockage results in a Level 1 current blockage (i.e. event capture),
which characterizes the beginning of an event. When the first strand that has the initial
ssDNA strand is translocated, the second strand coils in the vestibule of the nanopore. 307
This coiling results in a sharp and short upshot of the current blockage after the Level 1
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blockage.6 The current drops again as the second strand begins to translocate. 314 If the
second strand exits the nanopore, then the signal will continue to return to the baseline after
the initial spike (Figure 32C).307
Overall, the mechanism of dsDNA strand dissociation is governed by the DNA
sequence (i.e. length, GC content) and by the environment that the DNA experiences (i.e.
voltage, ionic strength, temperature).309 Since the dsDNA region cannot enter the neck,
interactions between the dsDNA and the nanopore contribute to the unzipping.307 The
length of the dsDNA region also affects the ease at which a strand will unzip.312 Longer
dsDNA region associates with a more stable the DNA complex.312 This increase in stability
changes the energy interactions of the energy field and the pore.312 The force of the energy
field causes the dsDNA region to experience an upward shear force.313 As the dsDNA
region unzips, the complex also experiences a traction force as the strands are pulled
apart.313
7.4.2 Binding of MBD2 does not change event amplitude. We examined the
overall average current-blockage event amplitude (%I/Io) of u100, m100, and
m100•MBD2 DNAs (as shown in Figure 33). As mentioned previously, the samples
employed in this study had an identical sequence, but differ in 5’-mC content. Gaussianfitting of their current blockage information exhibited a prominent peak of %I/Io ~ 86.5 ±
1% (Figure 33),

which were slightly shallower than that of single-stranded DNA

translocation through the nanopore (as concluded in Chapter 6).238
Comparing between three samples, the mean current-blockage event amplitude
(%I/Io) increased in the order of u100 < m100 < m100•MBD2 (Table 14). Specifically, the
mean %I/Io were approximately:

85%, 85.6%, and 86.5% for u100, m100 and
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m100•MBD2 DNAs, respectively. Moreover, we performed an unpaired t-test and %I/Io
of all samples was statistically significant from each other at 99% confident interval
(adjusted p << 0.01), as shown in Figure 33. The slight difference in %I/Io of u100 and
m100 DNAs observed herein was resulted from interaction of methylated cytosine with
adjacent bases, as previously discussed (see Chapter 6; Conclusions).238 Addition of MBD2
protein resulted in a 0.9% increase in the event average %I/Io (from 86.5% in m100 DNA
to 86.5% in m100•MBD2 DNA). This change was visible during the strand dissociation
step but not during event capture (Figure 32D). In other words, after the m100•MBD2
complex was captured and started unzipping, the MBD2 protein got pulled toward the pore
entrance, partially blocked the nanopore cis opening, resulting in a slightly deeper %I/Io.

Figure 33. Changes in current blockage amplitude. Distribution of the overall current
blockage amplitude (%I/Io) of three DNA samples, including: u100 (pink), m100 (green)
and m100•MBD2 (blue). All samples exhibited a normal distribution curve, with a
prominent peak at approximately 85 – 87%. Student’s [STUDENTS’?] test showed
significant change in all samples.
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Table 14
Summary of current blockage event amplitude (%)
Condition

Mean (%)

Max (%)

Min (%)

Median (%)

Std.

u100

84.06

92.37

75.29

84.33

3.25

m100

84.71

94.95

75.17

85.60

3.55

m100•MBD2

85.40

98.13

75.02

86.39

3.93

While each current blockage event was a step-wise function, the duration of each
amplitude level was greatly different. In the majority of the dsDNA that successfully
melted and translocated through the pore, strand dissociation was the rate-determining step;
thus, consequently dominates the final value of the average event amplitude. We suspect
that the slight decrease in value of event current blockage of dsDNA observed herein, in
comparison to that of ssDNA, most likely was due to technical limitations. Specifically,
translocation of dsDNA through the nanopore occurs in two steps of capture and
dissociation, leading to a step-wise function in current blockage event amplitude. As shown
in Figure 32D, capture of ssDNA overhang caused a shallow blockage amplitude of 73 ±
0.5%, while the strand dissociation step was characterized by a prominent long block at
87.5 ± 1% (similar to ssDNA translocation). When detected by Clampfit software, the
current blockage amplitude was automatically calculated as an average of the whole event
amplitude, thus leading to a slight decrease in %I/Io of dsDNA translocation.
7.4.3 Increased strand-dissociation time in methylated DNA and MBD2-bound
DNA. Event translocation time reflects the structural stability and interaction with the pore.
In Figure 34, we plotted the distribution of event dwell time for u100, m100 and
m100•MBD2 DNAs in the same experimental condition. Under a +180mV applied voltage
and an ionic concentration of 1M – 1M NaCl (in the cis and trans chambers), the average
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translocation time, ∆t, increased in the order of u100 < m100 < m100•MBD2 DNA (∆t =
1.2, 1.7, and 2s, respectively (Table 15)). In other words, ∆t of m100 and m100•MBD2
DNA increased approximately 1.4 and 1.6 times for m100 and m100•MBD2, respectively,
in comparison with ∆t of u100 DNA.

Figure 34. Changes in translocation time. (A) Boxplot of event dwell time distribution for
unmethylated DNA, methylated DNA and MBD2-methylated DNA complex. Students’
test determined a statistically significant change in dwell time of m100•MBD2, in
comparison to u100 DNA> (B) Bubble plot of event dwell time, associated with two stages
in dsDNA translocation through the nanopore: (1) capture of single-stranded overhangs
and (2) dissociation of complimentary base-pairs in double-stranded section. The majority
of change in dwell time exhibited in the strand dissociation time, reflecting an increase in
duplex stability in m100 and m100•MBD2 DNA.

Table 15
Summary of current blockage event dwell time (ms)
Condition

Mean

Max

Min

Median

Std.

u100

1262.17

23077.65

1.25

153.55

3041.21

m100

1719.08

34113.85

1.05

267.45

3678.56

m100•MBD2

2026.84

44168.05

0.70

344.80

4198.51
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Notably, ∆t of identical DNA sequences from the same group of samples was
greatly varied (from ms to tens of seconds), due to the random thermal activation required
for separation.256 The melting process of dsDNA occurs in two steps: the first is the initial
separation to overcome the energy barrier, and the second is the unzipping of the rest of
the strand.316 The energy barrier refers to the amount of energy required to break the
hydrogen bonds of the dsDNA region.309 The energy that breaks the hydrogen bonds is
fueled by the energy field within the nanopore.321 The electrons in the energy field within
the nanopore causes the dsDNA to denature and begin to unwind.314 Sometimes, trouble
arises during the transition from the initial metastable state to a final stable (lower-freeenergy) state. When this happens, the dsDNA can get stuck inside the nanocavity, causing
current blockage events lasting minutes or indefinitely.315
On the other hand, the overall increase in ∆t among different samples, as observed
from Figure 34A, was a consequential result of increased DNA duplex stability. As
mentioned previously, each translocation event of dsDNA consists of two steps: event
capture and strand dissociation. Through manual analysis of the data, we found the time of
strand capture was similar among the three samples (~250 ±70ms), while strand
dissociation times significantly increase in m100 and m100•MBD2 DNA (as shown in
Figure 34B). As the methylated cytosine is at the 44th base of the DNA sequence, distance
between MBD2 protein and the 5’- or 3’- end of the DNA was sufficiently long (~ 15nm)
to prevent the binding of MBD2 from affecting the capture of ssDNA overhangs.
This explains the reason why capture time remained similar between three samples,
while increases in ∆t of the strand dissociation step indicated enhanced stability of dsDNA
structure in m100 and m100•MBD2. Specifically, the strand dissociation time of u100,
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m100 and m100•MBD2 were 0.87, 1.36 and 1.75s, respectively. In other words, compared
to u100 DNA, there were 1.6 and 2 times increase in strand dissociation time in m100 and
m100•MBD2, respectively. Using an unpaired t-test, we determined that there was
statistically significant change in ∆t of m100•MBD2 in comparison with u100 DNA
(adjusted p value = 0.018). The main contributing factor to enhanced duplex stability was
the presence of methylated cytosine on the 44th base. Previous studies showed that DNA
templates with different content of cytosine methylation have different melting
temperatures.18 DNA methylation increases the DNA duplex stability, reflecting through
both its thermal and mechanical properties. In the context of nanopore experiments,
dsDNA translocating through the pore went through a force-induced strand separation,
which is greatly affected by the strand mechanical stability.
In m100•MBD2 sample, both the presence of methylated cytosine and MBD2
contributed to the prolonged strand dissociation time. As mentioned earlier, in order for
the m100•MBD2 complex to translocate through the pore, MBD2 protein must first
dissociate from dsDNA. A previous study reported MBD2 to have a dissociation constant
(KD) of 2.1 𝝻M.316 The structure of MBD2 consists of a long finger-like projection that is
composed of three strands of 𝛃 sheets.316 When binding to DNA, MBD2 interacts with
approximately 10-11 nucleotide base pairs.316-317 Its finger-like projection extends into
major grooves of the DNA where it contacts the CpG sequence. In particular, the region
contacting the DNA is well structured and thus creates a stable connection.316 This stable
bond is created by interactions between specific amino acids that make up the MBD and
bases of the CpG sequence. Specifically, Arginine (R), Tyrosine (Y), and Aspartic Acid
(D) residues make specific base interactions with the CpG sequence that cause a flat
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orientation.316-318 The Arginine forms hydrogen bonds with symmetrically opposed
Guanine bases. This allows its side chains to pack against neighboring methylated cytosine
groups. This dense packing causes the Arginine side chains to form van der Waals contacts
with the DNA, which further stabilizes the bond.316-317 Finally, the Tyrosine and Aspartic
Acid also form hydrogen bonds with the surrounding complex, which further strengthens
the connection and locks MBD2 into place.316-317 As dsDNA is pulled through the
nanopore, MBD2 protein is anchored at the pore entrance until there is sufficient energy to
break its connection to the DNA; thus, prolonging the event dwell time.
7.4.4 MBD2 enhance methylation detection accuracy. Having determined the
changes in amplitude and stability of the three samples (u100, m100, and m100•MBD2),
we tested the efficiency of using machine learning algorithms to distinguish methylated
from unmethylated DNAs. Specifically, we performed comparative analysis using the
same set of five different algorithms in duplicate on: (1) u100 and m100 DNA and (2) u100
and m100•MBD2 DNA. The final goal was to determine whether employing MBD2
protein enhanced the nanopore’s ability to detect methylated cytosine on dsDNA.
The five algorithms we used included: K-Nearest Neighbor (KNN), Logistic
Regression (LR), Linear Discrimination Analysis (LDA), Quadratic Discrimination
Analysis (QDA), and Random Forest (RF). In each DNA sample group, we randomly
selected 500 current-blockage events, then used 80% of the dataset for model training and
the remaining 20% for validation purposes. Two features of the current-blockage event, ∆t
and %I/Io, were used as input for the models.
To evaluate the overall performance of the models on classifying u100 from m100
DNA and from m100•MBD2 DNA, we constructed two vertical box-and-whisker plots, as
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shown in Figure 35A – B, respectively. In this plot, the box and whiskers show the median
of ARUOC as a dot, and the interquartile range of each distribution as a box around the
median. The x-axis represents the area under the Receiver Operating Characteristics curve
(AUROC). The closer the AUROC value is to 1, the better the model at is correct
classification. Generally, a better model would have higher median AUROC and smaller
range between minimum and maximum AUROC. For a binary system, the threshold is
AUROC is equal to 0.5 (shown as a red line) and maximum AUROC value is equal to 1.

Figure 35. Machine learning classification of methylated and unmethylated DNA. Five
machine learning models were employed to classify u100 from m100 or m100•MBD2. The
models include: K-nearest neighbor (KNN), Random forest (RF), Logistic regression (LG),
Linear discrimination analysis (LDA), and Quadratic discrimination analysis (QDA). Boxand-whisker plots represent distribution of area under the receiver operating characteristic
curve (AUROC). Model’s performance was ranked based on increasing median AUROC
value (shown at the dot).

Classification models for u100 and m100 DNA yielded relatively poor results, with
the majority of the models having a median ARUOC ≤ 0.65. The QDA classifier had the
best performance with a median AUROC of 0.76. The classifier’s optimal sensitivity and
specificity were 78% and 54%, respectively. On the other hand, when applying the
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classifying models on u100 and m100•MBD2 dataset, all classifiers returned a median
AUROC value ≥ 0.75 (comparing to 0.65 for the u100 – m100 dataset).
KNN model had the highest median AUROC of 0.83, with the optimal sensitivity
and specificity of 88% and 86%, respectively. It is worth noting that according to the
decision tree (Figure 36 and Figure 37), the current-blockage event amplitude outweighed
dwell time and played the most important role in classification of u100 from m100 and
m100•MBD2 DNA.
Altogether, our study showed that the addition of MBD2 protein significantly
improved the probability of correctly distinguishing unmethylated DNA from methylated
DNA. A limitation in our prediction model comes from having nonhomogeneous control
samples, specifically m100•MBD2 population. When working with dynamic experimental
conditions, such as those investigated here, the process of MBD2 protein
binding/unbinding to dsDNA happens constantly; thus, there is always a mixture of both
bound and unbound dsDNA in the m100•MBD2 sample. This creates bias in the training
set for the machine learning models and hindered the model performance.
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Figure 36. Decision tree for classification of u100 DNA from m100 DNA.
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Figure 37. Decision tree for classification of u100 DNA from m100•MBD2 DNA.

7.5 Conclusions
In this work, we showed that the α-hemolysin nanopore can be used as a biosensor
for detecting the methylation status of dsDNA. Since a level amount of methylation directly
affects the DNA’s stability and its corresponding translocation time, it is possible to build
a panel of dsDNA translocation times in correlation with the sequence length, GC content,
and methylation level. Previous studies have shown that methylation of a certain level (i.e.
40% CpG is methylated in CDKN2B gene) can result in complete gene silencing, regardless
of the CpG methylation pattern.22 While it will remain challenging to understand the exact
number of methylation sites on a random DNA fragment, it is feasible to determine whether
the sequence is hypermethylated or under methylated (compared to a threshold methylation
percentage), using nanopore aided with machine learning prediction algorithms.
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Chapter 8
Gone Fragments: Capturing Circulating-Tumor DNA
8.1 Abstract
Compared to traditional tissue biopsy methods, the use of plasma or urine samples
(the so-called “liquid biopsy”) is less invasive, improves the patient’s quality of life, while
offering a more reliable and frequent detection of cancer signal over time with longitudinal
sampling. Unfortunately, current methods to analyze liquid biopsy samples are timeconsuming, expensive and biased towards a specific fraction of the genome or mutations.
In this chapter, we describe two novel sample-preparation strategies that enable sequencing
of long cfDNA fragments, which are often missed by the current Next-generation
sequencing (NGS) platforms (i.e. Short-read Illumina sequencers). These techniques,
which employed rolling-circle amplification (RCA) or blunt-end ligation, transform
cfDNA fragments into long strands that are easily captured by the nanopore sequencer. The
proposed techniques can reduce the time required to process and analyze liquid biopsy
samples (from weeks currently to less than 2 days). This study was carried out under the
supervision of Dr. Florent Mouliere (Amsterdam UMC) and in collaboration with the group
from Dr. Jeroen de Ridder (Utrecht UMC).
8.2 Introduction
Liquid biopsy is the study of tumor material collected in a minimally invasive
manner through sampling of blood, urine and other bodily fluids.319 Presence of cell-free
DNA (cfDNA) in human blood was first described by Mandel and Metais in 1948.
Abnormally high concentration of cfDNA in cancer patients was first observed in 1977.320
In 1989, Stroun et al. reported that a fraction of cfDNA from the plasma of cancer patients
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originated from tumor cells, giving rise to the term ‘circulating tumor DNA’ (ctDNA).321322

Among the potential signals of cancer in the bloodstream,323-325 ctDNA has
strongly emerged as a major tool and biomarker for precision medicine in the past
decade.326-328 ctDNA is tumor-derived, fragmented DNA found in bodily fluids. Though
the existence of ctDNA is now widely accepted, the mechanisms by which ctDNA enter
the bloodstream are still unclear.329 There are two main proposed mechanisms for cfDNA
release: (1) apoptosis/necrosis, or (2) active secretion.330-332 CfDNA, which was first found
in the circulation, has been detected in various bodily fluids, including urine, saliva, pleural
fluid, and cerebrospinal fluid.333-338 Epigenetic and methylation analysis revealed that in
healthy individuals and cancer patients, the majority of cfDNA originates from
hematopoietic cells.339-340 These cells have a modal size of approximately 166bps, which
corresponds to the length of DNA wrapped around a nucleosome (~147bp) plus linker
DNA.319 Demonstration by PCR and sequencing revealed that ctDNA molecules are
normally shorter than non-mutant cfDNA, with an average size of 134bp – 144bp.341
However, the cause of shortening in ctDNA fragment is unclear.319
As ctDNA exhibits both the genetic and epigenetic alterations from their cancer
cell origin,339, 342-343 and can reflect tumor type and stage, it has therefore been hypothesized
as a prognostic and predictive marker in cancer treatment selection 326, 344 and detection.345
Specifically, various types of genomic and epigenomic DNA alterations have been
observed in cfDNA, including for example mutation, DNA hypermethylation, copy
number

variation,

microsatellites

instability,

rearrangements

and

losses

of

heterozygosity.346 It is more beneficial to detect cancer earlier when the disease is easier to
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treat. However, the potential use of ctDNA for detecting early-stage cancer still presents
great challenges. For example, ctDNA amount in total cfDNA is usually very low; thus,
demanding techniques with sensitivity for detecting low tumor fraction and high technical
and biological background signal. In healthy individuals, cfDNA concentration tends to
range between 1 and 10 ng per ml in plasma (Figure 38).347-348 In cancer patients, the
concentration of cfDNA in plasma or serum can increase over 10-fold (compared to healthy
individuals), with an average of 180 ng per ml.349 The exact amount of ctDNA released
into the blood stream varies depending on the stage and type of cancer.350-351 While the
concentration of ctDNA content can be much higher in late-stage cancer patients,350, 352-353
they usually make up less than 10% of total cfDNA.354-356 Thus, it is still challenging to
detect and diagnose tumor-related cancers with a good specificity and sensitivity, reducing
the clinical implementation of such methods.

Figure 38. Changes in cfDNA concentration in plasma collected from three non-small cell
lung cancer patients. Samples were collected multiple times for up to three months
(longitudinal sampling). (A) Concentration of cfDNA ranges between 0 – 10ng/µL
(Qubit). (B) Changes in cfDNA overtime and treatment, as normalized by the starting
cfDNA concentration at the first collection time (t = 0). A high cfDNA concentration could
be an indication for high ctDNA in the sample, though more tests are usually followed to
confirm the exact concentration of ctDNA.
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Currently, monitoring disease burden is performed using imaging or molecular
methods, which are associated with radiation exposure or logistical burden.319,

357

Conventional methods for sampling solid tumor, such as needle biopsies, are subjected to
high procedure complication rate (1 out of 6 cases in some cancer types),358 and sampling
biases that arise from tumor genetic heterogeneity.359-361 Compared to the traditional
surgical biopsy, liquid biopsy is less invasive, improving the patient’s quality of life, while
offering a more reliable detection of tumors and mutations over time with longitudinal
sampling. Since the half-life of cfDNA is between 16 minutes to 2.5 hours in circulation,362364

analysis of ctDNA can be considered as ‘real-time’ dynamic snapshot of disease

burden.319
Currently, the majority of liquid biopsy samples are analyzed with PCR methods
or Next Generation Sequencing systems (e.g. Illumina, Roche, or Ion Torrent), whose
optimal DNA read length range between 75-500bp (i.e. short-read sequencing). As these
systems sequence through enzymatic reaction, their efficiency significantly reduces when
the DNA fragment is longer than 500bp.365 While Next-generation sequencing can be
highly accurate, this platform may not practical in clinic, due to extensive processing time
and the restriction imposed by the gene panel used. Another common method for cfDNA
analysis is digital droplet PCR, which has been proven to be a fast and efficient tool for
studying a single locus (a fixed position on a chromosome). However, when the targeted
gene does not have a hotspot (i.e. TP53), it is challenging to design and employ the correct
set of probes, even more if the location of point mutation is unknown.
However, there is a population of cfDNA fragments that is currently missing from
the picture: long cfDNA fragments (Figure 39). Early works using electrophoresis on low-
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percentage agarose gel showed a variation in size of cfDNA, ranging between 0.18 – 21
kbs.349, 366 Recently, long cfDNA fragments (>1000bp) have also been identified in healthy
individuals using long-read sequencing techniques.367 These fragments might be released
to the circulation in association with exosomes,368-369 or by tumor cells via necrosis.370 A
portion of long cfDNA fragment could come from fusion genes or oncogene-carrying
extrachromosomal DNA (ecDNA, 1-3Mbs long),371 which is a potent mechanism leading
up very high copy number of oncogenes.372 Unfortunately, these long cfDNA fragments
are usually poorly recovered due to bias in DNA extraction methods,373-374 sequencing
library preparation,375 and limitation in the enzymatic reaction of the current short-read
Illumina sequencing platforms.319
Nanopore sequencing offers a shorter processing time, lower capital cost, and high
flexibility. At the moment, MinION (Oxford Nanopore) is the most well-known nanopore
sequencer that is commercially available and has been successfully employed in multiple
fields, including oncology research, agriculture, and outbreak surveillance (i.e.CoVid19,
Ebola, Zika virus outbreaks). Unlike other sequencing platforms, nanopore uses electrical
signal disruption (as explained in previous chapters), instead of synthesis. Thus, it does not
suffer from enzymatic reaction exhaustion when sequencing DNA fragments > 500bp (e.g.
long-read sequencing). While nanopore can effectively capture long DNA fragments, it
still suffers from (1) low base-calling accuracy fragments shorter than 1kbp,304and (2) high
amount of DNA input required.
Compared to short-read sequencing platform like Illumina chemistry, read-length
of nanopore is the same as the length of the native DNA fragment in cell nucleus. This
offers a great advantage in analyzing cfDNA size distribution of the whole cfDNA size-
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range, fragmentation, and also gene fusion. While the Oxford Nanopore is attractive with
its ability to directly sequence DNA without PCR amplification, this is not yet an option
when working with cfDNA. Specifically, most of nanopore library preparation kit requires
at least 500ng - 1 µg gDNA input (or 100fmol of shorter DNA), which is approximately
100 times higher than the normal input for other NGS library preparation. As the average
concentration of cfDNA is 1 – 10ng/ ml in plasma, whole genome amplification is a
necessity to increase the starting amount of material for library preparation.

Figure 39. Presence of long cfDNA fragments. Bioanalyzer results of cfDNA extracted
from (A-D) cancer cell cultures media, (E) urine sample, and (F) plasma sample of cancer
patients. Preliminary results showed that the size distribution and concentration of cfDNA
greatly varied among samples and sample types. Besides the characteristic peaks of cfDNA
(~166bp), multiple samples exhibited a presence of long cfDNA fragments (1-3kbs), which
are often missed in sequencing a downstream analysis.
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Thus, it is essential to develop a new protocol for nanopore sequencing that could
effectively capture both short and long fragments of cfDNA. As long cfDNA fragments
(e.g. fusions, extrachromosomal DNA) are currently missed by standard Illumina
sequencing, the nanopore could have here a conceptual advantage for analyzing them.
To tackle this issue, we developed two new protocols to perform the preprocessing
cfDNA for nanopore sequencing, using: (1) rolling-circle amplification to create long
fragments with tandem repeats, and (2) blunt-end ligation to create DNA concatemers.
Specifically, we will discuss technology development and evaluate preliminary results of
using these two techniques on plasma samples from non-small cell lung cancer patients.
8.3 Materials and Methods
8.3.1 Cell culture and sampling. 143B Human metastatic osteosarcoma cells were
cultured in IMDM +/+ (+10% FBS + 1% penicillin/streptomycin). Cells were plated at
30% confluency and allowed to attached for 4hr. Once attached, media was changed to
4mL serum free media. Cells were serum starved for 24hr to synchronize. First collection
was done (0h) at the end of serum starvation, and processed. After that, media was changed
to 4mL regular growth media and media was collected in duplicate at 4h, 24h, 48h and 72h
from the same flask. At 72h, all cells were dead due to lack of space and nutrient and we
excluded this timepoint from the study.
8.3.2 Cell sample processing. Upon media collection, duplicated sample was
divided into two groups (A and B), then immediately processed to remove supernatant.
Specifically, samples in group A were centrifugated at 500 g for 5 minutes (removal of
cells), then 2000 g for 5 minutes (removal of large apoptotic bodies). Samples in group B
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were processed similar to group A, but had a third centrifugation step at 10,000g for 10
minutes (removal of micro-vesicles). All samples were then stored at -20˚C.
8.3.3 Extraction of cfDNA from cell culture. Samples were thawed at room
temperature for 1 hour, then quickly vortexed and spinned down. For each sample, cfDNA
was extracted from 500 µL cell media using QIAamp Blood MiniKit (following
manufacturer’s instruction). Sample was eluted in 200 µL nuclease-free water, and
concentrated to 50µL using SpeedVac at 37˚C. Finally, all samples stored at -20˚C until
quantification.
8.3.4 Extraction of cfDNA from plasma. Blood samples of non-small cell lung
cancer patients were collected aseptically and processed using the standard operating
procedure validated by the Liquid Biopsy Center, Cancer Center Amsterdam (the
Netherlands). For each sample, cfDNA was extracted from 3 mL plasma using
QIASymphony automatic extraction system and magnetic beads chemistry, followed by
elution in 90 µL nuclease-free water and stored at -20˚C. Concentration of cfDNA
extracted checked with Qubit according to the manufacturer’s instructions.
8.3.5 Agilent Bioanalyzer 2100. Size distribution analysis of cfDNA were
performed by capillary electrophoresis using Agilent 2100 Bioanalyzer (Santa Clara, CA),
in combination with a High-sensitivity DNA Chip (Agilent Technologies). Agilent 2100
Bioanalyzer is a microfluidic-based platform for sizing and quantification of DNA and
RNA, using fluorescent dye molecules. The assay was performed according to
manufacturer’s specific instruction for High-sensitivity DNA chip. After separated
analogously to CE, nucleic acids are normalized for size to a ladder and two DNA markers,
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which are then represented graphically as a virtual band. Size and concentration of each
band are automatically calculated by 2100 Expert Software (B.02.08.SI648, Agilent).
8.3.6 Gel electrophoresis. 2% agarose gel (w/v) was prepared by dissolving 1g
agarose in 50mL 1X Tris-Borate-EDTA (TBE) buffer, and 2.5 uL Ethidium Bromine. Gel
was casted and settled at room temperature for at least 30 minutes prior to experiment.
FastRuler Low Range DNA ladder (Thermo Scientific) and O’GeneRuler 1kb Plus DNA
ladder (Thermo Scientific) were used as references. All electrophoresis experiments were
performed at 100mV for 15-45 minutes.
8.4 Methods Development
8.4.1 Detection of long cfDNA in cell culture. Release of cfDNA was
characterized over time (Figure 40). We divided the collected cell culture media into two
group of samples— group A and group B (see Materials and Methods for detailed
information on the difference in sample processing). Comparing between the two groups,
there was no significant change in peaks positions at any given time point. Specifically, at
the end of serum starvation, there was a minimal amount of long cfDNA fragments (~13kbps) observed (collection time t = 0, Figure 40A and E). After growth medium renewal,
the amount of cfDNA increased incrementally, notably peaked after 24h and continued to
increase at 48h. This could be explained by the increasing number of cells in the culture
over time. In addition, previous reports reported that more cfDNA was released also per
cell.376-378
At t = 24h and 48h, we observed an expected peak at 166bp and ladder pattern,
which could indicates an apoptotic origin.379-380 The pattern was reminiscent to that
obtained by apoptotic cells was also observed in both sample groups at 24h and 48h.
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However, besides a peak at ~160 bps, there was a much more prominent peak near ~2kbps
that consistently appeared in all samples, except for at 4h. Previous studies on the same
cell line (143B) showed that these long cfDNA fragments were neither from apoptotic or
necrotic origin.380

Figure 40. Short and long cfDNA fragments in cell culture overtime. Bioanalyzer results
of cfDNA extracted from 143B osteosarcoma cells culture media, collected at 0h, 4h, 24h,
and 72h. (A-D) samples in groups A was centrifuged at 0.5g x 5min and 2g x 5min. (E-H)
samples in group B was centrifuged at 0.5g x 5min, 2g x 5min, and 10g x 10min. Presence
of long cfDNA fragments (1-3kbs) from both groups indicated that they may not come
from dying cells, apoptotic bodies, or microvesicles.
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Samples in both groups were collected at the same time, but processed slightly
differently (Materials and Methods). Because of the difference in centrifugations, samples
in group A contained intermediate-size extracellular vesicles (e.g. microvesicles, 1001000nm), while those in group B only contained smaller extracellular vesicles (e.g.
exosomes, 30-100 nm). Thus, it was interesting that concentrations of long fragments
(~2kbps) at 24h and 48h are higher in group B than in group A. We suspected that these
long fragments might be DNA bound to surfaces of extracellular vesicles that were released
with centrifugation.381 Currently, it is still challenging to access these long fragments using
short-read sequencing platforms.
8.4.2 Methods to capture both short and long cfDNA fragments. Herein, we
describe two sample-preparation strategies that convert cfDNA into long fragments that
can be sequenced on the nanopore systems. The main goal of both protocols was to produce
> 500ng of long cfDNA fragments (>1000bps), through two main steps: (a) whole-genome
amplification and (b) long-fragment synthesis.
8.4.2.1 Method 1: Rolling-circle amplification. The first sample-preparation
strategy enables capturing and sequencing of both short and long cfDNA fragments
through circularization, followed by whole-genome amplification of cfDNA using rollingcircle amplification technique. Rolling-circle amplification is an isothermal enzymatic
process where short, circularized DNA or RNA is quickly amplified to form a long singlestranded fragment with multiple tandem repeats.382 As the RCA products can be tailordesigned through manipulation of the original circular template, this technology has been
widely utilized for biotechnology, drug delivery, diagnosis, and many other techniques.382
For each sample, approximately 40-50ng extracted cfDNA from the plasma of lung cancer
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patients were first end-repaired to create blunt end fragments, then cleaned up with a
commercial reaction cleanup kit. After that, the blunt-end fragments were a phosphorylated
at the 5’ end. This population will be referred to as the insert (I). At the end of each step,
the sample was cleaned up using a column-based reaction clean-up kit in order to remove
excess enzymes and waste products. After the second clean up, we used Qubit to quantify
the concentration of end-repaired DNA samples. The Qubit results indicated that there were
approximately 4.5ng of end-repaired DNA product, reflecting approximatively a 90% loss
of DNA input.
As nanopore sequencing requires at least 500ng -1µg of input DNA (or 50-100 fmol
of shorter DNA fragments), it was essential to perform a whole genome amplification. In
this protocol, the circular template for amplification consisted of two components: the
cfDNA insert (I) and the barcoded backbone sequence (BB). The BB sequence (a 250bp
blunt-end, synthetic DNA fragment) was designed to contain a phi29 DNA polymerase
binding domain, a restriction enzyme cutting site, DNA barcode, and a CRISPR cutting
domain. Phi29 DNA polymerase was chosen for its exceptional processivity and strand
displacement ability.383
Note that in order for ligation to happen, at least one fragment (either I or BB) needs
to be phosphorylated. Backbone and insert cfDNA were mixed and incubated together for
5.6 hr, allowing ligation and circularization. The BB was unphosphorylated, in order to
minimize the amount of backbone-backbone ligation (e.g. containing no cfDNA). After
ligation, there were four possible products: circularized BB:I, circularized BB:BB,
circularized I:I, and linear fragments. As the circularized BB:BB population contained no
biological information of the tested sample, we discarded this group to reduce waste in
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sequencing. In order to do so, backbone DNA was designed so that when two BB:BB
ligated, they would form a sequence recognized and cut by CRISPR. This step prevented
BB:BB products from being amplified by phi29 and sequenced.

Figure 41. Flow chart of sequencing using a guided system. (A) Each cfDNA fragment is
end-repaired and attached to a backbone, then amplified with rolling circle amplification.
This procedure takes approximately two days, yielding an end product containing long
DNA fragments, each of which contains tandem repeats of the backbone and one insert
cfDNA. After that, the sample is ready for nanopore library preparation and sequencing
(24-48hrs). (B) Gel image of DNA after RCA reaction. (C) Preliminary results of all
sequencing reads (Patient 1) from a Flongle flow cell after 48 hours. There were
approximately 70,000 reads in total. (D) Histogram of the insert (cfDNA) length
distribution.

140

The results from the gel electrophoresis (Figure 41B) indicated that for both
samples (Patient 1 and 2), RCA reaction creates DNA fragments of over 20kbps
(undigested). Upon digestion with restricted enzyme, digested samples exhibited three
distinct bands at 250, 400, and 20kbps+. The first two bands corresponded to BB:BB and
BB:I fragments, respectively. Long fragments that remained after restriction enzyme
digestion could result from inefficient digestion, or simply because they did not contain a
backbone sequence (e.g. multiple insert cfDNA ligated together).
Next, RCA primers were annealed to the circular template. RCA reaction was
carried out with 12h incubation (overnight) at 30˚C, then heat inactivated at 60˚C for 10
minutes. RCA reaction yielded > 100µg final product, providing a sufficient amount of
DNA for quality control and multiple sequencing runs. After a final clean up with
Dynabeads, the RCA products were ready for library preparation using 1D Ligation Kit
(Oxford Nanopore Technology) and sequencing.
To evaluate the efficiency of the technique, we performed whole-genome
sequencing on an Oxford Flongle using the RCA product from Patient 1. Compared to the
MinION’s traditional flowcell, a Flongle only has 126 channels, instead of 512; thus, the
output yield is also significantly reduced. However, as the cost per sample is low
(approximately $200), it is suitable for smaller experiments, such as preliminary testing
and quality check. Thus, we first sequenced the RCA product from Patient 1 sample on a
Flongle flow cell. A 48 hr run yielded approximately 70,000 reads, each of which contained
information from a unique fragment post-RCA. Figure 41C shows that about 10% of the
sequenced fragments had no insert (B:B). Only one third of all the reads (blue) had the
expected combination (BB:I, with I > 50bps), whereas the other one third (green) contained
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no backbone (I:I). The rest of the reads (gray) contained extremely short inserts (BB:I, with
I < 50bps) and were discarded from analysis. The number of repeats indicated how many
tandem repeats a fragment had. As RCA is an enzymatic reaction, the number of tandem
repeats could not be precisely controlled.
We selected reads with more than five tandem repeats (approximately 10,000 of the
70,000 total reads) to examine the distribution of cfDNA fragment length (Figure 41D).
As can be seen, the histogram is left-skewed, with a prominent peak near 166 bps, similar
to read length distribution obtained from Illumina sequencing (data not shown). However,
there is a long right tail representing cfDNA fragments of up to 500bps. Also, it is important
to note that Figure 41D only reflects 10% of the total sequencing data.
At the moment, we are working on our bioinformatic pipeline to include RCA
fragments that only contained inserts (I:I). Since the backbone sequence was 250bp, the
optimal length of insert DNA ranged between 90 – 160 bp. While the system could capture
insert fragments outside of the optimal range (as shown in Figure 41D), its efficiency had
not been determined. Thus, we expected the fragment size distribution of fragments
without BB would be quite different from the one shown in Figure 41D. As preliminary
data obtained from Flongle flow cell showed promising results of capturing long cfDNA
fragments, we multiplexed and sequenced RCA products of both patients 1 and 2 using a
PromethION flow cell. While the cost of running a PromethION flow cell is about 10 times
higher than a Flongle, the actual cost per Gb of data is much lower, due to higher output
and ability of multiplexing.
8.4.2.2 Method 2: DNA Concatenation. The second method of sample-preparation
produces a long cfDNA concatemers through a straightforward procedure of whole-
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genome amplification followed by ligation (Figure 42A). First, we used a commercially
available NGS library preparation kit to perform whole-genome amplification of extracted
cfDNA (Plasma-Seq, Takara). For this reaction, up to 10 µL of isolated cfDNA (e.g. 110ng total) were used for reaction input. Briefly, isolated cfDNA was first end-repaired,
then blunt-end ligated to NGS sequencing adaptors (i.e. library synthesis). Sequencing
indexes were then added through high-fidelity amplification using PCR (i.e. library
amplification). After the addition of sequencing adaptors and indexes to the two ends,
length of cfDNA fragments increased by 150bps (length of adapters + indexes). Finally,
we used magnetic beads to clean up the post PCR product. This process of NGS library
preparation took approximately 3 hours, yielding 100-400ng DNA output.
Then, we performed phosphorylated the NGS library for 30 minutes at room
temperature, allowing blunt-end ligation in the next step. Long DNA concatemers were
created by adding NEB Blunt-end ligation mixture to the sample and incubated at room
temperature for four hours, to maximize the amount and length of DNA concatemers.
Finally, we cleaned up the reaction and eluted final product in nuclease-free water. To
check for concatemers quantity and size distribution after the reaction, we used Qubit and
a DNA high sensitivity chip with Bioanalyzer Agilent 2100, respectively.
The final clean up step was necessary to remove T4 ligase enzyme and any reaction
chemicals that could potentially interfere with sequencing. During the development of this
protocol, we tested both column-based and gel-based purification methods. The latter one
was quickly ruled out due to low recovery (only up to 80%) and long processing time (over
20 minutes). As our target was whole-genome sequencing, rather than a size-specific
fragment, column-based purification was referred for a faster procedure and higher
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recovery. It is important to note that the DNA size selection range of the selected column
should be carefully considered, in order to maximize recovery of long fragments while
efficiently removing T4 ligase enzymes. In this protocol, we used NucleoSpin Gel and PCR
Clean up kit (Takara Bio), which allowed recovery of fragments between 50 – 20,000bps
(within 10 minutes).

Figure 42. Sample-preparation method: Concatenation. (A) Flow chart of sequencing using
DNA concatenation. Sample containing extract cfDNA undergoes the standard Nextgeneration sequencing library preparation, followed by end-repair and blunt-end ligation
to create long DNA fragments. The procedure takes approximately one day. (B-E)
Bioanalyzer traces of Patients 1 and 2 samples after step 1 (NGS library preparation) and
step 2 (blunt-end ligation / concatenation). Disappearance of the prominent peaks, and
upward-shifting baseline in the second step indicated successful formation of long DNA
fragments.
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Overall, this second strategy of sample-preparation takes approximately 8 hours
and yield between 100-400ng of DNA that can be directly used for ONT 1D ligation library
preparation and nanopore sequencing. The final amount of concatemer obtained strongly
depends on the output of whole-genome amplification with PCR.
We applied this protocol to prepare samples from lung cancer Patient 1 and 2 for
nanopore sequencing. Comparing the bioanalyzer trace at each step (isolated cfDNA – after
library amplification – after DNA concatenation), we observed a clear shift in fragment
size distribution (Figure 42B – G). After DNA concatenation (Figure 42D and G), the
prominent peaks that previously showed Figure 42B-C and E-F disappeared, replaced by
multiple smaller peaks that stretched passed the end marker (10380 bp).
These results indicated successful ligation and formation of DNA concatemers with
random length. Since ONT 1D ligation library preparation kit requires at least 500ng – 1µg
DNA input per sequencing run, we plan to pool these two samples (from Patient 1 and 2)
together in one nanopore flow cell. As these two samples contained two different NGS
index combinations, it is possible to sequence them as is, without a second step of
multiplexing using ONT barcode. Currently, a new bioinformatic pipeline is under
development to analyze the sequencing results of DNA concatemers prepared using this
second strategy. As each DNA concatemers consist of several individual cfDNA fragments
that are separated to each other by a duplicate pair of adaptor and index, we need this
bioinformatic tool to: (1) divide one concatenated strand into its component fragments, (2)
trim the adaptor and index at 3’ and 5’ end of each fragment, (3) align the fragments to a
reference human genome, and (4) perform downstream analysis (i.e. copy number
variation, SNP, fragmentation, methylation and bacterial DNA.).
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Table 16
Comparison between sequencing methods

Amount cfDNA input
Amount DNA output2
Sample preparation time
Sequencing time
Wait time
Read length

Reference:
Illumina (NGS)
< 10 ng
100 – 500 ng
3 – 5 hours
24 – 80 hours3
~ 3 weeks
Short (< 500 bps)

Method 1:
RCA
40 ng1
> 100 µg
~ 24 hours
24 – 48 hours
Fragment length

Method 2:
Concatenation
< 10 ng
100 – 500 ng
8 – 10 hours
24 – 48 hours
Fragment length

* Note:
About 90% of cfDNA input was lost before ligation of cfDNA and backbone,
due to reaction cleanups and fragment blunting.
2 Amount of DNA output after whole-genome amplification.
3 Run time depends on the sequencer model.
1

8.5 Results and Discussion
So far, we have shown evidences of long cfDNA fragments, and described in
detailed two recently developed strategies for sample-preparation before nanopore
sequencing. These protocols enabled capture of both short and long cfDNA fragments. In
Table 16, we give a brief comparison between the two strategies and Illumina sequencing.
These two protocols, while having the same end goal, had different wet lab approaches that
brought in unique advantages and disadvantages. Specifically:
8.5.1 Method 1: Rolling-circle amplification. Summary:
(1) High accuracy: End product consisted of long fragments with tandem repeats,
allowing a highly accurate sequencing result that could be used for SNP detection
(i.e. mutation).
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(2) High amount of output: RCA reaction yielded over 100 µg DNA, which exceeds
the input requirement of nanopore sequencing; thus, allowing quality controls and
multiple testing.
(3) Fragment length: ability to capture long-fragments that previously missed by shortread platforms, as indicated by preliminary sequencing with the Flongle flow cell.
(4) Long processing time: Sample preparation time took 24 hr total. However, there
was a long waiting period between steps, and the process actually took 2-3 working
days, which is not practical in clinics.
(5) High amount of isolated cfDNA input: depending on the concentration of cfDNA,
4 – 40mL of plasma is needed, in order to obtain 40-50ng cfDNA input per sample.
Moreover, as 90% of the DNA input was lost before RCA reaction, the diversity of
the RCA product was significantly reduced.
8.5.2 Method 2: DNA concatenation. Summary:
(1) Simpler and shorter processing time: sample preparation plus ONT library
preparation takes approximately 8 hours. Thus, DNA sequencing can be started
within the same day.
(2) Adaptable procedure from short-read technology: since the first half of this protocol
used a common NGS library preparation method, this protocol is highly convenient
for laboratories that currently rely on short-read platforms, but would like to try out
long-read sequencing. Specifically, the sample can be divided for sequencing with
both short-read platform (i.e. Illumina) and long-read platform (i.e. Nanopore).
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(3) Low DNA output: as nanopore sequencing requires at least 50-100fmol (or 500ng
– 1µg) of DNA input, at least two or more samples will have to be multiplexed for
a sequencing run.
(4) Unavailable bioinformatic pipeline: This protocol is a combination of both NGS
and nanopore sequencing, thus it requires a new, adapted pipeline. We estimate that
it will take approximately 1-3 months to develop and employ this new
bioinformatic pipeline.
8.6 Conclusions
Up-to-date, long fragments of cfDNA are still missing from the analysis, due to
bias in sample preparation and sequencing limitations.326 Nanopore technology can be a
potential tool to retrieve these missing fragments, thanks to its ability to perform long-read
sequencing. However, sequencing ctDNA with nanopore sequencer is still challenging, due
to the high input requirements and low base-calling accuracy with fragments shorter than
1kbps. In this study, we showed two novel sample-preparation methods that can capture
both short and long cfDNA fragments for sequencing with high accuracy using nanopore
technology. At the moment, these methods are still under development and optimization to
lower the cost and maximize sequencing output. We have sent samples from patients 1 and
2 to sequence with both Illumina and nanopore sequencers. In the future, it is our goal to
conduct a full-scale comparison of the advantages and disadvantages of WGS using three
techniques: Next-generation sequencing (Illumina), Nanopore sequencing (using RCA and
DNA concatenation strategies).
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Chapter 9
Summary and Conclusion
This thesis focuses on exploring the α-hemolysin nanopore’s capability to detect
and study molecular markers of cancer for precision medicine. The studies described
herein, and summarized below, showcase different techniques to improve nanopore
sensitivity in molecular detection and demonstrate how to bring the application of this
technique from the lab-bench to the clinic.
In Chapter 2, current work on applying nanopore technology in studying cancer
biomarkers is summarized. We provided an overview of the essential genetic and
epigenetic modifications in cancerous tissue and the progression of cancer cells. With the
complexity of the human body and more specifically cancer tissues, many of the
mechanisms for cancer proliferation remain unknown. Nanopore membranes have shown
their ability to detect various biomolecules’ chemical and structural modifications, as well
as genetic and epigenetic modifications. There is a growing opportunity for more
significant research in this field to be conducted in the next few decades.
Unlike solid-state nanopores, whose size can vary, α-hemolysin is a bacterial toxin
that forms a nanopore with well-defined structure and consistent dimensions. This feature
allows a reproducible sensing of molecular structure. Taking advantage of the α-hemolysin
nanopore’s size selection, in Chapter 3, we evaluated the pore’s ability to sense DNA
secondary structures that were different in size. The employed C-rich single-stranded DNA
were able to adopt an i-motif structure in solutions with pH less than 6.15 and a linear
strand when pH is higher than 6.15. However, we found that in highly concentrated buffers
(1M KCl and 1M NaCl) cations can bind to and induce the compaction process on C-rich
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DNA, as the exocyclic amino group of cytosine allows strong cation-nucleotide binding
because of resonance effects. This process created secondary structures larger than 2.6nm
(nanopore cis opening), resulting in shallow current blockage events (%I/Io < 30%) that
could be sensed by the pore. In either type of solution (1M NaCl or 1M KCl), both DNA
compacting and translocating events were observed, hinting that the 15C-ssDNA adopted
both elongated and compacted forms and could spontaneously shift from one conformation
to the other.
Formation of G-quadruplexes in the promoter region of Ckit1 proto-oncogene
suppresses gene expression and prevents cancer cell replication. Excessive activation of
the C-kit1 DNA sequence is implicated in several human malignancies and its expression
is downregulated by the stabilization of its G-quadruplex structure. In Chapter 4, we
studied the formability, stability and responsiveness to CX-5461 cancer drug of Ckit1 Gquadruplex in K+ and Na+ environment. Using circular dichroism, we determined that Ckit1
G-quadruplex adopted a parallel folding topology in both environments, with a more tightly
packed structure in the presence of K+. While formation of a stable G-quadruplex was
observed in both environments, Na+ G-quadruplex folded much slower and unfolded more
rapidly than K+ G-quadruplex. Binding of CX-5461 effectively increased the structural
stability and structural volume of G-quadruplex in both Na+ and K+ environments.
Subsequent validation by thermal denaturation with circular dichroism revealed a 13˚C and
11˚C increase in melting temperature of (CX-5461 bound versus unbound) K+ and Na+ Gquadruplex, respectively. Moreover, through exploratory analysis using clustering, we
identified two distinct populations of current blockage events, representing the two stages
of (i) capturing (%I/Io = 67.4±3.9%) and (ii) translocation of G-quadruplex through the

150

pore (%I/Io = 85.1±2.9%). The volume of G-quadruplex is correlated with the cation
species and presence of CX-5461. As the stability and volume of Ckit1 G-quadruplex were
dependent on cations and ligand-binding status, it was feasible to distinguish different
structures of Ckit1 G-quadruplex using nanopore data alone (e.g. predicting the binding
state of CX-5461 to Ckit1 G-quadruplex in Na+ environment: 92.4% sensitivity, 70.3%
specificity, and 81.3% average accuracy).
In addition to binding of ligands (e.g. CX5461), other factors, such as point
mutation, can also strongly affect the stability of G-quadruplex. Activating mutation on
Ckit1 has been observed in several types of malignancy; however, their direct effect on
cancer drug efficacy (i.e. CX5461) remains unclear. Therefore, in Chapter 5, we evaluated
the ability of mutated Ckit1 sequences to form G-quadruplex, as well as their stability with
respect to ligand binding. We employed six samples that were variations of the Ckit1
sequence, including one wild-type (control) and five sequences containing 1-6 guanine
mutations. Nanopore dwell time analysis of these mutated structures revealed a general
decrease in G-quadruplex structural stability, with the most significant changes present
when there was more than one mutation of the same G-quartet. Thermal denaturation study
with circular dichroism showed that sequences with more than one mutation on the same
G-quartet lost their characteristic positive peak (at 263nm), hinting a partial or uncomplete
formation of G-quadruplex. While addition of CX5461 to mutated Ckit1 DNA sequences
increased the overall stability of G-quadruplex structure formed by most samples,
sequences with mutations on the outer G-quartet did not exhibit statistically significant
changes. This result indicated the important role of the outer G-quartet for ligand-binding
and stabilizing the structure. Furthermore, we implemented random forest classifier to
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nanopore sensing data to distinguish mutated from unmutated Ckit1 DNA ( AUC = 0.89,
sensitivity = 81.9%, specificity = 83.4% and balanced accuracy = 82.7%). Understanding
the potential effect of mutation on drug efficiency can have implications in the
implementation of cancer therapies. Our results indicate the potential of using a nanopore
biosensor to study DNA molecular stability and their interaction with cancer drugs for
constructing methods to predict therapeutic response, as well as personalizing cancer
treatment.
In addition to DNA secondary structure, other types of DNA modifications, such
as methylation of DNA, are important markers for cancer diagnosis and therapeutic
response prediction. While conventional methods can detect cytosine methylation with
high accuracy, they still require a high amount of input and extensive sample processing.
In Chapter 6, we performed, for the first time, label-free detection of cytosine methylation
on single-stranded DNA, using an α-hemolysin nanopore sensor. One of the main
challenges with nanopore sensing is low accuracy due to fast translocation speed of
biomolecules through the pore. To tackle this issue, we employed a concentration gradient
of salt across the experimental chambers. As the cations move down the concentration
gradient, they move against DNA translocation direction, thus, significantly lowering the
electrophoretic drive of the system and DNA translocation speed. With a 15-fold increase
of LiCl concentration going from the cis to the trans chamber, DNA translocation speed
was effectively decreased by 5 times, allowing a clear distinction between methylated and
unmethylated DNA. Distribution of current blockage amplitude for methylated –
unmethylated DNA mixtures exhibited bimodule distributions, with peaks’ height
relatively proportional to the mixture content (unmethylated : methylated DNA ratio).
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Results of this study indicate the potential of simplifying label-free cytosine methylation
detection with nanopore, using LiCl salt concentration asymmetry.
While label-free detection of cytosine methylation is feasible, current blockage
amplitude of methylated DNA varies based on the local-sequence context, thus,
complicating the computational aspect. Therefore, in Chapter 7, we employed methylbinding protein (MBD2) to enhance the signal of methylated cytosine going through the
nanopore. Binding of MBD2 to duplex DNA increased the structural stability and
significantly prolonged the event translocation time through the pore. Applying machine
learning classification models on nanopore results revealed that utilizing MBD2 protein
provided a good discriminatory power for cytosine methylation detection with an optimal
AUC of 0.83, 88% sensitivity and 86% specificity (using KNN algorithm).
Finally, we explored the potential of applying nanopore technology to capture
cancer biomarkers in a clinical setting. Liquid biopsy—a technique to study cancer through
circulating-tumor DNA—offers a minimally invasive and reliable detection of tumors’
genomic evolution through longitudinal sampling. Current work with cell-free DNA
obtained from cancer cell culture media reflected the existence of long cfDNA fragment
(>1kbps). However, current sequencing techniques, which depend on enzymatic reaction,
are limited by the read-length (<500bps). Compared to conventional methods, the nanopore
offers a shorter sample processing time and the ability to capture long cfDNA fragments.
However, because of their rapid translocation speed, short DNA fragments (<1kbps) are
often missed by the nanopore. In Chapter 8, we developed two methods to capture both
short and long fragments of cell-free DNA using commercially-available nanopore assay.
In the first method, we utilized a guide system to capture cfDNA, then performed rolling-
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circle amplification to amplify and convert them into long fragments with tandem repeats.
In the second method, we used standard sequencing library preparation (NGS library) to
perform whole-genome amplification, after which, long fragments were generated through
blunt-end ligation (Gibson assembly). We tested the two methods using plasma samples
obtained from the same lung cancer patients. Sequencing results with Flongle showed
successful capture of both short and long cfDNA fragments (50bps to over 600bps). While
further validations and optimization are needed, our study demonstrated the potential
benefits and applications of nanopore in sequencing cfDNA for monitoring treating
progression.
Overall, in this thesis, we aimed to validate and improve α-hemolysin nanopore
assays toward precision medicine in oncology. Specifically, we investigated the potential
of lab-based and commercially available nanopore assays for molecular sensing and
ctDNA sequencing. While lab-based assay offers the flexibility for controlling and finetuning of parameters, commercial assay provides higher sensing resolution and throughput.
Each method certainly has its own potential area in precision medicine. Thanks to its low
capital cost and small footprint, nanopore technology offers a higher mobility and more
flexibility than conventional techniques. Our study demonstrated the nanopore’s ability for
rapid molecular sensing and sequencing (within a few days, compared to the standard three
weeks’ waiting period for NGS sequencing). The biggest challenge remaining for both
types of assays is their high input requirement, compared to clinical standards. Therefore,
there is a need for future advancements in both wet lab and technological development for
a multi-targets nanopore assay.
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Appendix A
Example of R Code for Dwell Time Boxplots
################ Dwell time distribution - Grouped Boxplot ##################
dwelltime <-read.csv("Amplitude_Dwelltime_allconditions_mut_4columns_new.csv", sep = ",",
header = TRUE)
dwelltime.f <- dwelltime %>%filter(dwelltime$Amplitude > 60 & dwelltime$Dwell.Time > 1)
head(dwelltime.f)
## Amplitude Dwell.Time Condition Treatment
## 1 86.263
1.80
L1M1 No CX
## 2 86.226
7.92
L1M1 No CX
## 3 85.990
1.84
L1M1 No CX
## 4 85.956 818.26
L1M1 No CX
## 5 85.549 27910.62
L1M1 No CX
## 6 85.416
2.54
L1M1 No CX
# annotation table with adjusted pvals and y-position of the labels
anno_df = compare_means(Dwell.Time ~ Treatment, group.by = "Condition", data = dwelltime.
f) %>%
mutate(y_pos = 40)
## Warning: `cols` is now required.
## Please use `cols = c(p)`
p <- ggplot(dwelltime.f, aes(x=Condition, y=Dwell.Time)) +
geom_boxplot(aes(fill = Treatment)) +
scale_fill_brewer(palette = "Dark2")+
scale_y_continuous(trans = 'log10')
p <- p + stat_compare_means(comparisons = list(c("No CX", "With CX")), size = 4)+
theme(legend.position="none")+ # Remove legend
# set transparency
theme(
panel.grid.major = element_blank(),
panel.grid.minor = element_blank(),
panel.background = element_rect(fill = "transparent",colour = NA),
plot.background = element_rect(fill = "transparent",colour = NA)
)
p
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ggsave(p, filename = "Ckit_Mut_Dwelltime_GroupedBoxplot.png", bg = "transparent")
## Saving 5 x 4 in image
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Appendix B
Example of R Code for Summary Statistic and Pairwise Comparison
##########Summary of the dwell time table: mean, max, min, median## #########
dwelltime <-read.csv("Amplitude_Dwelltime_allconditions_mut_new.csv", sep = ",", header = T
RUE)
dwelltime.f <- dwelltime %>%filter(dwelltime$Amplitude > 50 & dwelltime$Dwell.Time > 1)
stat.sum <- as.data.frame(dwelltime.f %>%
group_by(Condition)%>%
summarise(Mean = mean(Dwell.Time), Max = max(Dwell.Time), Min =min(
Dwell.Time), Median = median(Dwell.Time), Std = sd(Dwell.Time) ))
stat.sum
## Condition
Mean
Max Min Median
Std
## 1
Ckit1 3677.865950 114411.352 1.0500 5.5500 12755.3138
## 2 Ckit1_CX 10245.271661 152850.000 1.0200 31.1900 25301.9010
## 3
L1M1 3455.983506 51802.340 1.0200 3.5500 9639.9690
## 4 L1M1_CX 1664.956641 39545.141 1.0230 8.8000 5819.8137
## 5
L1M2 8.650711 296.945 1.0160 2.7190 22.9824
## 6 L1M2_CX 563.404257 39771.090 1.0200 4.4885 3364.7391
## 7
L2M1 2055.286784 65396.621 1.0200 5.2800 7247.3926
## 8 L2M1_CX 30.167402 1447.891 1.0310 3.2660 132.3704
## 9
L2M2 30.100872 1447.891 1.0310 3.2830 132.2039
## 10 L2M2_CX 6388.554461 119939.500 1.0200 8.9800 16950.6187
## 11
M2C 14.967050 3449.960 1.0200 4.0800 121.7973
## 12 M2C_CX 312.115897 29303.414 1.0155 4.8599 1863.5142
# Compute the analysis of variance
res.aov <- aov(Dwell.Time ~ Condition, data = dwelltime.f)
# Summary of the analysis
summary(res.aov)
##
Df Sum Sq Mean Sq F value Pr(>F)
## Condition 11 4.461e+10 4.056e+09 78.04 <2e-16 ***
## Residuals 9294 4.830e+11 5.197e+07
## --## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
#Multiple pairwise comparison
TukeyHSD(res.aov)
## Tukey multiple comparisons of means
## 95% family-wise confidence level
##
## Fit: aov(formula = Dwell.Time ~ Condition, data = dwelltime.f)
##
## $Condition
##
diff
lwr
upr p adj
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## Ckit1_CX-Ckit1 6.567406e+03 4934.7940 8200.017464 0.0000000
## L1M1-Ckit1
-2.218824e+02 -2252.6909 1808.925998 0.9999999
## L1M1_CX-Ckit1 -2.012909e+03 -3553.2472 -472.571381 0.0011828
## L1M2-Ckit1
-3.669215e+03 -4968.2458 -2370.184726 0.0000000
## L1M2_CX-Ckit1 -3.114462e+03 -4391.5832 -1837.340205 0.0000000
## L2M1-Ckit1
-1.622579e+03 -2778.6092 -466.549135 0.0002834
## L2M1_CX-Ckit1 -3.647699e+03 -5097.9737 -2197.423364 0.0000000
## L2M2-Ckit1
-3.647765e+03 -5096.7379 -2198.792281 0.0000000
## L2M2_CX-Ckit1 2.710689e+03 1130.0860 4291.291062 0.0000014
## M2C-Ckit1
-3.662899e+03 -4600.9346 -2724.863192 0.0000000
## M2C_CX-Ckit1 -3.365750e+03 -4313.9376 -2417.562523 0.0000000
## L1M1-Ckit1_CX -6.789288e+03 -9130.8543 -4447.721959 0.0000000
## L1M1_CX-Ckit1_CX -8.580315e+03 -10511.9957 -6648.634339 0.0000000
## L1M2-Ckit1_CX -1.023662e+04 -11981.9661 -8491.275828 0.0000000
## L1M2_CX-Ckit1_CX -9.681867e+03 -11410.9679 -7952.766882 0.0000000
## L2M1-Ckit1_CX -8.189985e+03 -9831.6775 -6548.292229 0.0000000
## L2M1_CX-Ckit1_CX -1.021510e+04 -12075.7621 -8354.446464 0.0000000
## L2M2-Ckit1_CX -1.021517e+04 -12074.8136 -8355.527950 0.0000000
## L2M2_CX-Ckit1_CX -3.856717e+03 -5820.6555 -1892.778875 0.0000000
## M2C-Ckit1_CX -1.023030e+04 -11726.5199 -8734.089282 0.0000000
## M2C_CX-Ckit1_CX -9.933156e+03 -11435.7565 -8430.555048 0.0000000
## L1M1_CX-L1M1 -1.791027e+03 -4069.2174 487.163654 0.2970685
## L1M2-L1M1
-3.447333e+03 -5569.8293 -1324.836297 0.0000073
## L1M2_CX-L1M1 -2.892579e+03 -5001.7379 -783.420553 0.0004611
## L2M1-L1M1
-1.400697e+03 -3438.8127 637.419207 0.5154649
## L2M1_CX-L1M1 -3.425816e+03 -5644.1058 -1207.526398 0.0000293
## L2M2-L1M1
-3.425883e+03 -5643.3211 -1208.444185 0.0000289
## L2M2_CX-L1M1
2.932571e+03 626.9657 5238.176197 0.0019255
## M2C-L1M1
-3.441016e+03 -5363.8847 -1518.148260 0.0000003
## M2C_CX-L1M1
-3.143868e+03 -5071.7086 -1216.026666 0.0000065
## L1M2-L1M1_CX -1.656306e+03 -3315.6580 3.046169 0.0509311
## L1M2_CX-L1M1_CX -1.101552e+03 -2743.8095 540.704725 0.5550697
## L2M1-L1M1_CX
3.903301e+02 -1159.6294 1940.289674 0.9996296
## L2M1_CX-L1M1_CX -1.634789e+03 -3415.0328 145.454347 0.1080353
## L2M2-L1M1_CX -1.634856e+03 -3414.0385 144.326988 0.1074817
## L2M2_CX-L1M1_CX 4.723598e+03 2835.6694 6611.526193 0.0000000
## M2C-L1M1_CX
-1.649990e+03 -3044.9377 -255.041525 0.0062430
## M2C_CX-L1M1_CX -1.352841e+03 -2754.6356 48.954072 0.0703972
## L1M2_CX-L1M2
5.547535e+02 -863.6426 1973.149735 0.9818354
## L2M1-L1M2
2.046636e+03 736.2110 3357.061151 0.0000217
## L2M1_CX-L1M2
2.151669e+01 -1554.5882 1597.621562 1.0000000
## L2M2-L1M2
2.145016e+01 -1553.4564 1596.356705 1.0000000
## L2M2_CX-L1M2
6.379904e+03 4683.1089 8076.698634 0.0000000
## M2C-L1M2
6.316339e+00 -1116.5013 1129.133975 1.0000000
## M2C_CX-L1M2
3.034652e+02 -827.8473 1434.777718 0.9993243
## L2M1-L1M2_CX
1.491883e+03 203.1727 2780.592311 0.0085447
## L2M1_CX-L1M2_CX -5.332369e+02 -2091.3336 1024.859929 0.9939262
## L2M2-L1M2_CX -5.333034e+02 -2090.1880 1023.581211 0.9938793
## L2M2_CX-L1M2_CX 5.825150e+03 4145.0693 7505.231125 0.0000000
## M2C-L1M2_CX
-5.484372e+02 -1645.8334 548.959014 0.8968496
## M2C_CX-L1M2_CX -2.512884e+02 -1357.3747 854.798014 0.9998642
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## L2M1_CX-L2M1 -2.025119e+03 -3485.6096 -564.629147 0.0003670
## L2M2-L2M1
-2.025186e+03 -3484.3829 -565.988946 0.0003600
## L2M2_CX-L2M1
4.333268e+03 2743.2872 5923.248193 0.0000000
## M2C-L2M1
-2.040320e+03 -2994.0726 -1086.566828 0.0000000
## M2C_CX-L2M1
-1.743171e+03 -2706.9101 -779.431707 0.0000002
## L2M2-L2M1_CX -6.652969e-02 -1701.8739 1701.740880 1.0000000
## L2M2_CX-L2M1_CX 6.358387e+03 4543.1927 8173.581461 0.0000000
## M2C-L2M1_CX
-1.520035e+01 -1310.0120 1279.611326 1.0000000
## M2C_CX-L2M1_CX 2.819485e+02 -1020.2365 1584.133537 0.9999157
## L2M2_CX-L2M2
6.358454e+03 4544.2996 8172.607599 0.0000000
## M2C-L2M2
-1.513382e+01 -1308.4866 1278.218929 1.0000000
## M2C_CX-L2M2
2.820150e+02 -1018.7194 1582.749409 0.9999145
## M2C-L2M2_CX
-6.373587e+03 -7812.8732 -4934.301617 0.0000000
## M2C_CX-L2M2_CX -6.076439e+03 -7522.3612 -4630.515953 0.0000000
## M2C_CX-M2C
2.971488e+02 -390.0911 984.388807 0.9612128
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Appendix C
Example of R Code for Machine Learning Classification Models
####Machine learning: predicting methylated from unmethylated DNA #####
## With MBD2
bothend.ml <-read.csv("bothend_nome_MBD2_ml.csv", sep = ",", header = TRUE)
head(bothend.ml)
## Amplitude Dwell.Time Condition
## 1 82.35037 20704.35
nome
## 2 86.29356 802.45
nome
## 3 89.52220 206.75
nome
## 4 55.81189
14.75
nome
## 5 79.11031
6.35
nome
## 6 60.56889
3.95
nome
dim(bothend.ml)
## [1] 1151

3

dwelltime$Condition <- as.factor(dwelltime$Condition)
df_ML <- bothend.ml
df_ML <- na.omit(df_ML)

df_ML.f <- df_ML%>%filter( df_ML$Amplitude > 75 & df_ML$Dwell.Time > 100 & df_ML
$Dwell.Time <10000) #Filtering data: only choose data with dwell time > 50ms.
dim(df_ML.f)
## [1] 360 3
df_ML.f$Amplitude_scaled <-scale(df_ML.f$Amplitude)
df_ML.f$Dwell.Time_scaled <-scale(df_ML.f$Dwell.Time)
set.seed(35)
train_indx <- createDataPartition(df_ML.f$Condition, p = 0.80, list = FALSE)
train_set <- df_ML.f[train_indx,]
test_set <- df_ML.f[-train_indx,]
nrow(train_set)
## [1] 289
dim(train_set)
## [1] 289 5
nrow(test_set)
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## [1] 71
##################### Train the algorithm ############################
fitControl <- trainControl(method="boot",
number = 10,
preProcOptions = list(thresh = 0.99), # threshold for pca preprocess
classProbs = TRUE,
savePredictions = TRUE,
summaryFunction = twoClassSummary)
#################### Random Forest #################################
model_rf <- train(Condition~ Amplitude_scaled+Dwell.Time_scaled,data = train_set, method="r
f", metric="ROC",
preProcess = c('center', 'scale'), trControl=fitControl)
## note: only 1 unique complexity parameters in default grid. Truncating the grid to 1 .
pred_rf <- predict(model_rf, test_set)
cm_rf <- confusionMatrix(pred_rf, test_set$Condition, positive = "nome")
cm_rf
## Confusion Matrix and Statistics
##
##
Reference
## Prediction me_MBD2 nome
## me_MBD2
28 7
## nome
7 29
##
##
Accuracy : 0.8028
##
95% CI : (0.6914, 0.8878)
## No Information Rate : 0.507
## P-Value [Acc > NIR] : 2.446e-07
##
##
Kappa : 0.6056
##
## Mcnemar's Test P-Value : 1
##
##
Sensitivity : 0.8056
##
Specificity : 0.8000
##
Pos Pred Value : 0.8056
##
Neg Pred Value : 0.8000
##
Prevalence : 0.5070
##
Detection Rate : 0.4085
## Detection Prevalence : 0.5070
##
Balanced Accuracy : 0.8028
##
##
'Positive' Class : nome
##
############################### Using LDA #####################################
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model_lda_df <- train(Condition ~., data = train_set, method = "lda", metric = "ROC", preProces
s = c("scale", "center"),
trControl = fitControl)
prediction_lda_df <- predict(model_lda_df, test_set)
cm_lda_df <- confusionMatrix(prediction_lda_df, test_set$Condition, positive = "nome")
cm_lda_df
## Confusion Matrix and Statistics
##
##
Reference
## Prediction me_MBD2 nome
## me_MBD2
26 16
## nome
9 20
##
##
Accuracy : 0.6479
##
95% CI : (0.5254, 0.7576)
## No Information Rate : 0.507
## P-Value [Acc > NIR] : 0.01165
##
##
Kappa : 0.2976
##
## Mcnemar's Test P-Value : 0.23014
##
##
Sensitivity : 0.5556
##
Specificity : 0.7429
##
Pos Pred Value : 0.6897
##
Neg Pred Value : 0.6190
##
Prevalence : 0.5070
##
Detection Rate : 0.2817
## Detection Prevalence : 0.4085
##
Balanced Accuracy : 0.6492
##
##
'Positive' Class : nome
##
################## Logistic regression ####################
model_logreg_df <- train(Condition ~., data = train_set, method = "glm",
metric = "ROC", preProcess = c("scale", "center"),
trControl = fitControl)
cm_logreg_df <- confusionMatrix(prediction_logreg_df, test_set$Condition, positive = "nome")
cm_logreg_df
## Confusion Matrix and Statistics
##
##
Reference
## Prediction me_MBD2 nome
## me_MBD2
26 16
## nome
9 20
##
##
Accuracy : 0.6479
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##
95% CI : (0.5254, 0.7576)
## No Information Rate : 0.507
## P-Value [Acc > NIR] : 0.01165
##
##
Kappa : 0.2976
##
## Mcnemar's Test P-Value : 0.23014
##
##
Sensitivity : 0.5556
##
Specificity : 0.7429
##
Pos Pred Value : 0.6897
##
Neg Pred Value : 0.6190
##
Prevalence : 0.5070
##
Detection Rate : 0.2817
## Detection Prevalence : 0.4085
##
Balanced Accuracy : 0.6492
##
##
'Positive' Class : nome
##
################## K-nearest neighbor #############################
model_knn <- train(Condition~.,
data = train_set,
method="knn",
metric="ROC",
preProcess = c('center', 'scale'),
tuneLength=10,
trControl=fitControl)
pred_knn <- predict(model_knn, test_set)
cm_knn <- confusionMatrix(pred_knn, test_set$Condition, positive = "nome")
cm_knn
## Confusion Matrix and Statistics
##
##
Reference
## Prediction me_MBD2 nome
## me_MBD2
27 11
## nome
8 25
##
##
Accuracy : 0.7324
##
95% CI : (0.6141, 0.8306)
## No Information Rate : 0.507
## P-Value [Acc > NIR] : 9.002e-05
##
##
Kappa : 0.4653
##
## Mcnemar's Test P-Value : 0.6464
##
##
Sensitivity : 0.6944
##
Specificity : 0.7714
##
Pos Pred Value : 0.7576
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##
##
##
##
##
##
##

Neg Pred Value : 0.7105
Prevalence : 0.5070
Detection Rate : 0.3521
Detection Prevalence : 0.4648
Balanced Accuracy : 0.7329
'Positive' Class : nome

########################### Model Evaluation ########################
model_list <- list(RF=model_rf, LG=model_logreg_df, LDA = model_lda_df,
KNN = model_knn
resamples <- resamples(model_list)
bwplot(resamples, metric = "ROC", main = "Evaluating performance of different algorithms")
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